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Therapeutic monoclonal antibodies based on the IgG class of antibodies are glycoproteins 
that contain glycosylation sites within their Fc region. Glycosylation is important for Fc-
mediated effector functions such as Antibody Dependent Cellular Cytotoxicity (ADCC) and 
Complement Dependent Cytotoxicity (CDC). IgG has four subclasses: IgG1, IgG2, IgG3 and 
IgG4. All IgG subclasses contain a consensus glycosylation site in the CH2 domain at N297, and 
glycosylation at that site is considered essential for optimal Fc function and stability. IgG3 is the 
only subclass that has an additional glycosylation site in the CH3 domain at N392. This site has 
nearly gone unmentioned and was only recently shown to be partially glycosylated in serum 
IgG3; however, the biological role of N392 glycosylation remains uninvestigated in the 
literature. The primary focus of this dissertation work is to study the effect of N-glycosylation on 
Fc receptor interactions, structure and physical stability of IgG3.  
LC-MS based glycopeptide mapping studies revealed that the N392 site is partially 
glycosylated in human serum IgG3 and the glycans at the N392 site showed significant 
differences compared to the N297 site in levels of core fucosylation, bisecting GlcNAc and 
mannosylation. The presence of glycosylation at the N392 site in the naturally occurring IgG3 
establishes its biological relevance and makes a case for its characterization. For structural and 
biochemical characterization studies, the Fc fragment of IgG3 was expressed in a glycosylation-
deficient strain of the yeast Pichia pastoris. Two variants of IgG3 Fc were produced, one with 
both sites glycosylated and another with only the N297 site glycosylated. These two forms were 
compared to investigate the effect of N392 glycosylation on the Fc receptor binding activity and 
physical stability of IgG3 Fc. Our results indicate that presence of the additional N392 glycan 
 iv
does not affect the binding of IgG3 Fc with the FcγRIIIA and FcRn receptors but does affect the 
conformational stability and aggregation propensity of IgG3 Fc. 
Additionally, crystal structures of both the IgG3 Fc variants were determined with a 
resolution of 1.8-2.0 Å and were compared with the published structures of Fc fragments from 
the other IgG subclasses. Structural analysis of key amino acid differences between IgG3 and 
other IgG subclasses provided insight into IgG3-specific properties, especially related to binding 
with protein A, protein G, and the FcRn receptor. The importance of N297 glycans for IgG3 Fc- 
FcγRIIIA interaction was also demonstrated from a structural perspective. The location and 
orientation of the N392 glycans in the IgG3 Fc structure provided a probable explanation for the 
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Chapter 1 Introduction 
 
 2 
1.1 Structure and function of immunoglobulins G (IgG) 
 
Immunoglobulins G (IgG) are heterodimeric proteins consisting of two identical heavy 
(H) chains and two identical light chains (L) (Fig 1.1). Each light chain is bound to a heavy chain 
by an inter-chain disulfide bonds. The identical heavy chains are held together by disulfide bonds 
in the hinge region and strong, non-covalent interactions in the CH3 domain. IgG structure can be 
functionally divided into two components: Fab (fragment antigen binding) and Fc (fragment 
crystallizable). The Fab imparts specificity to IgG by binding to unique epitopes on the surface 
of antigens. The Fc imparts biological activity to IgG that results in the removal or destruction of 
antigens with the help of immune effector cells. The Fab is structurally divided into a variable 
region consisting of the VH and VL domains and a constant region consisting of the CL and CH1 
domains. The Fc is divided into CH2 and CH3 domains. The complementarity-determining region 
(CDR) in the variable domain of the Fab provides diversity to antibodies by enabling them to 
bind to an infinite number of different epitopes. Finer details of IgG structure can be found in the 
reviews by Schroeder et al.1 and the Kuby Immunology textbook.2  
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Figure 1.1: Structure of Immunoglobulin G (IgG). 
 
Immunoglobulins/antibodies are mediators of the humoral immunity branch of the 
adaptive immune system. Upon exposure to antigen, naïve B cells are activated through a 
process that is generally initiated by helper T cells.3 Activated B cells then differentiate into 
antibody-secreting plasma B cells and memory cells. The immune functions of IgG can be 
broadly classified into four pathways, as illustrated in Fig. 1.2.3 These are (i) Neutralization: By 
binding to a pathogen or its toxins, an antibody can either prevent the pathogen’s entry into cells, 
its replication or block its toxins from interacting with cell receptors. (ii) Antibody Dependent 
Cellular Phagocytosis (ADCP)/opsonization: IgG can coat the surface of pathogen and facilitate 
its uptake by phagocytic cells like macrophages. ADCP is mediated by binding of the Fc portion 
of pathogen-bound antibodies (immune complex) to the Fc receptors present on the surface of 
phagocytic cells. (iii) Complement activation: The Fc portion of IgG in an immune complex 
binds with the first complement protein C1q, which initiates a cascade of complement activity 
that ultimately results in the destruction of the pathogen by forming pores in its membrane. (iv) 
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Antibody Dependent Cellular Cytotoxicity (ADCC) is mediated by non-phagocytic cells like NK 
cells, basophils, and mast cells through binding of cell surface Fcγ receptors to the Fc region of 
IgG in an immune complex. Consequently, these activated cells release stored chemical 
mediators (perforins and granzymes) to lyse the target.  
 
 
Figure 1.2: Modes of antibody action engaged in removal or destruction of pathogen or killing of 
a tumor cell. 
1.2 Immunoglobulin isotypes and IgG isotype 
 
There are five isotypes of immunoglobulins in humans: IgG, IgA, IgM, IgD, and IgE. 
The isotypes vary in their heavy chain domains and biological activities. IgM (5-10% of total 
serum immunoglobulin) is the first immunoglobulin to be expressed on a B-cell during its 
development and is present in a monomeric form on naïve B cells. An oligomeric (pentameric) 
form of IgM is secreted as part of the primary immune response that is initiated by opsonization 
of antigen and complement fixation.1 IgD is also expressed on the surface of B cells, however its 
role in immunity is not fully understood. IgA (10-15% of total serum immunoglobulin) is 
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predominantly present in external secretions such as breast milk, saliva, and at mucosal surfaces 
of the gut, urogenital system and respiratory tract. It plays an important role in protection of 
mucosal surfaces from pathogens and their toxins.4 IgE mediates hypersensitivity reactions from 
allergen exposure. Its activation leads to mast cell degranulation and an allergic response.  
IgG is the most abundant isotype in serum consisting of 80% of serum immunoglobulins 
and is the most extensively studied isotype. IgG can elicit a pro- or anti-inflammatory response 
by variable binding to Fcγ receptors present on different immune cells. It is the only isotype that 
can cross the placenta and has the longest serum half-life among Ig isotypes.2 The IgG isotype 
has four subclasses: IgG1, IgG2, IgG3 and IgG4, which are numbered in accordance to their 
serum levels. The IgG subclasses exhibit 90-95% homology in their heavy chain amino acid 
sequence.5 In addition to amino acid differences, there are distinct structural differences among 
IgG subclasses with regards to the length of the hinge region and the position and location of the 
inter-chain (H-L) disulfide bonds (Fig 1.3). The subtle amino acid differences between the IgG 
subclasses are responsible for the observed differences in their Fcγ receptor interaction pattern 
and other IgG properties (Table 1.1). For example, IgG1 and IgG3 bind tightly to the majority of 
Fcγ receptors, whereas IgG2 and IgG4 bind weakly to most Fcγ receptors.6 IgG3 is considered as 
the most efficient IgG subclass for eliciting complement activity followed by IgG1.7 IgG2 is less 
efficient at activating complement and IgG4 does not activate complement at all. Preferential 
transport across the placental barrier occurs most readily for IgG1, followed by IgG4, IgG3 and 
IgG2.8 The diversity in biological functions of IgG subclasses enables the immune system to 
choose a suitable IgG subclass for the intended immune response. Generally, IgG1 and IgG3 are 
associated with antibody-mediated pro-inflammatory responses, whereas IgG2 and IgG4 are 
associated with an immunomodulatory role. Moreover, the type of IgG subclass produced in 
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response to a natural infection also depends on the chemical nature of the antigen. For example, 
an IgG1 and IgG3 dominant response is observed for protein-based antigens, whereas 
polysaccharide based antigens trigger an IgG2 dominant response.1  
Table 1.1: Properties of IgG subclasses. 
 IgG1 IgG2 IgG3 IgG4 
Molecular mass (kDa)2  146 146 170 146 
Adult serum levels (mg/ml)2  5-12 2-6 0.5-1 0.2-1 
Relative abundance (%) 60 32 4 4 
Hinge9 
Amino acid residues 













Allotypes5 4 1 13 0 
Half-life (days)10 21 21 7 21 
Binding to Fcγ receptors6     
FcγRI +++ - ++++ ++ 
FcγRIIAH131 +++ ++ ++++ ++ 
FcγRIIAR131 +++ + ++++ ++ 
FcγRIIB/C + - ++ + 
FcγRIIIAF158 ++ - ++++ - 
FcγRIIIAV158 +++ + ++++ ++ 
FcγRIIIB ++ - ++++ - 
Binding to C1q11 + + +++ - 
Binding to Protein A12 + + - + 




Figure 1.3: Schematic representation of structural variation with respect to inter- and intra-chain 




1.3 IgG3 subclass 
 
IgG3 is the third most abundant IgG subclass consisting of 5-8% of total serum IgG and 
is a unique subclass for a variety of reasons.5 It possesses the longest hinge region consisting of 
11 disulfide bonds compared to the 2-4 disulfide bonds found in the other IgG subclasses. The 
IgG3 hinge is made of 62 amino acids, which includes 21 prolines and 11 cysteines, and adopts a 
rigid poly-proline helical structure.13 In contrast, the hinge region in the other IgG subclasses 
consists of 12-15 amino acids and are encoded by a single exon for each subclass. In the case of 
IgG3, the longer hinge is due to extra copies (1-3) of a second homologous exon that is not 
present in the other IgG subclasses.14 The actual hinge length of IgG3 varies among its allotypes 
depending upon the presence or absence of these multiple exons5 (Fig 1.4). The long hinge is 
responsible for the higher MW (~170 kDa) of IgG3 relative to the other subclasses (~150 kDa).15 
It also provides a higher degree of flexibility between the Fab and the Fc region and also 
between the two Fab arms.16-17 The long hinge is thought to provide additional flexibility for 
antigen binding, which is particularly important for sparsely distributed antigens.16, 18 IgG3 
shows extensive polymorphism with the largest number of known allotypes, 13, compared to 4, 
1, and 0 allotypes known for the IgG1, IgG2, and IgG4 subclasses respectively.19 Amino acid 
variations between IgG3 allotypes primarily reside in the hinge and the Fc region. The half-life 
of IgG3 is remarkably shorter (~7 days) than the other subclasses (~21 days).10 This difference 
has been attributed to a single amino acid difference in the IgG3 Fc region (R435 in IgG3 versus 
H435 in the other IgG subclasses, although some IgG3 allotypes have H435 and display a longer 
half-life).20 Another difference is that protein A, an Fc binding protein from S. aureus commonly 
used for IgG purification, doesn't bind to IgG3, while it binds tightly to all the other IgG 
subclasses.12 All the IgG subclasses have a single consensus N-glycosylation site at N297 in the 
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CH2 domain of the Fc, while IgG3 is the only subclass that has an additional unique N-
glycosylation site at N392 in the CH3 domain. While the glycosylation at the N297 site in IgG3, 
like in case of IgG1, is known to be important for Fcγ receptor and C1q complement binding21-23, 
the biological role of the N392 site glycosylation is not known, and its investigation is one of the 
research topics described in this dissertation work.  
 
 
Figure 1.4: Amino acid differences in IgG3 allotypes (G3m). (+) and (-) indicate the presence 
and absence of the hinge exon. Amino acids in bold are unique to IgG3 or its allotype, and the 
underlined amino acids are present in other IgG subclasses (isoallotypes). The IMGT (in bold) 
numbers of IgG3 allotypes (IGHG3*) and the encoded protein accession numbers are shown on 
the right. This figure is reproduced from Vidarsson et al. Frontiers in immunology 2014, 5, 520 
under Creative Commons Attribution License. 
 
IgG3 has potent pro-inflammatory properties since it is the most efficient IgG subclass 
for eliciting complement dependent cytotoxicity (CDC) and has an equivalent ADCC activity as 
IgG1.5 IgG1 and IgG3 levels are generally increased in response to bacterial and viral pathogens 
with IgG3 appearing first during the initial phase of infection.24 For example, IgG3 has been 
associated with immune protection in case of the malaria and chikungunya infections.25 IgG1 and 
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IgG3 levels are also elevated in autoimmune conditions, an effect that is attributed to the strong 
effector functions of IgG3.26 IgG3 deficiency is not known to be associated with any specific 
condition and is generally observed with concomitant deficiency of other IgG subclasses.27-28 
Recently, IgG3 has gained attention in the field of HIV vaccines. In the only successful HIV 
vaccine trial to date, the RV144 HIV trial, IgG3 was found as an immune correlate in vaccine 
protection. Subsequent analysis suggested a possible role of the Fc-mediated effector functions 
of IgG3 in the anti-viral activity.29 Human IgG3 was found to be the dominant IgG subclass in 
cryoglobulins associated with myeloma.30 In myeloma and autoimmune conditions, some IgG3 
show a tendency to self-associate which causes them to precipitate at low temperatures.31 The Fc 
region was shown to be important in this self-association property through Fc-Fc mediated 
interactions.32-33 The molecular basis of cryoglobulin formation is still unclear, although certain 
unusual IgG structural characteristics or factors that affect protein solubility34 are believed to be 
involved. At least in one case, the Fc fragment of a cryoglobulin IgG3, Jir protein from a 
myeloma patient was involved in IgG3 cryoglobulin formation.33 
The majority of the therapeutic antibodies (mAbs) are based on the IgG1 subclass 
primarily due to its superior effector functions and high serum abundance. There are a few mAbs 
that are based on IgG2 and IgG4, and these are mostly used when effector functions are 
undesired or not required, for instance when only a blocking activity is desired. Currently, there 
are no marketed IgG3 based therapeutics, and multiple reasons can be suggested for this 
disfavor: (i) its shorter half-life, (ii) due to large number of allotypes, there exists a potential for 
anti-drug antibodies when therapeutic IgG3 is administered to an incompatible population group, 
(iii) IgG3 does not bind to protein A (used for affinity purification of the other IgG subclasses), 
which is the preferred and well-established method of antibody production in biotech industry, 
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(iv) manufacturing issues due to long hinge and its susceptibility to proteolysis (proteases like 
papain, pepsin, trypsin, and plasmin cleave within the hinge or close to the hinge region of 
antibodies. The IgG3 hinge, being more flexible and accessible is prone to proteolysis35) and (v) 
since IgG1-based therapeutics have been traditionally used successfully for pro-inflammatory 
applications, there is not a pressing need to develop IgG3 based therapeutics currently. Despite 
these factors, IgG3 can be an attractive choice for treating conditions that require a potent pro-
inflammatory response (such as complement activation) owing to its strong effector functions. 
The shorter half-life of IgG3 may be beneficial in limiting the  stimulation of immune system. 
Alternatively, IgG3 can be an ideal antibody candidate for diagnostic purpose owing to its 
relatively rapid clearance. IgG3 subclass may be useful to target sparsely distributed antigens on 
a target cell since it possesses more flexibility owing to the longer hinge region. 
1.4 Fcγ receptors 
 
Fc receptors are a family of cell surface receptors present on immune cells that bind to 
the Fc portion of IgG. Fc receptors play an important role in immune regulation by serving as a 
link between antibody-mediated responses and cellular effector functions. Specific Fc receptors 
exist for each Ig isotype: FcαR (IgA), FcδR (IgD), FcεR (IgE), FcµR (IgM), and FcγR (IgG). 
There are three classes of human Fcγ receptor: FcγRI, FcγRII, and FcγRIII and their respective 
subclasses: FcγRIA/B/C, FcγRIIA/B/C, and FcγRIIIA/B.36 Functionally, Fcγ receptors can be 
classified as activating (FcγRI, FcγRIIA, FcγRIII) and inhibitory (FcγRIIB) receptors.37 FcγR are 
transmembrane receptors (except FcγRIIIB), where the extracellular domain binds to IgG Fc and 
the cytosolic part or its associated signaling adaptor molecule (γ chain) contains distinct 
functional motifs for signal transduction. The activating motif is referred to as the 
immunoreceptor tyrosine-activating motif (ITAM), and the inhibitory motif is referred to as 
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immunoreceptor tyrosine-inhibitory motif (ITIM).38 Generally, activation of an immune cell is 
not triggered by a monovalent FcγR (except FcγRIA) interaction, but requires cross-linking of 
FcγRs as found in an immune complex. Such a mechanism prevents constant stimulation of an 
immune response by monomeric IgG. Different immune cells show different patterns of FcγR 
expression and FcγRs engage with IgG subclasses with varied binding affinities.36 The outcome 
of a FcγR-mediated immune response is determined by the type of IgG subclass, the class of 
FcγR and the nature of immune cell engaged in the response.  
FcγRIIIA is a heavily glycosylated protein expressed on the surface of macrophages and 
monocytes. It is the sole Fcγ receptor present on the NK cells in most people. Two polymorphic 
variants of FcγRIIIA exist, the high affinity FcγRIIIA-V158 and low affinity FcγRIIIA-F158, 
which have marked differences in their IgG binding capacities. FcγRIIIA binds to the IgG 
subclasses with a rank order: IgG1=IgG3>>IgG4>IgG2. ADCC activity mediated by NK cells  
through binding with FcγRIIIA is considered important in the mechanism of action of many 
therapeutic monoclonal antibodies.39 Recognizing the importance of FcγRIIIA in mAb 
therapeutics, there have been several Fc engineering efforts to increase FcγRIIIA affinity to 
confer increased potency to IgGs [see section 1.6, 1.8 (glycoengineering)]. 
1.5 Neonatal Fc receptor (FcRn) 
 
FcRn is a heterodimer composed of a MHC-class-I-like heavy chain and β2 
microglobulin (β2m).40 The two well-known functions of FcRn are placental transfer of maternal 
IgG to fetuses (transcytosis) and the maintenance of long circulating half-lives of serum IgG and 
albumin (recycling). Although the precise site of recycling is not known, it is widely suggested 
to be in the vascular endothelium. The FcRn expressed in the placental syncytiotrophoblasts is 
responsible for transcytosis.41 The receptor binds to the Fc portion of IgG at an acidic pH (<6.5) 
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but shows no binding at physiological pH (7.4). IgG and albumin are constantly pinocytosed by 
cells, where both the proteins bind to FcRn in the acidic environment of endosomes. The bound 
proteins are then recycled back to the cell surface and released at physiological pH (Fig. 1.5). 
This recycling mechanism rescues IgG and albumin from lysosomal degradation and thereby 
regulates its serum persistence. A similar pH dependent mechanism is involved in the FcRn-
mediated directional transcytosis across placental epithelial barriers.42 In recent studies, immune-
related functions of FcRn have emerged that suggest its possible role in antigen presentation by 
professional APC cells and for conferring mucosal protection.43 A good correlation between 
FcRn affinity and in-vivo half-life is known, and this led to Fc engineering strategies aimed at 
increasing serum half-lives of mAb therapeutics.44 The involvement of the Fc in maintenance of 
IgG half-life has led to the development of a new class of biologic drugs, Fc-fusions, where 
biologically active peptides or proteins that otherwise clear rapidly are fused to the Fc region of 
IgG to increase their serum persistence.45 
 
Figure 1.5: Recycling of IgG by FcRn receptor (Reprinted by permission from Macmillan 
Publishers Ltd: Nat Rev Immunol42, copyright (2007). 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1.6 Monoclonal antibody (mAb) therapeutics and antibody engineering 
 
mAbs are antibodies that bind to a specific epitope on an antigen and are produced from a single 
B-cell clone. mAbs were first produced in 1975 from hybridoma cells, generated from the fusion 
of an immortalized myeloma cell and a B-cell clone from mouse.46 A mouse B-cells was first 
used instead of human B-cells since the technology available at the time would have required 
injection of antigens into humans instead of mice to get the B-cells with the sacrifice of the 
subject. The first generation of therapeutic mAbs were murine mAbs, which were approved and 
used, though most have now been taken off the market because they induced a strong immune 
response due to their non-human amino acid sequence. This limitation was eliminated with the 
advent of chimerization and humanization technologies in mid 1980’s.47-48 Chimerization 
involves grafting of the variable regions from the Fab domain of a murine antibody onto the 
constant region of a human antibody. Humanization involves grafting of only the 
complementarity determining region (CDR) of the murine antibody on the human antibody. The 
further reduction in mouse-specific content in humanized therapeutic mAbs significantly reduced 
immunogenicity, and since then humanization technology has proved to be a successful antibody 
generation platform. In the last 15 years, fully human antibodies have been developed using 
phage display or the use of transgenic animals and are potentially better tolerated than the 
humanized antibodies.49 Therapeutic mAbs have shown outstanding clinical outcomes compared 
to small molecule therapies, and have been successfully used in treating cancer, autoimmune 
diseases, inflammation and infections.  
Since the Fc region of IgG is crucial for effector functions and half-life, there is an 
immense interest in Fc engineering approaches to improve the therapeutic efficacy and 
pharmacokinetic properties of antibody therapeutics. Engineering approaches mainly fall under 
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two categories: (i) protein engineering by replacing and/or deleting specific amino acids and (ii) 
alteration of N-linked glycans on the Fc (glycoengineering, discussed in section 1.8). Protein 
engineering using rational design or directed evolution has been successfully used to optimize 
the Fc amino acid sequence to improve FcγR binding and C1q binding and thereby modulate the 
strength and selectivity of effector functions.50 The following are a few examples of engineered 
IgG with improved functions. First, a triple mutant Fc (S239D/I332E/A330L) and double mutant 
Fc (S239D/I332E) both showed higher affinity for the activating receptor FcγRIIIA over the 
inhibitory receptor FcγRIIB resulting in a significantly enhanced ADCC activity.51 Second, 
removal of glycans from IgG results in loss of FcγR binding ability, and in another study, 
specific amino acids mutations were introduced to restore the FcγR binding ability of 
aglycosylated IgG.52-53 This is a significant finding since aglycosylated IgG can be produced in 
E.coli with significantly lower production costs. Third, a Rituximab Fc variant with a double 
mutation (K326W/E333S) showed five-fold higher C1q binding and over two-fold higher CDC 
activity.54 An another Rituximab variant based on an IgG1/IgG3 hybrid showed higher CDC than 
either IgG1 or IgG3. The hybrid contained the CH1 domain from IgG1, and the CH2 and CH3 
domains from IgG3 (with the exception of an IgG1-like C-terminal CH3 domain to restore 
protein A binding capacity of the hybrid).55 Fourth, multiple Fc variants with mutations that 
specifically increases affinity to FcRn at an acidic pH have been identified and have been shown 
to have longer half-life in animal models.56-58 A well-known example of an engineered antibody 
with extended half-life is motavizumab (an IgG1 antibody) with the YTE mutation in the Fc 
region (M252Y, S254T, T256E). The mutant antibody resulted in a 10-fold increase in FcRn 
affinity at pH 6.0 and a 2 to 4 fold increase in serum half-life in humans compared to the native 
motavizumab.59  
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1.7 Protein glycosylation 
 
Glycosylation is a post-translational modification (often considered as a co-translational 
modification in case of N-glycosylation) that covalently attaches oligosaccharides to the growing 
polypeptide chain. It is estimated that more than half of all proteins synthesized in the body are 
glycosylated. Based on the site of attachment, glycosylation can be classified as N-linked or O-
linked. The Asn in a consensus sequence N-X-S/T (X is any amino acid but Pro) acts as an 
acceptor site for N-glycans, while any Ser or Thr in the protein sequence can be an acceptor site 
for O-glycosylation. Glycosylation, unlike protein synthesis is not a template driven process, but 
is dictated by glycosylation processing machinery consisting of sugar substrates, 
glycosyltransferases and glycosidases. N-glycosylation is the primary focus of this dissertation 
work and will be discussed in further details. 
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Figure 1.6: N-glycosylation biosynthesis pathway in humans and yeast. Enzyme abbreviations 
used in the figure are OST: Oligosaccharyltransferase, Man I/II: mannosidase, GnT: N-
acetylglucosaminyl transferase, GalT: galactosyltransferase, ST: sialyltransferase, ManT: 
mannosyltransferase. 
 
Human N-glycosylation biosynthesis is depicted in Fig.1.6 and is described below with 
limited details; more exhaustive information can be found elsewhere.60 N-glycosylation begins 
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on the cytosolic face of the endoplasmic reticulum (ER) by transfer of N-acetylglucosamine 
(GlcNAc) from UDP-GlcNAc onto dolichol-P-phosphate (lipid carrier). The initial GlcNAc-P-
dolichol is extended to Man5GlcNAc2-P-dolichol by addition of GlcNAc and Mannose sugars in 
glycosyltransferase reactions. This structure is then flipped across the ER membrane and into the 
luminal face of the ER. In the ER lumen, the structure is elongated to Glu3Man9GlcNAc2-P-
dolichol, which is then transferred from the dolichol carrier to the nitrogen atom of the Asn side 
chain with the help of a multi-subunit enzyme complex called oligosaccharyltransferase (OST). 
A glycosylation site on a protein may or may not be glycosylated, which generates copies of 
same protein with variable glycosylation site-occupancy, commonly referred as 
macroheterogeneity. 
The Glu3Man9GlcNAc2 structure on the protein is sequentially trimmed to Man9GlcNAc2 
by action of glucosidase I and II. Glucose trimming is critical for correct protein folding and is a 
part of protein quality control in the ER. Incorrectly folded proteins can be re-glucosylated and 
allowed to fold correctly. Chaperons such as calnexin and calreticulin are lectins that recognize 
glucose and help in the protein folding process.61 The Man9GlcNAc2 structure in a correctly 
folded protein is trimmed to a Man8GlcNAc2 structure by the removal of a terminal α-1,2 
mannose by ER mannosidase. Man8GlcNAc2 exits the ER and enters the golgi apparatus, where 
further trimming of mannose by mannosidase enzymes result in the Man5GlcNAc2 structure in 
the cis-golgi. At this point in humans, three different classes of N-linked glycans can be 
synthesized from the Man5GlcNAc2 glycan: high mannose, hybrid and complex types of glycan 
that share the common trimannosyl core (Fig. 1.7). High mannose glycans consist of all the five 
mannoses present in the Man5GlcNAc2 structure and may have additional mannose residues. 
Complex glycans consist of the trimannosyl core with GlcNAc attached to the α-1,3 and α-1,6 
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branches of the trimannosyl core and may have additional branching. Hybrid glycans consist of 
mannose residues on the α-1,6 branch (like high mannose glycans) but contains GlcNAc on the 
α-1,3 branch (like complex glycans).  
 
Figure 1.7: Types of N-glycan: high mannose, hybrid and complex  
For the formation of complex glycans, the Man5GlcNAc2 structure undergoes a series of 
step-wise glycoprocessing steps in the medial-golgi. First, a GlcNAc is added on the α-1,3 
branch of the Man5GlcNAc2 structure by N-acetyl glucosaminyl transferase I (GnTI) to produce 
hybrid glycan. This is then subjected to further mannose trimming by mannosidase II to cleave 
terminal α-1,3 and α-1,6 mannose residues to yield a GlcNAc1Man3GlcNAc2 structure. This 
structure is then converted to a complex-type glycan by addition of GlcNAc on the α-1,6 arm by 
GnTII. The resulting structure GlcNAc2Man3GlcNAc2 is referred to as the core heptasaccharide, 
a structural feature common to all the complex-type glycoforms.  
The core heptasaccharide structure can be further modified by galactose, bisecting 
GlcNAc, N-acetylneuraminic acid (Neu5Ac/sialic acid) and fucose in the trans-golgi (Fig. 1.8). 
The multiple glycan modifying enzymes and sugar substrates are localized across different golgi 
compartments which make biosynthesis of an N-glycan a highly complex process. The variable 
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addition of sugars on the core heptasaccharide results in microhetergeneity, which is the presence 
of different glycan structures (glycoforms) at the same site in different copies of the same 
protein. Additional branching to the biantennary structure generates tri- and tetra-antennary 
glycans, which introduces additional heterogeneity. The factors that control glycosylation are not 
fully understood, but glycosylation is believed to be a highly-regulated process. Factors like 
competition between glycoprocessing enzymes, availability of active-sugar donors, site-
accessibility, protein translocation rate, and golgi residence time contribute to this complex 
process.62  
 
Figure 1.8: Structure of a fully-processed complex-type glycoform. The variable addition of 
Fucose, bGlcNAc, Galactose and Sialic acid (marked by brackets) results in different glycoform 
structures.  
 
1.8 Importance of glycosylation on IgG and glycoengineering 
 
All the human IgG subclasses have a conserved N-glycosylation site at N297 in the CH2 
domain of the Fc. The majority of glycans at the N297 site are complex biantennary type with 
core fucose and a varying number of galactose, bisecting GlcNAc (bGlcNAc) and sialic acid 
sugar residues.63 There is also a minor presence of non-fucosylated complex biantennary glycans 
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with or without bisecting GlcNAc. High mannose and hybrid type glycans may also be present in 
trace amounts.64 Microheterogeneity from N297 glycosylation can produce over 30 different 
glycoforms. Changes in the IgG glycosylation pattern have been associated with physiological 
(such as age, pregnancy) and pathological conditions (such as autoimmune conditions and 
others).65 Altered glycoform distribution is well-characterized in autoimmune conditions, where 
elevated levels of agalactosylated glycoforms are found.66 The pro-inflammatory nature of 
agalactosylated IgG is hypothesized to be reflective of an overall increased inflammatory state in 
an autoimmune condition. In a contrasting scenario, increased levels of galactosylation and 
sialylation (suggested to have an anti-inflammatory activity) are found in pregnancy, where an 
increase in inflammatory state would be undesirable.67 With the success of antibody therapeutics, 
a significant amount of research work has focused on investigating the role of glycosylation on 
IgG effector functions.68-70 The outcome of these efforts has led to the development of antibodies 
with specific glycosylation patterns through glycoengineering approach to modulate immune 
responses. The following paragraph discusses the influence of variable sugar residues in complex 
glycans on the immune-related function of IgG.  
 Core fucosylation is addition of α-1,6 linked fucose to the first GlcNAc of the core 
heptasaccharide by fucosyltransferase. It is widely accepted that the removal of fucose from the 
N297 glycan in IgG1 significantly increases IgG1 affinity for FcγRIIIA and consequently its 
ADCC activity.71 This effect was also demonstrated for the other IgG subclasses but with 
different magnitudes of improvement.72 The molecular basis behind such an effect has been 
attributed to the formation of favorable glycan (Fc)-glycan (FcγRIIIA) contacts upon removal of 
fucose.73 Incidentally, more than 80% of the N297 glycans from serum IgG and IgG produced 
from CHO cells are fucosylated. Two approaches have been utilized to produce afucosylated 
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therapeutic antibodies that potentially have a higher in-vivo ADCC activity. The first approach 
involves deletion of the FUT8 gene in CHO cells that encodes for α-1,6 fucosyltransferase. The 
engineered CHO cell line was developed by Kyowa Hakko Kirin company and is presently used 
to produce mogamulizumab (currently approved in Japan, in clinical trial in US), the first 
marketed glycoengineered mAb. The second approach involves the overexpression of β-1,4 N-
acetylglucosaminyl transferase III (GnTIII), which adds a bisecting GlcNAc on the trimannosyl 
core. As a result, further addition of fucose is inhibited in CHO cells. This engineered CHO cell 
line was developed by Roche-Glycart and is used to produce obinutuzumab (approved in US).  
Originally, IgG glycoforms with bisecting GlcNAc were thought to have higher FcγRIIIA 
binding and ADCC activity, but it was later shown that this effect was largely due to lack of 
fucose rather than presence of bisecting GlcNAc.74 The evidence in literature for the role of 
galactose is conflicting. Some reports attribute higher ADCC activity to higher galactosylated 
forms of IgG, while others have suggested hypogalactosylated IgG to have more pro-
inflammatory activity. The presence of α-2,6 sialic acid has been shown to impart anti-
inflammatory activity to IgG. The suggested underlying mechanism behind such effect is 
attributed to upregulation of inhibitory FcγRIIB receptor upon binding of sialylated Fc to the 
SIGN-RI receptor in mice. These results are based on mouse models, and its applications in 
humans is currently contested.75 Producing antibodies with specific glycosylation patterns 
(glycoengineering) to engage specific immune response can be more beneficial than protein 
engineering strategies, since changes to the natural antibody sequence can be potentially 
immunogenic.  
1.9 Production of homogenously glycosylated proteins in the yeast Pichia pastoris 
 
Glycosylated antibodies have been traditionally produced in mammalian expression 
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systems. Commonly used mammalian cells are Chinese Hamster Ovary (CHO) and mouse 
myeloma cells (NS0 or SP2.0). The majority of therapeutic mAbs are produced in CHO cells, 
and these cells are considered as a reliable platform for industrial-scale mAb production.76 
Antibodies expressed in mammalian cells possess human-like glycosylation for the most part. 
The types of sugars and their linkages produced in non-human cell lines are very similar to 
humans; however, some non-human sugars can be still found in small amounts. For example, the 
SP2.0 or NS0 cells can produce α-1,3 galactose and N-glycolylneuraminic acid (Neu5Gc) sugars 
on IgG that are not found in humans. Also, antibodies expressed in mammalian cells exhibit 
microheterogeneity (like the endogenous antibodies), which is not suitable for investigating 
glycoform-dependent antibody properties.77 A few shortcomings of mammalian cell expression 
systems are high production cost, the requirement of complex growth media, slower growth, and 
a potential for viral contamination. To overcome these limitations, alternate expression systems 
using yeast, plant, and insect cells have been explored by researchers.  
Yeast is an attractive expression host because of lower production cost, faster growth 
times, high protein titers, and the ability to perform eukaryotic post-translational modifications 
like protein folding, disulfide bond formation and glycosylation.78 A major drawback of N-
glycosylation in yeast is that it produces hypermannosylated glycans, which are not found in 
humans (and hence immunogenic) and are recognized by macrophage mannose receptors leading 
to rapid clearance.79 The N-glycosylation biosynthesis pathway in yeast shares its initial steps (in 
the ER) with the human pathway (Fig. 1.6). The Man8GlcNAc2 structure synthesized in the yeast 
ER is similar to humans, but its further processing in the golgi is species dependent. In the yeast 
golgi, by action of an α-1,6 mannosyltransferase (encoded by OCH1 gene), α-1,6 mannose is 
added to the α-1,3 arm of the trimannosyl core. The resulting structure becomes a substrate for 
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other mannosyltransferases and ultimately generates a heterogeneous mixture of multi-branched 
hypermannosylated structures.79 Saccharomyces cerevisiae (baker’s yeast) and Pichia pastoris 
are the two commonly used yeast species for heterologous protein expression. P. pastoris is a 
preferred over S. cerevisiae due to lower levels of hypermannosylation and the absence of the α-
1,3 mannose linkage (a non-human linkage).78  
The last 15 years have witnessed significant advances in yeast N-glycosylation 
engineering to replace the native glycosylation pathway in the yeast with the human pathway. A 
breakthrough in yeast engineering efforts was achieved with the knock out of the OCH1 gene, 
first demonstrated in S. cerervisiae by the Jigami group80 and later in P. pastoris by the 
Contreras81 and Gerngross groups82. The OCH1 deletion in P. pastoris result in production of 
homogenous high mannose type of glycosylation consisting of mainly a Man8GlcNAc2 (Man8) 
structure. The Man8 structure was the starting point for introducing a human glycosylation 
pathway in yeast that produces fully-human, complex-type glycoforms, as shown by the 
Callewaert83 and Gerngross groups84. The humanization of the Pichia glycosylation pathway 
involves (i) introduction of genes that encode for various glycosidases and glycosyltransferases 
that allow trimming of mannose sugars and the addition of new sugars to synthesize complex 
glycoforms. These enzymes are localized to specific golgi compartments by use of appropriate 
signal peptides. (ii) expression of UDG-galactose and UDP-GlcNAc transporters to transfer 
sugars into the golgi.85 The glycosylation produced in the humanized Pichia was shown to be 
more homogenous than mammalian cell expressed IgG. Moreover, it provides a platform to 
produce antibodies with specific glycoforms as opposed to a mixture of glycoforms produced 
from mammalian cells.  
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Protein glycosylation is a post-translational modification that adds glycans to 
specific amino acid residues on proteins. It is well accepted that glycans play an 
important role in the cellular recognition and signaling functions of glycoproteins. 
Glycosylation exhibits a high degree of heterogeneity, which can be classified as macro- 
and micro-heterogeneity. Macroheterogeneity is generated by the variable occupancy of 
glycans at a glycosylation site. For a protein with multiple glycosylation sites, 
macroheterogeneity results in a mixture of fully, partially and non-glycosylated forms of 
the same protein. Microheterogeneity is generated from different glycoforms present at 
the same glycosylation site, which results in a heterogeneous mixture of the same protein 
but with different glycoforms.  
The immunoglobulin G (IgG) class of antibodies are glycoproteins, and their 
glycosylation analysis is a subject of immense interest since the glycans are linked to the 
biological functions of IgGs.1 All the four human IgG subclasses have a conserved N-
glycosylation site at N297 in the CH2 domain of the Fc region. For all of the IgG 
subclasses, the type of glycosylation found on the N297 site is mostly complex-
biantennary type of glycan, which is predominantly fucosylated and bears a variable 
number of sialic acid, galactose and bisecting GlcNAc residues.2 Glycosylation at the 
N297 site is essential for Fc-mediated effector functions such as binding to Fcγ receptors 
and C1q complement protein.3 Apart from the N297 site, N-glycosylation can also be 
found in the variable regions of  the Fab domains of about 15-25% of endogenous IgG.4 
There are no conserved N-glycosylation sites in the Fab domain but sites are generated as 
a result of somatic hypermutation. Glycosylation analysis of Fab domain glycans showed 
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higher levels of bisecting GlcNAc and sialylation and lower levels of fucosylation 
compared to the N297 site glycans from the Fc domain.5  
There is an additional unique glycosylation site at N392 in the CH3 domain of 
IgG3. This site has nearly gone unmentioned and remains under-investigated in the 
literature. Only recently, the N392 site has been shown to be partially glycosylated in 
human serum IgG3 by Stavenhagen et al.6 and the work described in this chapter. The 
Asn at the 392 position is not conserved across all the IgG3 allotypes as some IgG3 
allotypes and all the other IgG subclasses contain a Lys at that position. The Asn/Lys392 
difference in the 13 IgG3 allotypes is not a serologically-determined allotypic marker but 
is considered as a polymorphism that is present on 10 out of the 17 DNA sequence 
correlates of the IgG3 alleles that are known so far.7-8 The IgG3 sequence with Asn at 
position 392 is commonly accepted as the primary IgG3 sequence in the literature.  
Protein glycosylation is commonly characterized by mass spectrometry with a 
prior chromatographic separation (LC-MS).9-10 There are three approaches to characterize 
protein glycosylation: intact glycoprotein MS, glycan-based and glycopeptide-based MS 
analyses.11 The first approach involves molecular weight (MW) determination of intact 
glycoprotein, based on which the MW (and hence composition) of glycan can be deduced 
if the protein MW (i.e. its amino acid sequence) is known. The glycan-based approach 
involves release of glycans, either chemically or enzymatically, and their subsequent 
analysis. One drawback of this approach is that the information about the site of glycan 
attachment is lost, which is particularly important for glycoproteins with multiple 
glycosylation sites. For the glycopeptide-based approach, a glycoprotein is subjected to 
proteolysis to yield a mixture of peptides and glycopeptides, which can then be 
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chromatographically separated and detected by mass spectrometry. The advantage of this 
approach is that site-specific analysis of glycosylation is possible since the glycans 
remain attached to the peptides. Since MS analysis only provides the mass of 
glycopeptides, MS/MS analysis is often required for unambiguous glycopeptide 
assignment, particularly in the case of isobaric glycopeptides that differ in glycan 
composition or peptide sequence.12 For MS/MS analysis, a glycopeptide is selected and 
fragmented to provide detailed structural information. MS/MS with Collisional Induced 
Dissociation (CID) and Electron Transfer Dissociation (ETD) are often used together to 
provide complete and complementary glycopeptide structure information.13-14 CID 
provides glycan-specific information, whereas ETD provides peptide sequence 
information. Recently, an energy resolved CID fragmentation technique (application of 
differential collisional energy during MS/MS acquisition) has been developed that 
provides limited peptide sequence information in addition to the glycan-related 
information in a single MS/MS run.15-16   
In this chapter, the IgG3 subclass was isolated from a mixture of IgG subclasses 
obtained from human serum to investigate its glycosylation profile. LC-MS analysis 
revealed full glycosylation occupancy at the N297 site but only partial occupancy at the 
N392 site. Interestingly, the glycoform repertoire at the two sites showed significant 
differences in the levels of fucosylation and bisecting GlcNAc. The presence of 
glycosylation at the N392 site in endogenous human IgG3 suggests that this site is 
biologically relevant and thus makes a case for studying its influence on the structure, 




2.2.1 Isolation of IgG3 from human serum 
Gamma globulin from human serum (Sigma Aldrich, St. Louis, MO) was used as 
a source of human IgG3. IgG3 was purified from the mixture of IgG subclasses present in 
human gamma globulins using protein A and G affinity chromatographies, as per our 
previous work.17 Briefly, 100 mg of gamma globulin was passed over a protein A column 
to capture IgG1, IgG2, and IgG4 while IgG3 remained in the flow through. The captured 
IgG’s were then eluted, and the IgG3-containing flow through was passed one more time 
over the protein A column to capture any residual IgG1, 2, and 4 remaining in the flow 
through. The IgG3-containing flow through from the second protein A column pass was 
then passed over a protein G column to capture IgG3. The column was washed 
extensively, and IgG3 was eluted at pH 2.7 and immediately neutralized. IgG present at 
each step of the purification was checked by SDS-PAGE. The presence of IgG3 at the 
final step was confirmed by western blot using an anti-hIgG3 antibody-alkaline 
phosphatase conjugate (ThermoFisher, Waltham, MA).  
2.2.2 Deglycosylation of human serum IgG3 
Human serum IgG3 was treated with immobilized papain (Agarose resin, 
ThermoScientific) to digest IgG3 into Fab and Fc fragments. IgG3 was incubated with 
papain (E:S=1:80) in 20 mM sodium phosphate buffer, pH 7.0, 10 mM cysteine for 7 
hours at 37°C with shaking. The resulting Fc fragment was compared to a recombinantly 
IgG3 Fc fragment for the deglycosylation experiment. Deglycosylation was carried out 
using the PNGase F enzyme under non-denaturing and denaturing conditions (refer to 
chapter 3, section 3.2.3). The deglycosylated protein was detected by western blot using 
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an anti-human IgG Fc-alkaline phosphatase primary antibody.  
2.2.3 In-gel protease digestion  
The heavy and light chains of serum isolated IgG3 was separated using SDS-
PAGE under reducing conditions. The band corresponding to the heavy chain was 
excised, and used for in-gel protease digestion using protocol of Shevchenko et al.18 with 
some modifications. Briefly, the excised band was cut into smaller pieces, transferred to a 
microcentrifuge tube, and incubated with a washing solution of 0.2 M ammonium 
bicarbonate in 50% acetonitrile at 37°C for 45 min to completely remove the coomassie 
blue stain. The wash solution was discarded, and the gel pieces were allowed to air dry. 
The gel pieces were then incubated with 10 mM DTT in 100 mM ammonium bicarbonate 
with enough buffer to completely cover the gel pieces at 56°C for 30 min. The tube was 
brought to room temperature, and the DTT solution was discarded. The gel pieces were 
incubated with 55 mM iodoacetamide in 100 mM ammonium bicarbonate at room 
temperature for 20 min in the dark. Finally, the gel pieces were shrunk with neat 
acetonitrile for 20 min. Acetonitrile was removed, and the gel pieces were air dried. The 
gel pieces were treated with trypsin (1:50 ratio) and Asp-N (1:100 ratio) in 10 mM 
ammonium bicarbonate buffer at 37°C overnight. The gel pieces were then centrifuged, 
and the supernatant was used for mass spectrometry analysis.  
2.2.4 LC-MS analysis of N297 and N392 site glycosylation on human serum IgG3  
IgG3-digest samples were applied to a reverse phase (RP) column (C8, 
4.6x150mm, 300°A, Agilent, Santa Clara, CA) using a HPLC system (Agilent 1200). The 
column was equilibrated using 95% mobile phase A (water with 0.1% formic acid) and 
5% mobile phase B (acetonitrile with 0.1% formic acid) at 40°C at a flow-rate of 0.5 
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ml/min. A gradient elution to 45% B in 40 min and to 80% B in 10 min followed by an 
isocratic elution at 80% B for 3 min was employed. The HPLC was coupled online to an 
ESI-q-TOF mass spectrometer (Agilent 6520). The source parameters were as follows: 
drying gas of 11 L/min, capillary temperature of 350°C, and a voltage of 3.5 kV. The MS 
data was acquired using MassHunter acquisition software B.03 (Agilent) in a range of 
300-3000 m/z at the rate of 1 spectra/sec. For MS/MS, energy-resolved collision-induced 
dissociation (CID) was used for fragmentation of the selected glycopeptide precursor ion 
with collision energies of 40 eV and 20 eV. The data was analyzed using MassHunter 
qualitative analysis software B.03 (Agilent). For relative quantification of glycoforms, 
the peak intensity (of the most intense peak in the isotopic cluster) from the most 
abundant charge state of the glycopeptide/peptide was calculated.  
2.3 Results 
2.3.1 Isolation of IgG3 from human serum 
Human gamma globulin was used as a source of serum IgG consisting of the 
IgG1-4 subclasses purified from pooled human plasma. Protein G binds to all IgG 
subclasses, whereas protein A binds to all but IgG3. This selective binding property of 
protein A was used to purify IgG3 from the gamma globulin mixture of IgG subclasses. 
The IgG subclasses present at each step of purification were checked by SDS-PAGE (Fig. 
2.1A). The IgG mixture was loaded onto a protein A column to capture IgG1, 2, and 4 
while IgG3 remained in the flow through (first pass). The protein A-bound IgG’s were 
then eluted and the first-pass flow through was loaded again onto the protein A column to 
capture any remaining IgG1, 2, and 4. The second-pass flow through from the protein A 
column contained IgG3 with no notable presence of the other IgG subclasses, based on 
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SDS-PAGE. As an additional purification step for the collected IgG3, the flow through 
was passed over a protein G column. The column was washed extensively to remove any 
other contaminating serum proteins (that may be originally present in the gamma globulin 
starting material). IgG3 was eluted from the column, and its presence was confirmed by 
western blot using an anti-hIgG3 antibody (Fig. 2.1B). 
 
Figure 2.1: Isolation of IgG3 from gamma globulins. (A) SDS-PAGE (under reducing 
conditions) showing IgGs at each step of purification. Lanes 1: MW marker, 2: first-pass 
protein A flow through, 3,4: elution from protein A, 5: second-pass protein A flow 
through, 6: elution from protein G. The higher MW of IgG3 heavy chain is due to its long 
hinge. (B) western blot of isolated IgG3 using an anti-hIgG3-alkaline phosphatase 
antibody. The observed lower MW weights are likely from the heavy chain proteolysis.  
 
2.3.2 Checking occupancy of the N392 glycosylation site in human serum IgG3 
Human serum IgG3 was treated with the papain enzyme to convert full-length 
IgG3 to an Fc fragment (Fig. 2.2). The serum Fc fragment was compared with the yeast-
expressed IgG3 Fc fragment in a deglycosylation experiment to check for the occupancy 
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of the N392 site glycosylation in the serum sample. The results for deglycosylation of 
yeast-expressed WT IgG3 Fc (both N297 and N392 glycosylated) are described in detail 
in chapter 3, section 3.3.1. It was shown that glycans at the N392 site were cleaved by the 
PNGase F enzyme only under denaturing conditions but remained attached to protein 
under native deglycosylation conditions. This conclusion was drawn from the persistence 
of monoglycosylated band (in SDS-PAGE analysis) in the PNGase F treated yeast-
expressed Fc sample under non-denaturing conditions and its subsequent disappearance 
under denaturing conditions (Fig. 3.3). The serum Fc sample showed similar gel shifts as 
the yeast-expressed Fc, thereby indicating that the N392 site was also glycosylated in the 
serum sample (Fig. 2.3). A western blot was used for detection because extra bands in the 
serum Fc sample (likely from the light chain or proteolysis of the heavy chain) interfered 
with the observation of the coomassie-stained gel bands. Moreover, it was evident that 
the level of N392 glycosylation site occupancy in the serum sample was significantly 
lower than the yeast-expressed sample, as judged from the intensity of the 
monoglycosylated band.  
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Figure 2.2: Coomassie-stained SDS-PAGE under reducing conditions of papain-digested 




Figure 2.3: Western blot showing deglycosylated products of the serum IgG3 Fc and 
yeast-expressed WT IgG3 Fc following deglycosylation under reducing conditions with 
and without denaturation. An anti-hIgG Fc antibody-alkaline phosphatase conjugate was 
used to visualize the blot.  
 
2.3.3 LC-MS based site-specific glycosylation analysis of human serum IgG3  
The heavy chain band of serum IgG3 was excised from the SDS-PAGE gel and 
subjected to in-gel protease digestion to identify glycoforms at the N297 and N392 sites 
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using mass spectrometry. An in-gel digestion was performed to limit the peptide pool to 
contain only peptides of interest as the presence of any non-relevant peptides (from the 
light chains or other serum contaminant proteins) may suppress the ionization of the 
glycopeptides, especially those that are present at low levels. Two proteases, Asp-N and 
trypsin were used to produce peptides of varying lengths. Trypsin digest produces 9 and 
39 amino acid peptides at the N297 and N392 sites respectively. Asp-N digest produces 
32 and 23 amino acid peptides at the N297 and N392 sites respectively. Generating 
glycopeptides of varying sizes helped to confirm glycopeptide mapping results obtained 
from either of the digests. The digests were subjected to C8-LC-ESI-qTOF MS, and the 
glycoforms at the two sites were characterized. Both of the sites showed the presence of 
complex, biantennary glycans with an additional high-mannose glycan (GlcNAc2Man5 or 
Man5 glycoform) present only at the N392 site. No non-glycosylated N297 peptide was 
detected, whereas a prominent peak for the non-glycosylated N392 peptide was observed. 
The two sites showed a different repertoire of complex glycoforms with major 
differences in the levels of fucosylation and bisecting GlcNAc. The m/z spectra for the 
glycopeptides from the trypsin and Asp-N digests are shown in Figures 2.4 and 2.5, 
respectively. Table 2.1 shows the relative percentage of each glycoform at both the sites 
in the total N-glycan pool. A majority of glycans at the N297 site were core fucosylated 
(89.7% for the trypsin peptide, 90.1% for the Asp-N peptide), but no fucosylated glycans 
were detected at the N392 site. A majority of the N392 glycans contained a bisecting 
GlcNAc (75.5% from the trypsin peptide, 71.8% from the Asp-N peptide), while only 16-
17% of the N297 glycans contained bisecting GlcNAc. The N392 site showed higher 
levels of sialylation (~30%) than the N297 site (~21-24%). Interestingly, 11% of the 
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N392 glycans were of high mannose type (the Man5 glycoform). The glycosylation site 
occupancy at the N392 site was determined to be 9-10% based on the sum of intensities 
of all the N392 glycopeptides relative to the intensity of the N392 non-glycosylated 
peptide. Our results are in good agreement with the recently reported study on IgG3 
glycosylation characterization by Stavenhagen et al.6 
 
Figure 2.4: MS analysis of serum IgG3 glycopeptides from trypsin digest for (A) the 
N297 site (EEQFNSTFR) (B) the N392 site 
(GFYPSDIAVEWESSGQPENNYNPPMLDSDGSFFLYSK). The charge states for the 





Figure 2.5: MS analysis of serum IgG3 glycopeptides from Asp-N digest for (A) the 
N297 site (DGVEVHNAKTKPREEQFNSTFRVVSVLTVLHQ) (B) the N392 site 
(DIAVEWESSGQPENNYNPPML). The charge states for the N297 and N392 






Table 2.1: Relative abundances of glycoforms present at the N297 and N392 sites in 
human serum IgG3 from the trypsin and Asp-N digests. The peak height of the most 
abundant peak in the isotopic distribution was used to calculate the percentage. 
 








(trypsin) (Asp-N) (trypsin) (Asp-N) 
G1F 20.1 19.6   
G0F 18.9 19.1   
G2F 15.8 15.7   
G2SF 13.7 15.8   
G0bF 7.3 5.6   
G1SF 6.1 7.2   
G1bF 5.9 5.6   
G1 5.9 1.8  0.4 
G2bF 1.9 1.5   
G0 1.8 2.4   
G2S 1.3 1.3 1.2 1.2 
G1b 0.7 1.7 2.7 2.2 
G2b 0.8 2.8 1.7 1.7 
G2bS   1.5 1.3 
G0b   1.4 1.4 
Man5   1.2 1.0 
G1bS   0.4 0.3 
Total 100.0 100.0 10.2 9.6 
 
To further confirm and validate our MS results for glycopeptide assignment, a 
MS/MS experiment was performed on selected glycopeptides from the N297 and N392 
sites using energy-resolved CID fragmentation. Generally, CID with low collisional 
energy results in preferential cleavage at glycosidic bonds in a glycopeptide, while higher 
energy collision results in limited peptide backbone fragmentation with almost complete 
loss of glycan.15 The G1F and Man5 glycopeptides from the N297 and N392 sites 
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respectively were selected for fragmentation at 20 eV and 40 eV. The MS/MS spectra of 
the N392-Man5 glycopeptide at 20 eV collisional energy was dominated by product ions 
formed by fragmentation at glycosidic bonds with an intact peptide backbone (Fig. 2.6). 
The observed product ions confirmed the glycan composition and sequence of Man5 
glycoform. A small number of product ions from peptide backbone fragmentation were 
also detected in the spectra with a prominent peak for y152+ ion generated by C-terminal 
cleavage after two Pro residues. At a collisional energy of 40 eV, the spectra exclusively 
contained product ions resulting from only peptide backbone fragmentation. The MS/MS 
spectra for the N297-G1F glycopeptide showed a similar fragmentation pattern. The 
lower collisional energy spectra yielded product ions from which the composition of G1F 
glycoform can be confirmed. The product ions from peptide backbone fragmentation at 
higher collisional energy were found in very low abundances (Fig. 2.7). Both the MS/MS 
spectra showed characteristic sugar oxonium ions (Hex: m/z 203, Hex-GlcNAc: m/z 366, 
Hex2- GlcNAc: m/z 528), which are a good indicator for presence of glycans in the 
selected precursor ion.  
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Figure 2.6: MS/MS spectra for the N392-Man5 glycopeptide at (A) 20 eV and (B) 40 eV 
collision energy. A precursor ion with m/z of 1402.34, z=4 was selected for CID 
fragmentation.  
 
Figure 2.7: MS/MS spectra for the N297-G1F glycopeptide at (A) 20 eV and (B) 40 eV 







IgG3 accounts for 5-8% of  total serum IgG with serum levels of 0.5-1 mg/ml in 
adult humans.19 IgG3 is generally purified from plasma samples using a two step affinity 
purification procedure employing protein A and G chromatographies.2, 20 Theoretically, 
using only protein A (which doesn’t bind to IgG3) should be sufficient to purify IgG3 
from the human gamma globulins, but an additional protein G purification step (binds to 
IgG3) improves the quality of the isolated IgG3. An affinity chromatography step 
specific for IgG3 is particularly useful since human gamma globulin is prepared from 
plasma fractionation and can potentially have contamination from other co-purified 
serum proteins. 
The inability of the N392 glycans to be cleaved with the PNGase F enzyme under 
native conditions was clearly demonstrated in the yeast-expressed IgG3 Fc. This property 
served as a simple identification test to check for the presence of the N392 glycans in the 
serum IgG3 sample. Based on these results, it can be concluded that the N392 glycans in 
the yeast-expressed Fc exist in a similar environment as the naturally occurring N392 
glycans, and therefore yeast can be used as a suitable expression host for producing IgG3. 
Moreover, this distinct property of N392 glycans can be readily used to check the 
glycosylation occupancy at the N392 site for IgG3 expressed in different glycoprotein 
expression hosts such as mammalian and plant cells.  
LC-MS analysis of the N297 and N392 site glycopeptides showed the presence of 
complex biantennary glycans, with additional high mannose glycans only at the N392 
site. Complex and high mannose glycans are fully and partially processed forms 
respectively of the human glycan processing pathway in the golgi. The two sites showed 
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differences in the glycan repertoire (Table 2.1), where a major difference was seen in the 
levels of fucosylation and bisecting GlcNAc accompanied by a minor difference in the 
sialylation level. These results clearly indicate that the two sites show differences in the 
extent of glycan processing. The protein structure near to N-glycan sites can affect site 
occupancy, glycan type and glycan processing.21 The fucosylation/bisecting GlcNAc 
difference can be explained on the basis of two factors. First, a glycan modified with 
bisecting GlcNAc is a poor substrate for α-1,6 fucosyltranferase (an enzyme that adds 
fucose to the first GlcNAc).22 Second, lower levels of fucosylation are observed for 
shielded glycosylation sites than accessible ones.21 Glycosylation site accessibility 
differences between the N297 and N392 sites in IgG3, based on IgG3 Fc structural 
analysis are presented in chapter 5, section 5.3.9. 
The glycosylation pattern found at the N392 site resembles closely the pattern of 
Fab glycosylation. Fab glycosylation has been shown to have higher levels of glycans 
with bisecting GlcNAc, galactose, sialic acid, and high mannose, but also to have low 
levels of core fucose.5 The biological significance of Fab glycosylation is still unclear, 
but it is generally thought to affect antigen binding, half-life and stability of antibodies. 
The level and glycosylation pattern of Fab glycosylation was found to be sensitive to 
physiological and pathological conditions like pregnancy and auto-immune conditions 
respectively, indicating a possible immunomodulatory role.4 Based on this, the N392 
glycans of IgG3 can be hypothesized to involved in an unknown 
physiological/pathological condition.  
The N392 site glycosylation is only partially glycosylated with about 10% site-
occupancy, whereas the N297 site was found to be completely glycosylated. Based on 
 50
this, if we assume that the formation of an Fc dimer is independent of N392 glycosylation 
site occupancy at one heavy chain of the Fc (and considering 100% occupancy at N297 
site), it can be deduced that approximately 1% of endogenous IgG3 has all four sites 
glycosylated (tetraglycosylated) and about 18% (2*9%, considering N392 site is 
glycosylated on either of the heavy chains) of IgG3 has three sites glycosylated. There 
are mannose-binding receptors in mammalian tissues that clear glycoproteins with 
terminal mannose sugars.23 Since the Man5 glycoform is detected at the N392 site, it may 
be possible that the actual N392 site-occupancy is higher when IgG3 is produced by B 
cells but low levels are detected in the circulating IgG3 due to faster clearance of IgG3 
with the Man5 glycoform.  
N-linked glycosylation is initiated in the ER when oligosaccharyl transferase (a 
large heteromeric membrane protein complex) adds a sugar precursor 
(Glu3Man9GlcNAc2) to an Asn residue in the sequence Asn-Xaa-Ser/Thr (where X = any 
aa except proline). Amino acids around the sequence can affect this process by 
potentially altering  the local conformation or by interfering with the enzyme active site.24 
A striking example is the presence of proline residue immediately following the N-linked 
glycosylation sequence, resulting in a severe impairment of glycosylation efficiency. A 
survey of glycosylation site-occupancy on a large dataset of glycoproteins showed that 
only 50% of glycoproteins with the N-X-T-P sequence are glycosylated.25 It must be 
noted that some of these 50% glycosylated sequences may be actually partially 
glycosylated. In another report, glycosylation efficiency was estimated at the N-X-T-Y 
sequence by expressing a model glycoprotein with different amino acids at the Y 
position. Efficiency was around 10% for the Pro residue, whereas it was 81%-93% for all 
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the other residues.24 The N392 site (N392TTPPML) in IgG3 has two Pro residues 
following the glycosylation sequence, and that may contribute to its low site-occupancy. 
Thus, the differences in glycosylation occupancy and the type of glycans present at the 
N297 and N392 sites in IgG3 indicate a likely difference in the local protein structure 
around these sites. A higher level of site-occupancy at the N392 site was detected in the 
yeast-expressed IgG3 Fc fragment (chapter 3, section 3.3.1) compared to serum IgG3. 
This variation could be either due to differences in the oligosaccharyl transferase (OST) 
complex between yeast and human, size of the expressed protein (full-length IgG3 from 
serum vs. Fc fragment in yeast) or state of the cell producing glycoprotein (human B cells 
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Chapter 3 Production and characterization of human IgG3 Fc 
expressed in glycosylation-deficient strains of the yeast Pichia 




The biological activity of human IgG3 is equivalent to human IgG1, which is the most 
studied and therapeutically used IgG subclass. IgG3 mediates Antibody Dependent Cellular 
Cytotoxicity (ADCC) activity as efficiently as IgG1 and elicits the strongest Complement 
Dependent Cytotoxicity (CDC) among the IgG subclasses.1-2 All IgG subclasses have a 
consensus N-glycosylation site at N297 in the CH2 domain of the Fc region. The presence of 
glycosylation at the N297 site is critical for effector functions like ADCC and CDC.3-4 There is 
an extensive body of work on IgG1 glycosylation and how it influences its effector functions.5-7  
However, the role of N297 glycosylation on the effector functions of IgG3 subclass is under 
represented in the literature. Interestingly, there is an additional N-glycosylation site at N392 in 
the CH3 domain of the consensus sequence8 of IgG3 that is not present in any other subclass. 
Whether the N392 site is glycosylated or not in the naturally occurring endogenous IgG3 was not 
known for a long time. Only recently, the Wuhrer group9 and the Tolbert lab (Chapter 2) 
discovered partial glycosylation occupancy at the N392 site in human serum IgG3. This 
discovery makes the N392 site biologically relevant, but its role in IgG3 structure and function 
remains to be investigated. Given the importance of the N297 site glycosylation on IgG1 and the 
similarities in the effector functions of IgG1 and IgG3, it is of interest to evaluate the influence 
of N297 and N392 site glycosylation on the properties of IgG3. For carrying out such a study, it 
is necessary to produce IgG3 Fc with well-characterized glycosylation as a starting point. 
In this chapter, heterologous expression of the IgG3 Fc fragment in the glycosylation-
deficient yeast Pichia pastoris is described. Two versions of IgG3 Fc were produced, a WT and 
mutant IgG3 Fcs, where the N392 site was mutated to other amino acids. The expressed proteins 
were extensively characterized with respect to glycosylation at the N297 and N392 sites. Site-
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specific glycosylated variants of IgG3 Fc were produced: one with both the sites glycosylated 
(tetraglycosylated/Fc dimer) and other with only the N297 site glycosylated (diglycosylated/Fc 
dimer). These IgG3 Fc glycovariants were used to study the influence of N392 glycosylation on 
IgG3 Fc-Fc receptor binding and physical stability assessment of IgG3 Fc (Chapter 4) and 
structure of IgG3 Fc (Chapter 5). 
One of the advantages of using the glycosylation-deficient yeast P. pastoris to express 
antibody fragments is the relatively homogenous nature of its glycosylation. The yeast strain 
used in this study produces high mannose glycans comprising mainly of Man8-Man12 
(GlcNAc2Man8-12) glycoforms. However, there are some of drawbacks as well which include 
lower glycosylation site-occupancy and modifications of high mannose glycans such as mannose 
phosphorylation, β-mannosylation and incomplete removal of capping glucose residues. The 
yeast expression conditions can influence the levels of glycosylation site-occupancy and 
modified high mannose glycans, as we have seen some variability in the glycosylation pattern for 
the protein expressed in spinner flask (less controlled fermentation conditions) vs. fermentor 
expression (more controlled). In contrast to yeast expression, mammalian cells such as CHO 
cells produce complex glycans (found in humans) that exhibit a high degree of micro-
heterogeneity.10 The micro-heterogeneity is not well-suited for studies that focus on 
characterizing the effect of a single, specific glycoform on antibody immune functions. The high 
mannose glycans produced in the yeast can be converted to the complex-type glycans using two 
approaches. The first approach involves introduction of a new set of genes in the yeast secretory 
pathway that replicates the human glycoprotein biosynthesis.11-12 Whereas, the second approach 
involves producing high mannose glycans produced in yeast that are then modified through a 
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series of enzymatic in-vitro glycan processing steps that will ultimately generate complex-type 
glycans (Fig. 3.1).  
The Tolbert lab has adopted the second approach to produce IgG Fc with specific 
glycoforms since this approach allows for greater control over glycan processing and does not 
involve extensive genetic manipulation of yeast. The first step in the in-vitro glycan processing is 
the conversion of the high mannose glycans (Man8-Man12) to the Man5 (GlcNAc2Man5) 
glycoform using an α-1,2 mannosidase enzyme. Complete conversion to the Man5 glycoform is 
necessary since the undigested high mannose glycans will compromise the homogeneity of the 
glycoform produced at each step in the enzymatic pathway. Other groups have shown that P. 
pastoris can produce low levels of modified high mannose glycans that are not a substrate for α-
1,2 mannosidase. These modified glycans contains non-cleavable linkages (for α-1,2 
mannosidase enzmye) such as mannose-phosphate-mannose, β-mannose or capping glucose 
residues.13-16 Researchers have previously shown that some of these modifications can be 
reduced by knocking out specific genes in P. pastoris.12, 17 Based on this information, the 
members of the Tolbert lab knocked out additional genes (in addition to OCH1 gene) involved in 
the yeast glycosylation pathway. These genes include PNO1 and BMT1-2, whose gene products 
are responsible for phophomannosylation and β-1,2 mannosylation of high mannose glycans, 
respectively.18-19 The endomannosidase enzyme was used to convert glucosylated high mannose 




Figure 3.1: In-vitro enzymatic synthesis of Man5, hybrid and complex glycans from high 
mannose glycans. Man8-Man12 glycoforms are produced on glycoproteins expressed in the 
glycosylation-deficient (OCH1 KO) P. pastoris. The enzyme used at each step is indicated. 
 
The work herein investigates the pattern of high mannose glycans produced on IgG3 Fc-
N392K (chosen as a model system) expressed in different glycosylation-deficient strains of P. 
pastoris and its susceptibility to α-1,2 mannosidase digestion. These strains differ in the type of 
the glycosylation-related genes that are disrupted (Table 3.1). The α-1,2 mannosidase digestion 
efficiency was substantially improved upon deletion of the PNO1 and BMT genes. Additionally, 
a strategy to produce the Man5 glycoform in-vivo during protein expression was also carried out 
by introducing α-1,2 mannosidase activity to the yeast glycosylation pathway. 
Table 3.1: List of P. pastoris strains used for IgG3 Fc expression 
P. pastoris strain Gene(s) deleted Gene added 
Single KO OCH1 - 
Double KO OCH1, PNO1 STT3D 




High Mannose Hybrid Complex






2. N-acetylglucosamine transferase I (GnTI)
3. α-mannosidase II
4. N-acetylglucosamine transferase II (GnTII)
5. β-1,4 galactosyl transferase 
6. Sialyl transferase





3.2.1 Cloning of IgG3 Fc  
 
The cDNA of the Fc region of hIgG3 (ATCC: MGC-45809, accession: BC033178) was 
used as a template for PCR amplification. The forward and reverse primers used were 5’-
GGCCCGCTCGAGAAAAGAACATGCCCACGGTGCCCAGCA-3’ and 5’-
GGGCCCGCGGCGGCCGCTCATTTACCCGGAGACAGGGAGAG-3’, respectively. The 
primers were designed such that the Fc has a truncated hinge with only two disulfide bonds 
(from exon1: ELKTPLGDTTHT225CPRCP) instead of the natural hinge with 11 disulfide bonds 
(from additional exons 2,3 and 4). The designed construct codes from Thr225 to Lys447 according 
to EU numbering.21 The amplified DNA and Pichia pastoris expression vector pPICZαA were 
treated with EcoRI and NotI and then ligated using T4 DNA ligase. This cloning procedure was 
performed by Mark Pawlicki, a former Tolbert group member. For IgG3 Fc mutants, IgG3 Fc 
with N392K and N392Q mutations were produced using the QuickChange II site-directed 
mutagenesis kit (Agilent). The forward and reverse mutagenesis primers for N392K mutant were 
5’- GCAGCCGGAGAACAACTACAAAACCACGCCTCC-3’ and 5’- 
GGAGGCGTGGTTTTGTAGTTGTTCTCCGGCTGC-3’, respectively.  The forward and 
reverse mutagenesis primers for N392Q mutant were 5’- 
CAGCCGGAGAACAACTACCAAACCACGCCTCCCA-3’ and 5’- 
TGGGAGGCGTGGTTTGGTAGTTGTTCTCCGGCTG-3’, respectively. The WT and mutant 
IgG3 Fc plasmids were transformed into Top10’F by electroporation and selected on low-salt LB 
plates with 25 µg/ml zeocin. The colonies were screened by PCR for the presence of the insert 
and positive colonies were sequenced to ensure that no mutation occurred. The confirmed 
plasmid was purified from the colony and linearized with SacI for transformation into a 
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glycosylation-deficient P. pastoris yeast strain with OCH1 deletion (SMD1168)22. Additionally, 
the constructs were also transformed into two additional yeast strains produced during the course 
of this research: one with OCH1 and PNO1 deletion (double KO) and the other with OCH1, 
PNO1, BMT1 and BMT2 deletion (quadruple KO). Additionally, the STT3D gene from 
Leishmania major was added to the double and quadruple KO strain to improve the glycosylation 
site-occupancy.23 Transformants were selected on YPD pates with 100 µg/ml zeocin. Colonies 
were checked for protein expression on a small scale (2ml) and high expressing colonies were 
chosen for large-scale protein expression.  
3.2.2 Expression and purification of WT and mutant IgG3 Fc 
 
The frozen stocks of the yeast expressing WT and mutant IgG3 Fcs were used to 
inoculate starter cultures in 2 ml of YPD media with 100 μg/ml zeocin incubated at 25°C for 72 
hours with shaking. These starter cultures were used to produce the different forms of IgG3 Fc 
using the following general procedure. A 2 ml culture was used to inoculate a 50 ml YPD/zeocin 
culture in a shake flask for 1 L spinner flask expression or into a 250 ml YPD/zeocin culture in a 
baffled shake flask for fermentor expression. For spinner flask expression, the 50 ml culture was 
incubated for 72 hours and used to inoculate a 1 L of buffered glycerol-complex media (BMGY) 
containing 0.00004% biotin and 0.004% histidine in an aerated spinner flask. After about 60 
hours, protein expression was induced by the addition of methanol to a final concentration of 1% 
for three days. For the fermentor expression, the 250 ml culture was used to inoculate 7 L of 
fermentation basal salt media (BSM). The fermentation conditions and protein induction was 
carried out according to the method previously published by the Tolbert group.24  At the end of 
fermentation, the supernatant was separated from cells by centrifugation and was clarified. The 
supernatant was passed over a protein G affinity chromatography column, pre-equilibrated with 
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20 mM potassium phosphate buffer pH 6.0. The column was extensively washed with 20 mM 
potassium phosphate buffer pH 6.0, 500 mM NaCl, and the protein was eluted using 100 mM 
glycine-HCl buffer pH 2.7. The protein was immediately neutralized using 1 M Tris-HCl pH 9.0 
and dialyzed against 50 mM sodium phosphate buffer pH 7.0 for the next step. The purified WT 
and mutant IgG3 Fcs were analyzed by SDS-PAGE under reducing and non-reducing conditions.  
3.2.3 Deglycosylation of IgG3 Fc 
 
The WT and mutant IgG3 Fc were subjected to deglycosylation using the PNGase F 
enzyme under both non-denaturing and denaturing conditions. For the non-denaturing condition, 
the enzyme was directly added to the sample and incubated overnight at room temperature. For 
the denaturing condition, the sample was first denatured and reduced by adding 0.5% SDS and 
40 mM DTT. The sample was then incubated at 95°C for 10 min followed by cooling at room 
temperature. To prevent the SDS from inactivating PNGase F, NP-40 was added to a final 
concentration of 1%. Finally, PNGase F was added and the sample was incubated overnight at 
room temperature. The deglycosylated samples were analyzed by SDS-PAGE. 
3.2.4 LC-MS analysis of IgG3 Fc  
 
Glycosylation analysis of IgG3 Fc was carried using intact protein and glycopeptide 
mapping mass spectrometry. For intact MS, the sample (0.2 mg/ml) was reduced using a final 
concentration of 10 mM DTT. The electrospray ionization spectra of the reduced sample were 
acquired on an Agilent 6520 QTOF. The instrument was operated in positive ion mode and 
spectra were acquired covering mass range from 300-3000 m/z with acquisition rate of 1 
spectra/second. The samples (60 ul injections) were desalted on a reverse phase C4 column, 
50mm, 4.6mm I.D. (Vydac 214MS, 300 A pore size, 5 um particle size) using Agilent 1200 
series liquid chromatography system. The solvents used were A (99.9%H2O, 0.08% formic acid, 
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0.02% TFA) and B (99.9% acetonitrile, 0.08% formic acid, 0.02% TFA). A gradient was 
developed from 5% B to 90% B in 7 min with a flow rate of 0.5 ml/min. Intact MW was 
determined by maximum-entropy deconvolution function using an Agilent MassHunter software 
(version B.03). The percentage of each glycoform in the total N-glycan pool was calculated 
using peak intensities. For the glycopeptide mapping, the sample (0.5 mg/ml) was denatured 
using 0.1% SDS-PAGE, reduced using 50 mM DTT with incubation at 60 °C for 45 min, and 
alkylated using 100 mM iodoacetamide solution with incubation in the dark at room temperature 
for 30 min. The protein was then precipitated by cold absolute ethanol (1:10 v/v protein:ethanol) 
and kept at -20°C for overnight. The protein pellet was recovered after centrifugation and was 
washed with neat acetonitrile. Finally, the pellet was air-dried and re-dissolved in 200 μl of 50 
mM ammonium bicarbonate and 10 μg of trypsin (Promega, Madison, WI). The sample was 
incubated at 37°C for overnight, and the digest solution was used for glycopeptide analysis. IgG3 
Fc-digest samples were applied to a RP column (C8, 4.6x150mm, 300°A, Agilent, Santa Clara, 
CA) coupled to Agilent 6520 ESI-QTOF.  The column was equilibrated using 95% mobile phase 
A (water with 0.1% formic acid) and 5% mobile phase B (acetonitrile with 0.1% formic acid) at 
40 °C at a flow-rate of 0.5 ml/min. A gradient elution to 45% B in 40 min and to 80% B in 10 
min followed by an isocratic elution at 80% B for 3 min was employed. The ESI source 
parameters were as follows: drying gas of 11 L/min, capillary temperature of 350°C, and a 
voltage of 3.5 kV. The MS data was acquired using MassHunter acquisition software B.03 
(Agilent) in a range of 300-3000 m/z at the rate of 1 spectra/sec. The data was analyzed using 
MassHunter qualitative analysis software B.03 (Agilent). 
3.2.5 Preparation of IgG3 Fc glycovariants 
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IgG3 Fc glycovariants with site-specific glycosylation were purified from WT and 
mutant IgG3 Fc using hydrophobic interaction chromatography (HIC). A 75 ml column packed 
with phenyl sepharose high-performance (GE healthcare, UK) and AKTAmicro chromatographic 
system was used. The samples were dialyzed in Buffer A (50 mM sodium phosphate buffer, pH 
7.0, 1 M ammonium sulfate), and the column was pre-equilibrated in the same buffer. Separation 
was conducted in three gradient segments: 0% to 35% buffer B (50 mM sodium phosphate 
buffer, pH 7.0) in 5 CV, 35% to 50% B in 15 CV and to 100% B in 5 CV. 8 ml fractions were 
collected and checked for purity and identity of the glycovariant present by SDS-PAGE. The 
fractions containing a single glycovariant were pooled and checked by SDS-PAGE and mass 
spectrometry. 
3.2.6 In-vitro enzymatic modification of glycosylation 
 
The high mannose glycosylation on WT and mutant IgG3 Fc was converted to the Man5 
glycoform in an in-vitro enzymatic reaction using B.t. α-1,2 mannosidase (Bt 3990 from B. 
thetaiotamicron) with a 1:10 enzyme : protein ratio (w/w).25 The Bt3990 expression plasmid was 
gifted by the Gilbert laboratory at the Newcastle University. The proteins were extensively 
dialyzed in 10 mM MES, 150 mM NaCl, 5 mM CaCl2, pH 6.6 (reaction buffer) before starting 
the reaction. The reaction was incubated at room temperature for 72 hours. The progress of the 
reaction was monitored by intact protein MS. The percent conversion to the Man5 glycoform 
was calculated from the peak intensities obtained from the deconvoluted spectra. Separately, rat 
endomannosidase was used in combination with α-1,2 mannosidase under the same reaction 
conditions. The enzyme was produced in the Tolbert laboratory as follows: the gene (accession # 
NM_080785) encoding for the catalytic domain20(Asp60-Ser463) of rat endomannosidase was 
synthesized by Genscript. The construct was subcloned into pET28a using restriction enzymes 
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EcoRI and NotI and placed downstream of the N-terminal His6 tag in the vector. The enzyme 
was expressed in E.coli Rosetta 2 and purified using Ni2+-NTA affinity chromatography. The 
percentage conversion to Man5 glycoform was compared between digestion with α-1,2 
mannosidase alone and in combination with endomannosidase to check for contribution of the 
endomannosidase in mannose trimming.  
 
3.2.7 In-vivo enzymatic modification of glycosylation 
 
For introducing α-1,2 mannosidase activity into the yeast secretory pathway, members of 
the Tolbert laboratory cloned a murine mannosidase IA26 in the P. pastoris vector pPIC6αA with 
a N-terminal HDEL tag27 for retention in the endoplasmic reticulum. The linearized pPIC6αA-
mannosidase IA was transformed into the double KO (OCH1 and PNO1 KO) strain, and 
transformants were selected using blasticidin marker. The resulting strain with in-vivo α-1,2 
mannosidase activity was used to express WT and mutant IgG3 Fc. The mannose trimming 
efficiency of the strain was evaluated by intact protein MS analysis to check the type of 
glycosylation produced by these strains. 
  
3.3 Results  
 
3.3.1 Expression and purification of WT IgG3 Fc and mutant IgG3 Fc 
 
The glycosylation-deficient yeast strain with the OCH1 KO was used to express both the 
WT and mutant IgG3 Fc (N392K/Q) in a spinner flask or a fermentor. Additionally, the proteins 
were also expressed in the double and quadruple KO yeast strains (Table 3.1). The average yield 
per liter of expression for all the proteins was about 20 mg and 50 mg in spinner flask and 
fermentor, respectively. The Fc proteins were purified by protein G affinity chromatography and 
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analyzed by SDS-PAGE to assess the quality and the glycosylation state of the purified protein. 
Partial glycosylation site-occupancy was observed at both glycosylation sites, N297 and N392, 
irrespective of the yeast strain utilized, but an improvement in site-occupancy was observed in 
the double and quadruple KO strains due to introduction of the STT3D gene (data not shown). 
Since the Fc is a homodimer formed by disulfide bonds in the hinge, partial site-occupancy in the 
WT IgG3 Fc generated macro-heterogeneity that resulted in a mixture of the tetra-, tri-, di-, and 
mono-glycosylated Fc under non-reducing conditions. This mixture resulted in di-, mono-, and 
non-glycosylated monomers under reducing conditions (Fig. 3.2). Similarly, for both of the IgG3 
Fc-N392K/Q mutants, macro-heterogeneity resulted in di-, mono-, and non-glycosylated Fc 
under non-reducing conditions and corresponding mono- and non-glycosylated monomers under 
reducing conditions (Fig. 3.2). The intensities of the di- and mono-glycosylated WT IgG3 Fc 
monomers appears to be approximately equal upon visual assessment. Based on this, if we 
assume that formation of Fc-dimer is independent of Fc monomer glycosylation, then it can be 
deduced that nearly 50% of the WT IgG3 Fc mixture is tri-glycosylated and each of the tetra- 





Figure 3.2: Coomassie-stained SDS-PAGE for IgG3 Fc purified from yeast under (A) non-
reducing conditions and (B) reducing conditions. Lanes: (1) WT IgG3 Fc (2) IgG3 Fc-N392K (3) 
IgG3 Fc-N392Q (C) Schematic representation of glycovariants from the WT and mutant IgG3 Fc 
under reduced and non-reduced conditions.  
 
To verify if the multiple bands seen on SDS-PAGE were due to glycosylation related 
macro-heterogeneity, the Fc protein was subjected to deglycosylation under non-denaturing and 
denaturing conditions using the PNGase F. The outcome of the deglycosylation experiment was 
assessed by SDS-PAGE. Deglycosylation under non-denaturing and reducing condition for IgG3 
Fc-N392K resulted in the collapse of the mono-glycosylated band to the non-glycosylated band, 
suggesting that the N297 site glycans were labile to deglycosylation under the conditions used 
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(Fig. 3.3). Same treatment for the WT IgG3 Fc resulted in the loss of the di-glycosylated 
monomer band but persistence of the mono-glycosylated band, thereby implying that the N392 
site glycans are resistant to deglycosylation under non-denaturing/native conditions. 
Deglycosylation of WT Fc IgG3 Fc under denaturating conditions resulted in loss of the mono-
glycosylated band, which indicates that the N392 glycans are only cleaved if the protein is in an 
unfolded state (Fig. 3.3). This characteristic property was used to check if the N392 site was 
glycosylated in human serum IgG3 Fc, as described in chapter 2, section 2.3.2. Identical results 
for deglycosylation were observed for the WT IgG3 Fc and mutant IgG3 Fc expressed in the 
double and quadruple KO yeast strains.  
 
Figure 3.3: Coomassie stained SDS-PAGE showing deglycosylated products of the WT IgG3 Fc 
and IgG3 Fc-N392K under reducing conditions with and without denaturation. 
 
3.3.2 LC-MS analysis of the expressed WT and mutant IgG3 Fc 
 
The MW and glycosylation pattern of WT IgG3 Fc and IgG3 Fc-N392K expressed in 
different P pastoris yeast strains were determined by intact protein mass spectrometry. 
Incomplete site occupancy for the expressed protein was also evident in the MS spectrum as 
previously observed with SDS-PAGE. The IgG3 Fc-N392K expressed in the OCH1 KO strain 
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showed a peak corresponding to the non-glycosylated Fc and another set of peaks corresponding 
to high mannose glycoforms (GlcNAc2Man8-12 abbreviated as Man8-Man12) at the N297 site. 
Additional peaks with mass additions of 80 Da were also detected between the peaks 
corresponding to Man9-Man12 glycoforms (Fig. 3.4A). The +80 Da modification was 
determined to be present on the glycan and not the protein, since the MS spectrum for 
deglycosylated protein did not show this modification. The +80 Da peaks (expected average 
mass change for phosphorylation is +80 Da) may correspond to phosphorylated high mannose 
glycoforms (Man9P-Man11P), since it has been previously shown to occur on glycoproteins 
expressed in P. pastoris.18 The total percentage of phosphomannosylated glycans was 
determined to be 7.5% in the total N297 glycan pool based on their peak intensities. The level of 
phosphomannosylation varied between 4 to 7.5% for different batches of IgG3 Fc-N392K Fc 
expressed in a spinner flask. Higher levels of up to 12% were detected in the fermentor-
expressed protein. The WT IgG3 Fc expressed in same the P. pastoris strain showed a non-
glycosylated Fc peak and two sets of peaks; the first set showing glycoforms present on one of 
the two glycosylation sites (monoglycosylated monomer) and a second set showing glycoforms 
present on both the glycosylation sites (diglycosylated monomer) (Fig. 3.5A). The +80 Da peaks 
were also detected in both sets of peaks, but it is not possible to ascertain if 
phosphomannosylation occurred at one of the two sites or at both the sites of WT IgG3 Fc, based 
on intact protein MS analysis. From intact protein MS analysis of both the proteins, it is evident 
that the predominant glycoform present in the distribution of high mannose glycoform is the 
Man8 glycoform at both the glycosylation sites.  
Intact protein MS analysis of WT IgG3 Fc and IgG3 Fc-N392K expressed in the double 
OCH1 PNO1 KO strain showed a similar set of peaks as the OCH1 KO strain but with no 
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detectable levels of +80 Da peaks. This suggests that PNO1 disruption eliminated or reduced 
phosphomannosylation of high mannose glycans to a negligible level (Fig. 3.4-3.5B). Both the 
proteins expressed in the quadruple KO strain showed same set as peaks as seen in the double 
KO strain (Fig. 3.4-3.5C, Table 3.1). The BMT set of genes in Pichia adds β-1,2 linked mannose 
sugars in the high mannose glycans produced by Pichia.19 The intact protein MS cannot 
distinguish between the α- and β-linked mannose and therefore no differences in the 
glycosylation pattern produced by the double and quadruple KO strain were observed by mass 
spectrometry.   
 
Figure 3.4: Intact protein mass spectra of IgG3 Fc-N392K expressed in different glycosylation-
deficient strains of P. pastoris (Table 3.1) under reducing conditions. A set of peaks 
corresponding to high mannose glycoforms present at the N297 site and the non-glycosylated 
protein are observed due to incomplete glycosylation site-occupancy. Accompanying table 




Figure 3.5: Intact protein mass spectra of WT IgG3 Fc expressed in different glycosylation-
deficient strains of P. pastoris (Table 3.1) under reducing conditions. Two sets of peaks 
corresponding to high mannose glycans on one (monoglycosylated) or both (diglycosylated) 
glycosylation sites of WT IgG3 Fc along with a non-glycosylated protein peak are observed due 
to incomplete glycosylation site-occupancy. Accompanying table shows calculated mass for the 
WT IgG3 Fc glycoforms detected in the spectra. *NG: non-glycosylated 
 
The glycosylation pattern at the two glycosylation sites in WT IgG3 Fc (expressed in the 
OCH1KO strain) was additionally characterized by (glyco)peptide mapping to identify 
glycoforms specific to the N297 and N392 sites. The distribution of high mannose glycoforms on 
the respective glycopeptides from both the sites was similar to that observed in intact protein MS 
analysis. Interestingly, the level of phosphomannosylation was found to be higher at the N392 
site compared to the N297 site. A striking difference in the level of phosphomannosylated Man8 
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(Man8P) glycopeptide between the two sites was clearly visible in the spectra (Fig. 3.6). 
 
Figure 3.6: Site-specific characterization of glycosylation on WT IgG3 Fc expressed in the 
OCH1 KO P. pastoris. Peptide map showing high mannose glycans at the (A) N297 
glycopeptide and (B) N392 glycopeptide. The insets show isotopic cluster of the glycopeptide 
with Man8 glycoform. Glycopeptides from the N297 and N392 sites bear +2 and +4 charge 
states, respectively. 
 
3.3.3 Producing IgG3 Fc glycovariants with site-specific glycosylation 
 
To study the influence of N392 site glycosylation, it is necessary to produce Fc with the 
N297 and N392 sites glycosylated (tetraglycosylated/Fc dimer) and compare it with Fc that only 
has the N297 site glycosylated (diglycosylated/Fc dimer). Glycovariants from the WT IgG3 Fc 
(tetra-, tri-, di-glycosylated forms) were separated by phenyl sepharose chromatography (HIC) 
with partial resolution (Fig. 3.7). Variants with higher site-occupancy were eluted before the 
lower site-occupied variants under HIC elution condition. Each fraction was checked by SDS-
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PAGE to determine the fractions that contained only a single glycovariant. Fractions showing 
only tetra and tri-glcyosylated variants were pooled separately. Only a limited number of 
fractions with pure triglycosylated IgG3 Fc were recovered since it eluted between the tetra- and 
di-glycosylated forms without complete resolution. In a similar manner, the diglycosylated 
variant (with only N297 site glycosylated) from the IgG3 Fc-N392K/Q Fc was purified from the 
mixture of di-, mono- and non-glycosylated variants. These purified IgG3 Fc glycovariants will 
be used for Fc receptor binding studies and biophysical characterization (Chapter 4) and 
structural studies (Chapter 5). 
 
Figure 3.7: (A) Hydrophobic interaction chromatography (HIC) trace for WT IgG3 Fc and IgG3 
Fc-N392K. Representative IgG3 Fc glycovariant associated with elution peaks is shown besides 
each peak. (B) SDS-PAGE (under non-reducing conditions) shows the homogeneity of the 
produced IgG3 Fc glycovariants. Lane (1) WT IgG3 Fc mixture (2) tetra- and (3) tri-glycosylated 









3.3.4 In-vitro glycan processing of high mannose glycans on IgG3 Fc 
 
 
Figure 3.8: Conversion of high mannose glycans (GlcNAc2Man8-12/Man8-Man12) to Man5 
(GlcNAc2Man5) glycoform. 
 
High mannose glycans (GlcNAc2Man8-12/Man8-Man12) were found to be present at both 
the glycosylation sites in IgG3 Fc, irrespective of the yeast strain used. The conversion of high 
mannose glycans to complex type glycoforms through a series of in-vitro enzymatic 
glycoprocessing steps has been previously shown in the Tolbert lab (Fig. 3.1). The first step in 
this glycoprocessing scheme is conversion of the high mannose glycans to the Man5 glycoform 
by cleavage of α-1,2 linked mannoses (Fig. 3.8). Digestion of the IgG3 Fc-N392K expressed in 
the OCH1 KO strain with α-1,2 mannosidase yielded only 78% of Man5 glycoform in the total 
glycan pool (Fig. 3.11A). Among the undigested high mannose glycans, about 10% of the 
glycans were phosphomannosylated and the rest were presumably glycans that were resistant to 
α-1,2 mannosidase. High mannose glycans on glycoproteins expressed in P. pastoris that are 
resistant to α-1,2 mannosidase have been previously reported in the literature. These undigested 
glycans can be either phophomannosylated28, have β-linked mannose instead of α-linked 




















Figure 3.9: Structures of α-1,2 mannosidase resistant high mannose glycans (A) putative 
structure of a phosphomannosylated glycan (B) β-1,2 mannose present on α-1,3 arm of high 
mannose glycan (C) capping glucose on the α-1,3 arm of high mannose glycan structure. 
Chemical structures of phosphodiester bond between mannose residues and α- and β-linked 
mannoses are shown. Although the phosphate group shown here is between α-1,6 linked 
mannoses, it is not known for certain if phosphates are present in this linkage only.  
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In order to achieve a high level of conversion to the Man5 glycoform, it is necessary to 
eliminate these modified glycans. For this purpose, two additional yeast strains with an existing 
OCH1 KO background were generated: one with the disrupted PNO1 gene (double KO) and 
another with the disrupted PNO1, BMT1, BMT2 genes (quadruple KO). The PNO1 and BMT 
genes in P. pastoris are responsible for phosphomannosylation18 and β-1,2 mannosylation of 
glycans19, respectively. There are other genes such as MNN4B that are thought to be involved in 
mannose phosphorylation and have been deleted by other groups to reduce mannose 
phosphorylation.29-30 To remove the capping glucose residues that may be present on high 
mannose glycans, the IgG3 Fc-N392K was treated with an endomannosidase enzyme, whose 
enzyme product is a substrate for the α-1,2 mannosidase (Fig. 3.10). As a result of these efforts, 
an improvement in the yield of Man5 glycoform was observed. The IgG3 Fc-N392K expressed 
in the double KO strain yielded 92% Man5 glycoform after digestion with α-1,2 mannosidase 
and endomannosidase (Fig. 3.11B). An increase of up to 2% for conversion to the Man5 
glycoform was observed by using two enzymes versus using α-1,2 mannosidase alone. The IgG3 
Fc-N392K expressed in the quadruple KO strain yielded 96% of the Man5 glycoform upon 
digestion with two enzymes (Fig. 3.11C). The percentage of the Man5 glycoform was 
determined after correcting for the contribution of a single O-mannose glycan (O-glycosylation) 
present on the protein, which shares its MW with an undigested Man6 glycoform. The 
percentage of a single O-mannose glycan on IgG3 Fc-N392K was estimated to be 3% and 4.5% 
for the protein expressed in the double and quadruple KO strains, respectively. Estimation of the 
O-mannose was based on the intact protein MS peak intensities after digestion of the protein 
with PNGase F, which only cleaves N-glycans but not O-glycans. These results indicate that a 
significant improvement in the conversion of the N297 high mannose glycans to the Man5 
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glycoform can be achieved by eliminating the modified high mannose glycans produced by 
Pichia.  
 
Figure 3.10: Conversion of glucosylated high-mannose glycans to the Man5 glycoform. 
Endomannosidase cleaves α-1,2 mannosidic bond between two mannoses, where one of the 
mannose is linked to glucose residue. An endoglycosidase (like endomannosidase) cleaves inside 
a glycan structure), whereas an exoglycosidase (like B.t. α-1,2 mannosidase) cleaves terminal 
monosaccharide, which in this case is blocked by additional glucose residues. 
Digestion of WT IgG3 Fc with α-1,2 mannosidase resulted in an almost complete 
truncation to the Man5 glycoform at only one of the two sites, while incomplete truncation was 
observed at the other site (Fig. 3.12). Since it was previously determined that the N297 high 
mannose glycans in IgG3 Fc-N392K were converted to more than 95% of the Man5 glycoform, 
it can be implied that incomplete truncation occurred at the N392 site in the WT IgG3 Fc. As a 
result, a distribution of Man5-Man12 glycoforms at the N392 site was observed in the intact 
protein mass spectra (Fig. 3.12).  
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Figure 3.11: Intact protein MS spectra of IgG3 Fc-N392K expressed in different glycosylation-
deficient strains of P. pastoris (Table 3.1) under reducing conditions after α-1,2 mannosidase and 
endomannosidase digestion. The insets show magnified spectra for the undigested Man6-Man11 
glycoforms matched to the original spectra. Accompanying table shows observed and calculated 




Figure 3.12: Intact protein MS spectra of WT IgG3 Fc under reducing condition (A) before and 
(B) after α-1,2 mannosidase digestion. The set of peaks in (A) correspond to high mannose 
glycoforms on both sites of Fc (labeled with two glycoforms) and only one of the two sites of Fc 
(labeled with one glycoform). The peaks in (B) are labeled assuming complete truncation to 
Man5 glycoform at the N297 site and partial truncation at the N392 site based on results obtained 
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for IgG3 Fc-N392K (>95% truncation). Accompanying table shows calculated masses of the WT 
IgG3 Fc glycans detected in the spectra. 
  
An attempt to produce the Man5 glycoform directly out of yeast in place of the high 
mannose glycans was carried by introducing α-1,2 mannosidase activity in the yeast 
glycosylation pathway. This was performed by localizing the gene that expresses murine α-1,2 
mannosidase (mannosidase IA) in the yeast ER so that the high mannose glycans exiting the ER 
are trimmed by the enzyme and converted to Man5 glycoform.27 The IgG3 Fc-N392K expressed 
in the double KO strain with this additional enzyme showed less than 50% of Man5 glycoform in 
the total N-glycan pool at the N297 site. This result indicated that the in-vivo mannosidase 
activity showed poor mannose trimming efficiency compared to the in-vitro digestion. It must be 
noted that enzyme used in the two conditions belonged to different species; a bacterial α-1,2 
mannosidase (BT3990) for the in-vitro condition and a mammalian (murine) α-1,2 mannosidase 
for the in-vivo condition. Moreover, a striking difference in the level of Man5 glycoform was 
observed for IgG3 Fc-N392K expressed in a spinner flask (~17%) versus a fermentor expression 
(~44%) (Fig. 3.13). The WT IgG3 Fc expressed in the same strain (with an in-vivo α-1,2 
mannosidase) also showed incomplete mannose trimming at both the glycosylation sites.  
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Figure 3.13: Intact protein MS spectra of IgG3 Fc-N392K expressed in P. pastoris with in-vivo 
α-1,2 mannosidase activity in (A) spinner flask and (B) fermentor expression. The fermentor 
expressed protein showed a higher percentage of Man5 glycoform than the spinner flask 
expressed protein. Accompanying table shows observed and calculated mass for the IgG3 Fc-
N392K glycans observed in each spectra. *NG: non-glycosylated 
 
The high mannose glycans (Man5-Man15) present in the IgG3 Fc-N392K expressed in 
the strain with in-vivo α-1,2 mannosidase activity were subjected to in-vitro digestion with α-1,2 
mannosidase alone and in combination with endomannosidase. An improvement in conversion to 
the Man5 glycoform was observed with two enzyme digestion (~76%) compared to digestion 
with α-1,2 mannosidase alone (~70 %) (Fig. 3.14). In comparison, a modest 1-2% increase in 
conversion to the Man5 glycoform was observed with two enzyme digestion for the same protein 
expressed in the strain without the in-vivo α-1,2 mannosidase. This result led us to believe that 
there was a larger fraction of glucosylated high mannose glycans (that are only digestible with 
endomannosidase) produced by the yeast which is modified with an in-vivo α-1,2 mannosidase. 
A visual comparison of the undigested glycans from the single versus double enzyme digest 
show that the level of undigested Man8 glycoform (although present at low level) was reduced in 
the case of the two enzyme digest (Fig. 3.14). Based on this, it could be proposed that the 
endomannosidase enzyme might be digesting the Man8 glycoform (that remained undigested 
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after digestion with α-1,2 mannosidase) and thereby result in an increased conversion to the 
Man5 glycoform.  
 
Figure 3.14: Intact protein MS spectra of IgG3 Fc-N392K expressed in P. pastoris with in-vivo 
α-1,2 mannosidase activity after in-vitro digestion with (A) only α-1,2 mannosidase (B) α-1,2 
mannosidase and endomannosidase. Arrow points the difference in level of the undigested Man8 
glycoform from the two digestion reactions. 
 
 
 To conclusively determine if endomannosidase is digesting the Man8 glycoform, it is 
preferable to have IgG3 Fc-N392K with higher levels of Man8 glycoform and use that to test 
endomannosidase activity. This was achieved by fractionating the phenyl sepharose 
chromatography elution peak for the diglycosylated IgG3 Fc-N392K, wherein the larger high 
mannose glycans (Man8-Man15) elute earlier than the smaller high mannose glycans (Man5-
Man8) (Fig. 3.15). Fig 3.16 shows MS spectra for distribution of the high mannose glycans in the 
collected pools from the elution peak. It is clearly visible that pool 1 contained largest fraction of 
larger high mannose glycans (including Man8 glycoform) and therefore was an ideal substrate to 




Figure 3.15: Fractionation of phenyl sepharose elution peak of IgG3 Fc-N392K expressed in P. 
pastoris with in-vivo α-1,2 mannosidase activity. The elution peak was fractionated into four 
pools as shown in the figure.  
 
 
Figure 3.16: Intact protein MS spectra of the pools collected from fractionated phenyl sepharose 
chromatography of IgG3 Fc-N392K expressed in P. pastoris with in-vivo α-1,2 mannosidase 
activity. (A) distribution of glycans before separation; (B-E) distribution of glycans in the 
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collected pools (1-4) from the elution peak as shown in Fig. 3.15. Pool 1 shows highest level of 
larger mass high mannose glycans or lowest percentage of Man5 glycoform 
 
Digestion of the protein collected from pool 1 with only endomannosidase produced a 
largest decrease in the level of Man8 glycoform with a concomitant increase in the level of Man6 
glycoform (Fig. 3.17). In a separate experiment, the protein from pool 1 was digested with α-1,2 
mannosidase with and without endomannosidase to evaluate the overall contribution of 
endomannosidase in mannose trimming. The level of undigested Man8 glycoform in the only α-
1,2 mannosidase digestion reaction (~12%) was significantly reduced in the case of the digestion 
with both enzymes (~2%) (Fig. 3.18). The double enzyme digest increased the Man5 conversion 
by nearly 18%. Based on these results, it can be concluded that endomannosidase digests the 
Man8 glycoform to either the Man5 glycoform directly or to the Man6 glycoform, which can 
then be further digested by α-1,2 mannosidase to produce the Man5 glycoform. Consequently, if 
that interpretation is true, it can be implied that the composition of the Man8 glycoform is 
actually Glu1-2Man6-7GlcNAc2 and not Man8GlcNAc2. From a yeast expression perspective, 
these results indicate that higher levels of glucosylated high mannose glycans are produced by 





Figure 3.17: Intact protein MS spectra of IgG3 Fc-N392K Fc expressed in P. pastoris with in-
vivo α-1,2 mannosidase. Spectra (A) before and (B) after in-vitro digestion with 
endomannosidase Accompanying table shows percentages for each glycoform (GF) calculated 




Figure 3.18: Intact protein MS spectra after in-vitro digestion of IgG3 Fc-N392K Fc expressed in 
P. pastoris with in-vivo α-1,2 mannosidase. Spectra (A) before digestion (B) after digestion with 
α-1,2 mannosidase (C) after digestion with α-1,2 mannosidase and endomannosidase. 
Accompanying table shows percentages for each glycoform in (B) and (C) calculated based on 





3.4.1 Production and characterization of IgG3 Fc expressed in yeast P pastoris 
 
There are several reports in literature that describe recombinant expression of IgG3 in 
mammalian cells, wherein glycosylation at the N297 site is characterized, but there is no mention 
of the N392 site or its glycosylation occupancy.31-34 It is possible that these researchers failed to 
identify the second glycosylation site in the IgG3 sequence or didn't detect glycans at the N392 
site owing to its partial site-occupancy. A rare closely related example is that of an IgG1/IgG3 
hybrid antibody (with region around the N392 site from IgG3) showing about 10% glycosylation 
occupancy at the N392 site with presence of only Man6 glycoform.35 Interestingly, no 
glycosylation was detected in the serum isolated IgG3 or the recombinantly expressed IgG3 
antibody in the same study. We have expressed the WT and mutant IgG3 Fc (N392K/Q) in a 
glycosylation-deficient strain (OCH1 KO) of yeast P pastoris. The IgG3 Fc-N392K mutant was 
chosen since Lys is present at the 392 position in some of the natural allotypes of IgG3 as well as 
in the other IgG subclasses. The Gln in N392Q closely resembles Asn and is a good surrogate for 
IgG3 that is not glycosylated at the 392 position with a minimal change to the IgG3 Fc structure. 
Although partial glycosylation site-occupancy was observed at the N297 and N392 sites in IgG3 
Fc, it is demonstrated for the first time that the N392 site in recombinantly expressed IgG3 was 
glycosylated. Our group24 and other researchers36 have previously reported partial site-
occupancy at the N297 site in Pichia expressed IgG1 Fc. Thus, IgG3 Fc produced in yeast was 
suitable to conduct experiments that focus on glycosylation at the N297 site and more 
importantly at the N392 site.  
Digestion of IgG3 Fc with PNGase F enzyme with and without prior protein denaturation 
revealed differences in the susceptibility for deglycosylation at the N297 and N392 sites. The 
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N297 site glycans were cleaved at a much faster rate than the N392 site glycans in the native 
state of the protein. The N392 site glycans were readily cleaved in the unfolded state. The N297 
site the glycans in the IgG1, IgG2 and IgG4 subclasses are also cleaved without denaturation. 
This distinct property of the N392 site glycans serves as a simple identification test for checking 
its occupancy and possibly sheds light on its location in the protein structure. The PNGase F 
enzyme completely cleaves the glycan off the N-glycosylation site by cleaving between the first 
GlcNAc and Asn residue, acting close to the protein backbone (Fig. 3.19). The N392 site is 
located at the edge of CH3-CH3 dimerization interface and it might be inaccessible to the enzyme 
(more details in Chapter 5, section 5.3.9).  
 
Figure 3.19: Reaction mechanism of PNGase F. The amide bond of β-aspartylglycosylamine is 
hydrolyzed to produce glycosylamine (which is further hydrolyzed) and Asp residue. 
Due to the incomplete glycosylation site-occupancy, a mixture of glycovariants is 
produced from expression of WT IgG3 Fc (tetra-, tri-, di-, and mono-glycosylated) and IgG3 Fc-
N392K/Q (di-, mono-, and non-glycosylated). To independently investigate the effect of each 
glycosylation site on protein properties, it is essential to separate these individual glycovariants. 
The IgG1 Fc glycovariants (resembling the IgG3 Fc-N392K/Q) were previously separated in the 
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Tolbert lab using phenyl sepharose chromatography (HIC).24 Likewise, the tetra-, tri-, di-
glycosylated IgG3 Fc from WT IgG3 Fc were partially separated using HIC. Only a limited 
quantity of the pure triglycosylated variant was recovered since it eluted between the other two 
variants. Moreover, since the amount of diglycosylated variant recovered from the WT IgG3 Fc 
chromatography was insufficient and the associated ambiguity (as to where the glycans are 
located), the diglycosylated variant was purified from HIC of IgG3 Fc-N392K/Q Fc. Thus, using 
HIC and site-directed mutagenesis, IgG3 Fc glycovariants with the both sites glycosylated 
(tetraglycosylated) and with only the N297 site glycosylated (diglycosylated) were produced.  
Intact protein MS analysis of the WT and mutant IgG3 Fc showed micro-heterogeneity at 
both of the glycosylation sites. High mannose glycans with predominantly the Man8 glycoform 
along with low levels of Man9-Man12 glycoforms were detected at both the sites. Such 
distribution of glycan is commonly observed in glycoproteins expressed in the OCH1 disrupted 
P. pastoris.37 The OCH1 gene in the WT P. pastoris is responsible for addition of α-1,6 mannose 
to the α-1,3 arm of high mannose glycoforms and formation of hypermannosylated glycans (Fig. 
1.6). Glycopeptide mapping confirmed the presence of phosphomannosylation of glycans at both 
of the sites. Interestingly, a higher level of phosphorylated glycans was detected at the N392 site 
compared to the N297 site. This suggests that the phophomannosylation activity during 
glycoprotein biosynthesis in P. pastoris may be affected by the protein structure surrounding the 
glycosylation site. This is consistent with the results from site-specific glycosylation 
characterization of human serum IgG3, where glycoprocessing activity related to fucosylation 




3.4.2 In-vitro glycan processing of high mannose glycosylation on IgG3 Fc 
 
The N-glycosylation biosynthesis pathway begins in the ER with the transfer of a 
preassembled oligosaccharide Glu3Man9GlcNAc2 to the Asn of N-glycosylation site by the 
oligosaccharyltransferase (OST) complex (Fig. 1.6).38 The Glu3Man9GlcNAc2 is sequentially 
converted to Man8GlcNAc2 (Man8) by glucosidases and α-1,2 mannosidase in the ER. The 
resultant Man8 glycoform is processed by divergent pathways in the golgi of yeast and humans. 
In humans, Man8 is first converted to the Man5 glycoform, which undergoes further mannose 
trimming and ultimately matures into complex glycoforms through a series of glycan processing 
steps (Fig. 1.6).39 In the OCH1 deleted strain of yeast P. pastoris, the Man8 glycoform transits to 
the golgi, where additional α-1,2 mannoses may be added to the initial Man8 structure by golgi 
α-1,2 mannosyltranferase.37 As a result, the glycosylation produced by the OCH1KO strain is 
mainly comprised of the Man8-Man12 glycoforms. Our lab is interested in understanding the 
effect of glycosylation on antibody immune functions by changing the glycosylation on 
antibodies and assessing their impact. Under this approach, the high mannose glycosylation 
produced by the yeast will be converted to hybrid and complex type glycoforms using 
glycoprocessing enzymes (Fig.3.1). Such stepwise conversion of glycoforms will produce 
antibody fragments with a single specific glycoform, as opposed to a mixture of glycoforms, 
commonly seen with antibodies expressed in mammalian cell lines.  
The first step in the in-vitro high mannose glycan processing is the conversion of the 
Man8-Man12 glycoforms to the Man5 glycoform using the α-1,2 mannosidase enzyme. Only 
78% conversion to the Man5 glycoform (at the N297 site) was achieved for the IgG3 Fc 
expressed in the OCH1KO strain. Complete conversion to the Man5 glycoform is highly 
desirable since the undigested high mannose glycans (α-1,2 mannosidase resistant glycans) 
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compromise the homogeneity of the glycoforms produced at each step of glycoprocessing. The 
α-1,2 mannosidase resistant high mannose glycans on glycoproteins expressed in P. pastoris 
have been previously reported in the literature. Such glycans can be either be phosphorylated,28 
have a capping glucose sugar,20 or contain β-linked mannose.15 We have eliminated or reduced 
these modified high mannose glycans on the expressed glycoproteins by introducing additional 
gene disruptions in P. pastoris and using an endomannosidase enzyme to achieve a higher level 
of conversion to the Man5 glycoform.  
Prior studies have reported phosphomannosylation of high mannose glycans in some 
glycoproteins expressed in P. pastoris.13-14 The phosphate group was determined to be present in 
a phosphodiester linkage between two mannose units and hence resistant to alkaline 
phosphatases.14 One of the genes responsible for phosphomannosylation activity in P. pastoris 
was identified as PNO1 (Phosphomanosylation of N-linked Oligosaccahrides).18 The PNO1 gene 
was inactivated in the glycoengineered yeast strains developed by the Gengross12 28 and 
Contreas11 groups to produce antibodies with complex-type glycosylation. The Tolbert group has 
previously deleted the PNO1 gene in an IgG1 Fc expressing yeast strain, and the expressed 
protein in this strain showed no detectable levels of phosphomannosylation.24 The level of 
phosphomannosylated high mannose glycans (estimated from intact protein MS) in the IgG3 Fc 
was between 4 to 12%, which is an impediment to the conversion of high mannose glycans to the 
Man5 glycoform since phosphomannosylated glycans are not a substrate for α-1,2 mannosidase. 
Disruption of the PNO1gene proved to be beneficial since a significant increase in the level of 
Man5 glycoform after α-1,2 mannosidase digestion was achieved. 
Under normal N-glycosylation processing in the ER, the three glucose residues from the 
Glc3Man9GlcNAc2 precursor are cleaved by glucosidases. An alternate deglucosylation pathway 
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was proposed to be present in the golgi by the action of endomannosidase enzyme, which cleaves 
α-1,2 mannosidic bond between two mannoses, where one of the mannose is linked to glucose. 
This pathway would process the glucosylated N-glycans that have escaped the ER glucosidase 
machinery and thereby generate a substrate for the golgi α-1,2 mannosidase for continued 
production of complex glycoforms.40 It was previously reported that digestion of high mannose 
glycans produced in P. pastoris with endomannosidase resulted in trimming of high mannose 
glycans, thereby implying that glucosylated high mannose glycans can be produced by P. 
pastoris.20 Based on this information, it was possible that some proportion of the α-1,2 
mannosidase resistant high mannose glycans on the IgG3 Fc were glucosylated since 
glucosylated high mannose glycans are not a substrate for α-1,2 mannosidase. To check this, 
IgG3 Fc-N392K was digested with endomannosidase to produce deglucosylated glycans that can 
now be a substrate for α-1,2 mannosidase. A minor increase of 1-2% in conversion to the Man5 
glycoform with additional use of endomannosidase suggests that P. pastoris can produce low 
levels of glucosylated high mannose glycans.  
The other potential α-1,2 mannosidase resistant high mannose glycans produced in Pichia 
are high mannose glycans that have mannose sugars in a β-linkage instead of an α-linkage.15 The 
β-l,2 mannosyltransferase activity in P. pastoris was determined to be under the influence of 
BMT (BMT1-3) genes.19 It was shown that the disruption of three BMT genes (BMT 1-3) results 
in no detectable levels of β-linked mannose in the high mannose glycans.17 Based on this 
information, the Tolbert lab initiated the deletions of the BMT genes. A quadruple KO strain 
with additional BMT1, BMT2 KO on an existing strain with OCH1 KO and PNO1 KO was 
generated. The conversion to the Man5 glycoform upon digestion of IgG3 Fc-N392K (expressed 
in quadruple KO starin) with α-1,2 mannosidase and endomannosidase improved by nearly 4% 
 90
compared to the strain without BMT deletions. We did not identify the nature of the mannose 
linkage in our expressed proteins, but an increase in the conversion to the Man5 glycoform does 
indicate that some proportion of the high mannose glycans produced by P. pastoris contain 
mannose residues in β-linkage. 
Introduction of α-1,2 mannosidase activity in the P. pastoris glycosylation pathway was 
first demonstrated by the Contreras11 and Gengross12 groups while working on re-engineering the 
yeast glycosylation pathway. The Contreras group attached a tetrapeptide HDEL as an ER 
retention/retrieval tag to the C-terminus of α-1,2 mannosidase to localize the enzyme in the ER. 
They used a fungal α-1,2 mannosidase from Trichoderma reesi under the control of GAP 
promoter (constitutive expression), while the model glycoprotein was under AOX1 promoter 
(inducible expression).27 Complete trimming of α-1,2 mannose was reported in this study. The 
Tolbert lab used HDEL ER retention signal fused to a mouse mannosidase enzyme (mannosidase 
IA) under the control of AOX1 promoter. Man1A was used since it was previously shown to be 
expressed in P. pastoris in an active form.26 Only partial trimming of α-1,2 mannoses was 
observed for IgG3 Fc-N392K Fc expressed in yeast with in-vivo α-1,2 mannosidase activity 
suggesting a suboptimal enzyme activity. It is possible that the level of enzyme expression was 
insufficient for complete mannose trimming. The higher percentage of trimming for the 
fermentor-expressed protein is likely due to more consistent and controlled enzyme induction (by 
methanol addition rate) in the fermentor compared to the expression in a spinner flask. This 
disparity may suggest that the availability of the enzyme might be one of the limiting factor in 
mannose trimming. Further studies to produce Man5 in-vivo needs to be carried out by trying 
another retention signal and/or using α-1,2 mannosidase from a different species. More 
information about of these approaches can be found elsewhere.41-42  
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The partially truncated high mannose glycans of IgG3 Fc-N392K expressed in yeast with 
in-vivo mannosidase activity were further subjected to an in-vitro digestion with α-1,2 
mannosidase and endomannosidase for complete truncation to the Man5 glycoform. From this 
finding, it was concluded that significantly higher levels of glucosylated high mannose glycans 
(~10%) were produced by the yeast modified with in-vivo mannosidase activity compared to the 
unmodified yeast (~1-2%).  In the unmodified yeast, glucoses on high mannose glycans are 
trimmed by ER glucosidases during glycoprotein biosynthesis. In the modified yeast, an 
additional α-1,2 mannosidase activity is introduced in the ER that is not natural to the yeast. It 
may be possible that this may impair the ER glucosidase activity and cause the glucosylated 
glycans to end up in the golgi. To circumvent this issue, α-1,2 mannosidase from a different 
species (enzyme from rat species was used in our studies) can be tried or alternatively the α-1,2 
mannosidase activity can be introduced in the early golgi compartment instead of the ER.  
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Chapter 4 Influence of N392 site glycosylation on Fc receptor interactions 






















 Fcγ receptors play a central role in linking the humoral and cellular components of an 
antibody-mediated immune response. The activating and inhibitory Fcγ receptors present on the 
surface of leukocytes regulate cellular responses by binding to the Fc region of IgG.1-2 FcγRIIIA 
is one of the activating Fcγ receptors expressed on the surface of immune cells such as NK cells, 
macrophages, monocytes, and mast cells. Notably, the NK cells in most people3 exclusively 
express FcγRIIIA on their surface and are considered as an important mediator of Antibody 
Dependent Cellular Cytotoxicity (ADCC). NK cell mediated ADCC activity is believed to be an 
important mechanism of action for many therapeutic monoclonal antibodies.4 Two polymorphic 
variants of FcγRIIIA exist, the high affinity FcγRIIIA-V158 and low affinity FcγRIIIA-F158, 
which shows marked difference in the their IgG binding capacities.2 FcγRIIIA polymorphism 
also affects the clinical outcome of therapeutic antibodies, whose mechanism of action involves 
binding to FcγRIIIA as patients homozygous for the V158 variant respond better than patients 
homozygous for the F158 variant.5  
 Not only is glycosylation at the N297 site in IgG necessary for interaction with Fcγ 
receptors, but the type of glycosylation also influences the strength of the interaction.6-7 It is now 
well established that the removal of core fucose at the N297 site in IgG1 significantly increases 
its affinity to FcγRIIIA and results in an enhanced ADCC activity.8 This discovery has led to 
commercialization of afucosylated therapeutic antibodies, which are potent activators of NK-cell 
mediated ADCC. Examples of glycoengineered antibodies (described in detail in chapter 1, 
section 1.8) for cancer therapy are Mogamulizumab (approved in Japan in 2012)9 and 
Obinutuzumab (approved in US in 2013)10. IgG1 subclass has been extensively characterized for 
its glycosylation-dependent Fcγ receptor binding profile, however there is limited functional 
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characterization of glycosylation on the other human IgG subclasses. The IgG3 subclass is 
particularly important since it is known to interact as efficiently as IgG1 with most of the Fcγ 
receptors, while IgG2 and IgG4 subclasses show reduced affinity to majority of the Fcγ 
receptors.11 Most of the previous studies on IgG3-FcγRIIIA binding were performed using a 
heterogeneous mixture of IgG3 glycoforms.11-13 Such studies provided little information about 
any glycosylation-specific Fcγ receptor binding properties of IgG3. Moreover, the influence of 
N392 site glycosylation on Fc receptor binding remains under-investigated in the literature.  
The neonatal Fc receptor, FcRn, is involved in the placental transfer of maternal IgG to 
fetus and the prolonged half-life of circulating serum IgG and albumin.14 FcRn is primarily 
expressed in the vascular endothelial cells where it binds to IgG that are internalized via 
pinocytosis in the acidic endosomes. The bound IgG are recycled back to circulation by 
dissociating from the receptor at physiological pH. FcRn-mediated rescue prevents lysosomal 
degradation of antibodies and thereby maintains their long circulating half-life.15 FcRn binds to 
the CH2-CH3 domain interface of Fc in a strict pH-dependent manner.16 The half-lives of the 
IgG1, IgG2, and IgG4 subclasses are 21 days, while for the IgG3 subclass it is 7 days.17 The 
lower half-life of IgG3 has been attributed to a single amino acid difference, R435 in IgG3 vs. 
H435 in the other IgG subclasses.18-19 The occupancy of the N297 glycosylation site and type of 
glycosylation present does not appear to affect FcRn binding and is located away from the FcRn 
binding site. The N392 glycosylation site in IgG3 is located near the FcRn binding site; however, 
its influence on FcRn binding remained unknown at the start of these studies. The IgG3 Fc 
glycovariants produced as described in chapter 3 were used in this chapter to evaluate the 
influence of N392 glycans on binding to the FcγRIIIA and FcRn.    
 99
 Antibodies are complex protein molecules whose preservation of higher-order structure is 
critical for their biological activity. Antibodies, like other proteins, encounter various physical 
and chemical instabilities during production, storage, shipping, and patient administration that 
may compromise the efficacy of the drug.20 Therefore, it is essential to deliver the antibody drug 
in a stabilized formulation that would minimize the instability risks. Examples of physical 
instability are aggregation, precipitation, conformational changes, and unfolding.21 Biophysical 
techniques are commonly used to monitor conformational stability and colloidal stability of 
antibodies.22 The N297 site glycosylation is critical to the conformational stability and structural 
integrity of IgG.23-24 Removal of glycans at the N297 site in IgG1 was shown to lower the 
conformational stability of the CH2 domain and the aglycosylated IgG1 showed a higher 
aggregation propensity compared to its glycosylated counterpart.25 26 Glycosylation at the N297 
site is believed to stabilize the CH2 domain conformation, which happens to be the least 
thermally stable domain in the IgG molecule when compared to the Fab and the CH3 domains.27 
Although the underlying mechanism is not completely understood, it is widely recognized that 
protein-carbohydrate interactions play an important role in the stabilization of the CH2 domain.28 
The lower aggregation propensity of the N297 glycosylated IgG1 is believed to be due to 
shielding of aggregation prone motifs in the CH2 domain by the glycans.29 The N392 site in IgG3 
is located in the CH3 domain and its effect on the conformational stability and aggregation 
propensity of IgG3 Fc remains unknown.  
 In this chapter, the effect of N392 glycosylation on IgG3 Fc-Fc receptor (FcγRIIIA and 
FcRn) binding and IgG3 Fc physical stability is evaluated using IgG3 Fc glycovariants (Fig. 4.1). 
The production of Fc receptors for use in binding assay is also described. It was observed that the 
N392 site glycans do not affect the ability of IgG3 Fc to bind with Fc receptors but does impact 
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its physical stability. It was discovered that the N392 site glycans negatively affected the 
conformational stability but improved the colloidal stability of IgG3 Fc.  
 
Figure 4.1: Schematic representation of IgG3 Fc glycovariants and IgG1 Fc used for Fc receptor 
binding and physical stability assessment of IgG3 Fc. High mannose glycans are present on all 
the Fcs. For triglycosylated IgG3 Fc, the actual attachment site for the third glycan was not 
determined. It is likely be to present at the N297 site, given the higher site-occupancy at that site.   
 
4.2 Methods 
4.2.1 Expression and purification of FcγRIIIA 
FcγRIIIA-His6 (V158 polymorph) was expressed in a glycosylation-deficient strain of the 
yeast P. pastoris (SMD1168) and purified by Ni2+-NTA chromatography, as previously reported 
by the Tolbert lab.30 The receptor was further purified using phenyl sepharose chromatography to 
separate the higher glycosylated forms of the receptor from the partial and non-glycosylated 
forms, as previously reported by our group.31 
4.2.2 Cloning of FcRn receptor  
FcRn receptor is a heterodimer of two subunits: a transmembrane anchored α-heavy 
chain and a soluble β2microglobulin (β2m) light chain that are non-covalently associated. FcRn 



































single-chain version of the receptor with two subunits linked together in a single vector. For the 
first approach (Fig. 4.2A), the gene for human α heavy chain (accession # P55899, MGC # 1506, 
IMAGE # 3163446) was used as a template to amplify the extra-cellular domain (ECD) using 
primers 5’-GGCGCCCTCGAAGAAAAGAGCAGAAAGCCACCTCTCCCTCC-3’ and 5’-
CCGCGCGGCGCGGCCGCTTACAGCTCCACCCTGAGGGGCTG-3’. The ECD region of the 
α chain was identified based on the primers used in a previous study.32 The gene for β2m 
(accession # P61769, MGC # 45276, IMAGE #5502428) was amplified using primers 5’-
GGCGCCCTCGAGAAAAGAATCCAGCGTACTCCAAAGATT CAGGTTTAC-3’ and 5’-
GCGCGCGGGGCGGCCGCTTAGTGGTGATGATGGTG 
ATGCATGTCTCGATCCCACTTAACTATCTT-3’. In the designed primers, a hexahistidine 
(His6) tag was fused to the C-terminus of β2m. The amplified DNA from both the genes and P. 
pastoris expression vector pPICZαA were digested with XhoI and NotI and then each gene was 
separately ligated into pPICZαA using T4 DNA ligase to generate two plasmids, pPICZαA-α and 
α-β2m. These plasmids were transformed into Top10F’ by electroporation and selected on low-
salt LB plates with 25 μg/ml zeocin. The colonies were screened by PCR for the presence of the 
insert and sequenced to ensure no mutation occurred. The confirmed plasmid was purified from 
the colony and linearized with PmeI for integration into genomic AOX1 gene of a glycosylation-
deficient P. pastoris yeast strain with the OCH1 deletion (SMD1168). Transformants were 
selected on YPD pates with 100 μg/ml zeocin. The colonies were named pPICZαA-α and 
pPICZαA-β2m. The β2m gene was initially cloned in pPICZαA due to the available restriction 
sites in the multiple cloning region, however it would not be possible to select the β2m gene 
when transformed into P. pastoris that is already transformed with pPICZαA-α (due to the same 
zeocin selection marker). Therefore, the β2m was transformed into pPIC9K using SacI and NotI 
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restriction sites to produce pPIC9K-β2m. The construct was linearized with SalI, transformed 
into P. pastoris that was previously transformed with pPICZαA‐α and was selected on Minimal 
Dextrose (MD) plates. The resultant colonies were named pPICZαA-alpha+ pPIC9K-β2m. 
For the second approach (Fig. 4.2B), a single-chain FcRn (β2m-linker-α chain) 
expression plasmid, where both the subunits are linked together by a glycine-serine (GGGGS)3 
linker was gifted by the Dimitrov lab.33 The construct was received in the mammalian expression 
vector pSecTag2A. To use Pichia as an expression host, the single-chain FcRn was shuttled from 
pSecTag2A to pPICZαA. The insert was PCR amplified using primers 5’-
GGCGCCCTCGAGAAAAGAATCCAGCGTACTCCAAAGATTCAGGTTTAC-3’ (forward) 
and 5’- GCCGCGGCGGCCGCTTAATGATGATGGTGGTG 
GTGTCCACCTCCAGTTTCTGGCAATCCACCTCCACTAGATTTGGCTGGGCTTTCCAG-
3’ (reverse) that will add a sortase recognition tag (ST) and His6 tag to the C-terminus of the 
receptor. The amplified DNA was subcloned into pPICZαA using XhoI and NotI restriction sites. 
The ligated plasmid was transformed into P. pastoris using similar steps as described above. The 
colonies were named pPICZαA-β2m-L-α-ST-His6. 
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Figure 4.2: Cloning of FcRn into P. pastoris expression vector using (A) separate subunits in a 
dual-vector system and (B) linked subunits in a single vector system. Schematic representation of 
expressed subunits from both approaches are shown below the cloning strategy. 
4.2.3 Expression, purification and biotinylation of FcRn  
Single-chain FcRn was expressed in P. pastoris in a similar manner as FcγRIIIA and 
purified using Ni2+-NTA chromatography. The receptor was checked by SDS-PAGE for purity 
and MS for intact mass. A sortase-mediated ligation was used to attach biotin to the C-terminus 
of FcRn. For the ligation reaction, the receptor was extensively dialyzed in 50 mM Tris-HCl pH 
7.5, 150 mM NaCl. The reaction was carried out using 10 μM FcRn-ST-His6, 5 mM GGG-EDA 
(ethylene diamine)-biotin, 2 mM EDTA, 4 mM CaCl2 and 5 μM sortase enzyme at room 
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temperature for 24 hours. GGG-EDA-biotin was synthesized by Shaofeng Duan (former Tolbert 
group member).31 The reaction was quenched by adding an excess of EDTA to chelate the Ca2+ 
required for sortase activity. The biotinylation efficiency was determined by intact protein MS. 
The excess GGG-EDA-biotin was removed from the sample by extensive dialysis in PBS. The 
His6 and ST tags were designed in such a way that His6 is removed after ligation. The unreacted 
receptor was removed from the sample by passing the sample through Ni2+-NTA column and 
collecting the biotinylated FcRn in the flow through.  
4.2.4 Kinetic analysis of IgG3 Fc-FcγRIIIA binding  
The interactions between different IgG3 Fc glycovariants (tetra-, tri-, and di-glycosylated 
IgG3 Fc) and FcγRIIIA were measured by BioLayer Interferometry (BLI) using BLItz (ForteBio, 
Menlo Park, CA). A protein G biosensor tip was hydrated with PBS buffer (50 mM sodium 
phosphate pH 7.4, 150 mM NaCl) with 1 mg/ml casein as a blocking agent for 15 min. The tip 
was then dipped in PBS buffer for 15 min. The binding experiment was conducted as follows: an 
initial baseline was established by dipping the tip in PBS buffer for 30 sec. Next, the tip was 
loaded with IgG3 Fc glycovariants at a concentration of 0.88 μM for 120 sec to a achieve a 
response level of 2 nm. A new baseline was established for 30 sec in PBS, then an association 
and dissociation phase for 180 and 360 sec, respectively was recorded by dipping the tip in 
FcγRIIIA and PBS, respectively. The FcγRIIIA concentrations used were from 800 nM to 50 nM 
in two-fold serial dilutions. Between each run, the tip was regenerated using two cycles of 10 
mM HCl for 30 sec with one 60 sec cycle of PBS in between. Binding curves were globally 
fitted to 1:1 binding model and analyzed using BLItz Pro software (ForteBio).  
4.2.5 Kinetic analysis of IgG3 Fc-FcRn binding  
The interactions between IgG3 glycovariants (tetra- and di-glycosylated IgG3 Fc) and 
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FcRn were measured by BLI using streptavidin (SA) biosensor tip. The SA tip was first hydrated 
with PBS pH 6.0 and then with PBS pH 6.0 with 0.05% tween 20 (kinetic buffer) for 15 min 
each. The tip was loaded with biotinylated FcRn (at 3 μg/ml concentration) in kinetic buffer for 
250 sec to a response level of 6 nm. The binding experiment was conducted as follows: a 
baseline was established by dipping the tip in kinetics buffer for 30 sec. Then, association and 
dissociation curves recorded by dipping tip in different concentrations of Fc and kinetics buffer, 
respectively for 60 sec. The Fc concentrations used were from 2727 nM to 170 nM in two-fold 
serial dilutions. The tip was regenerated between each concentration by two cycles of PBS pH 
8.0 for 30 sec with one cycle of PBS pH 6.0 for 60 sec in between. Binding curves were globally 
fitted to 1:1 binding model and analyzed using BLItz Pro software.  
4.2.6 Assessment of physical stability of IgG3 Fc glycovariants  
Differential Scanning Calorimetry (DSC) was performed using a MicroCal VP-Auto DSC 
instrument (MicroCal). IgG3 Fc glycovariants at 0.4 mg/ml in 20 mM citrate-phosphate buffer 
adjusted to an ionic strength of 0.15 by adding NaCl at pH 6.0 (CP buffer) were prepared. 
Thermograms were obtained from 10°C to 100°C with a scanning rate of 60°C/hr. Data was 
analyzed using MicroCal of DSC plug-in for Origin 7.0. The final sample thermogram was 
obtained from buffer subtraction, baseline fitting, and normalizing concentration. Data was fitted 
to a non-2-state unfolding model with 2 transitions to calculate heat capacity maximum value 
(Tm). 
Intrinsic (Trp) fluorescence was measured using a PTI Quantum master fluorimeter with 200 μl 
of 0.2 mg/ml sample in CP buffer. For thermal stability measurements, the temperature was 
raised in increments of 1.25°C with equilibration time of 120 sec at each temperature. The 
maximum peak intensity value was calculated using a mean spectral center of mass method 
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(MSM) and plotted against temperature. Static light scattering intensity was measured 
simultaneously in the fluorimeter by using a second detector placed at 180° from the 
fluorescence detector and peak intensity changes at 295 nm were monitored as a function of 
temperature.  
Extrinsic fluorescence measurements (Differential Scanning Fluorimeter) were performed using 
MX300P QPCR system (Agilent). 100 μl of 0.2 mg/ml sample in CP buffer mixed with 1x of 
SYPROTM orange dye (Invitrogen, Carlsbad, CA) were used. Data was collected from 25°C to 
90°C using 60°C/hr heating rate. The fluorescence intensity was recorded as a function of 
temperature.  
Turbidity measurements were performed using a Cary 100 UV-Vis spectrophotometer (Varian 
medical systems). 200 μl of 0.2 mg/ml of sample in CP buffer in a 1 cm path length of quartz 
cuvette were used. Optical density (OD) at 350 nm was monitored as temperature was raised in 
increments of 1.25°C from 10-90°C with a heating rate of 60°C/hr.  
Far UV Circular Dichroism (CD) was recorded using Chirascan (Applied Photophysics) 
equipped with a peltier temperature controller. A CD spectra was collected for wavelength range 
260 to 200 nm with a resolution of 0.2 nm and a bandwidth of 1 nm. 200 μl of 0.2 mg/ml of 
sample in CP buffer in a 0.1 cm path length of quartz cuvette were used. The CD signal changes 
at 228 nm were recorded as temperature was raised from 10°C to 90°C at 2.5°C intervals with a 
scanning rate of 15°C/hr and 5 min equilibration time at each temperature.  
4.3 Results  
4.3.1 FcγRIIIA expression/purification/characterization 
Human FcγRIIIA receptor bears five N-glycosylation sites: N39, N46, N75, N163, and 
N170.34 The yield of the receptor from Ni2+-NTA chromatography was 15-20 mg per liter of 
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expression. The heavily glycosylated receptor migrates as a smear on SDS-PAGE (Fig. 4.3). The 
receptor was further purified using phenyl sepharose chromatography as a polishing step and to 
remove the partially glycosylated forms of the receptor (due to incomplete glycosylation site-
occupancy). Based on the elution profile of the WT IgG3 Fc (Chapter 3), it is expected that 
higher glycosylated forms of the receptor would elute first. As a result, only the first-half of the 
receptor elution peak was isolated to recover the fully glycosylated form of the receptor. The use 
of partially glycosylated forms of the receptor in the FcγRIIIA-IgG3 Fc binding assay would be 
undesirable since the occupancy of N163 glycosylation is known to be important for high affinity 
interaction of FcγRIIIA with IgG.34 The purity of the receptor was improved by phenyl 
sepharose purification and the protein migrated as a consolidated band in SDS-PAGE (Fig. 4.3).  
  
Figure 4.3: Coomassie-stained SDS-PAGE of FcγRIIIA receptor purified from Ni2+-NTA 
affinity (lane2) and phenyl sepharose (lane3) purification 
  
4.3.2 FcRn expression/purification/characterization 
FcRn receptor is a heterodimer of α heavy chain and β2m, which are non-covalently 
associated in their functional form. An initial attempt was made to express FcRn by cloning the 
individual subunits into two separate vectors and then sequentially transforming them into P. 
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pastoris. Both the subunits were placed under the control of strong AOX1 promoter (inducible 
by methanol) and theoretically should be co-expressed and secreted in the media in a 
heterodimeric form. Unfortunately, no detectable levels of protein expression were observed. For 
the next attempt, a single-chain version of FcRn receptor was used, where both subunits are 
covalently connected by a glycine-serine (GGGGS)3 linker. The single-chain FcRn construct was 
gifted by the Dimitrov lab, which expressed the receptor in 293 FreeStyle cells (mammalian cell 
line) in a functional form.33 For expression in P. pastoris, the single-chain version of the receptor 
was shuttled from the existing mammalian expression vector into the Pichia expression vector. A 
sortase recognition tag (ST) consisting of amino acids LPETGGG and a hexahistidine tag (His6) 
was added to the C-terminus of the receptor to allow biotinylation and Ni2+-NTA purification of 
the receptor respectively. About 15-20 mg of the receptor (referred as FcRn-ST) was expressed 
from 1L spinner flask. The receptor has one N-linked glycosylation site at N102 and migrated as 
a single band on SDS-PAGE (Fig. 4.4). Digestion of receptor with PNGase F resulted in a gel 
shift suggesting that the receptor was expressed in a nearly fully glycosylated state. Intact protein 
MS showed a set of peaks corresponding to the glycosylated receptor and a small peak for the 
non-glycosylated protein, consistent with the SDS-PAGE results (Fig.4.5).  
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Figure 4.4: Coomassie-stained SDS-PAGE analysis of FcRn-ST receptor. Lanes (1) MW weight 
marker (2) FcRn-ST (3) PNGase F digested FcRn-ST (4) FcRn-biotin FcRn-biotin was prepared 
using sortase-mediated ligation. 
 
The distribution of high mannose glycans on the receptor were more skewed toward 
larger high mannose glycans (>Man10, Fig. 4.5). This is in contrast to IgG3 Fc expressed in the 
same P. pastoris strain, where the most dominant glycoform present was Man8 (Chapter 3). This 
variation suggests that the glycosylation pattern produced in P. pastoris is influenced by the 
nature of the glycoprotein expressed and/or the location of the glycosylation site in the protein. 
Intact protein MS of the PNGase F-digested receptor showed a peak corresponding to the 
expected MW of the protein (Fig. 4.6A). The additional peaks observed in the spectra are likely 
due to cysteine modifications since these peaks disappeared with reduction of the sample (Fig. 
4.6B). The peak with an additional mass of 305 Da could be assigned to glutathionylation of 
cysteine.35 The peaks with mass additions of 29 and 48 Da could be possibly assigned to 
formation of other cysteine adducts (Fig. 4.6A). The receptor has 6 cysteines, out of which two 
exist as free cysteines (based on X-ray crystal structure) and hence can be potentially modified.36  
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Figure 4.5: Intact protein mass spectra of FcRn-ST under reducing conditions. Multiple peaks 





Figure 4.6: Intact protein mass spectra of FcRn-ST under (A) non-reducing conditions and (B) 
reducing conditions. Expected MW of the deglycosylated FcRn-ST is 45041.2 Da. 
 
4.3.3 Sortase-mediated ligation of FcRn receptor 
Sortase, a bacterial enzyme was used to attach biotin to the C-terminus of FcRn for use in 
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streptavidin based binding assay.37 The ligation requires an N-terminal glycine-containing 
peptide and a C-terminal recognition motif LPETG (ST). FcRn-ST-His6 and an N-terminal 
polyglycine compound containing biotin separated by a ethylene diamine linker (GGG-EDA-
Biotin, Shaofeng Duan from our lab produced this compound) were used in the ligation reaction. 
The sortase catalyzes cleavage between Thr-Gly and makes a new peptide bond between the N-
terminal glycine of GGG-EDA-Biotin and the C-terminus of Thr of FcRn (Fig. 4.7). The His6 tag 
was placed downstream of the sortase recognition motif so that it is removed in the ligated 
product. Such a design allowed separation of any unreacted FcRn-ST-His6 in the reaction 
mixture by capturing it on Ni2+-NTA column, while the ligated product remains in the flow 
through. The EDA linker separates biotin from the C-terminus of FcRn, and thereby may 
provides some degree of separation between streptavidin and FcRn to prevent potential 
interference of streptavidin in the FcRn binding assay. The ligation reaction conditions were 
required to be optimized since the receptor was found to instantly precipitate upon addition of 
Ca2+. To circumvent this issue, EDTA was added to the reaction prior to addition of Ca2+, which 




Figure 4.7: Production of biotinylated FcRn using sortase-mediated ligation between FcRn-ST-
His6 and GGG-EDA-Biotin. EDA: ethylene diamine 
 
The reaction progress was monitored by intact protein MS, which showed a peak 
corresponding to the biotinlylated receptor (Fig. 4.8B). The ligation reaction was shown to be 
98% complete based on the peak intensities of the ligated and the unligated receptor. The 
biotinylated FcRn was used in BioLayer Interferometry (BLI) based FcRn binding assay for 
immobilizing the receptor on a streptavidin biosensor tip.  
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Figure 4.8: Intact protein mass spectra of biotinylated FcRn prepared using sortase-mediated 
ligation under reducing conditions. The receptor was deglycosylated prior to MS characterization 
for ease of peak assignment. Panels show peak(s) corresponding to (A) FcRn-ST (B) FcRn-
Biotin.  
 
4.3.4 Binding interactions of IgG3 Fc glycovariants with FcγRIIIA  
Kinetics of IgG3 Fc-FcγRIIIA binding interactions were assessed by BioLayer 
Interferometry (BLI) using protein G biosensors. IgG3 Fc glycovariants were first immobilized 
on a protein G tip, and the receptor was placed in solution (analyte). An immobilization level of 
2 nm was achieved using 0.88 μM solution of various IgG3 Fc glycovariants. Then, a baseline 
was established and association of FcγRIIIA was recorded by dipping the biosensor tip into 
solution of different concentrations of FcγRIIIA. Once the complex was formed, the dissociation 
step was recorded by dipping the biosensor in PBS buffer. The kinetic parameters, kon 
(association rate constant) and koff (dissociation rate constant), were obtained by fitting the curves 
to 1:1 binding model. Equilibrium dissociation constant (KD) were calculated from ratio of koff 
and kon. The applied binding model is consistent with biochemical and structural analysis of this 
interaction.12, 38 Fig. 4.9 shows the representative binding curves for the binding of IgG3 Fc 
glycovariants to FcγRIIIA and Table 4.1 shows the corresponding kinetic parameters. 
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Tetraglycosylated (N297 and N392 sites occupied) and diglycosylated (only N297 site occupied) 
IgG3 Fc were compared to check the influence of N392 site glycosylation on receptor binding. 
Two versions of diglycosylated IgG3 Fc were used, one produced from IgG3 Fc-N392K and the 
other from the IgG3 Fc-N392Q. Additionally, the diglycosylated IgG1 Fc that naturally has a 
Lys (K) at the 392 position was also tested for comparison purposes. All the IgG3 Fc 
glycovariants showed high affinity binding to FcγRIIIA with minor differences. The 
tetraglycosylated variant showed slightly weaker affinity (56.4 nM) than the diglycosylated 
N392K variant (41.4 nM) but a comparable affinity to the diglycosylated N392Q variant (50.9 
nM). The diglycosylated IgG1 Fc showed the strongest affinity (36.2 nM) compared to all the 
IgG3 Fc glycovariants. Taken together, these results indicate that IgG3 Fc shows comparable 
affinity as IgG1 Fc for binding to FcγRIIIA, and the additional presence of N392 glycans in 
IgG3 Fc does not adversely affect its high affinity binding.  
 115
 
Figure 4.9: Representative BioLayer Interferometry (BLI) binding curves for the interaction of 





Table 4.1: Kinetic parameters obtained for binding of FcγRIIIA with IgG3 Fc glycovariants. 







Fc Variant Average kon*105  
(1/M.sec) 
Average koff*10-3  
(1/sec) 
Average KD  
(nM) 
Diglycosylated IgG3 Fc-N392K  1.6 ± 0.1 6.5 ± 0.2 41.4 ± 2.7 
Diglycosylated IgG3 Fc-N392Q 1.21 ± 0.02 6.1 ± 0.7 50.9 ± 5.8 
Tetraglycosylated IgG3 Fc 1.6 ± 0.1 9.0 ± 0.2 56.4 ± 3.7 
Diglycosylated IgG1Fc  0.93 ± 0.05 3.4 ± 0.4 36.2 ± 4.5 
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4.3.5 Binding interactions of IgG3 Fc glycovariants with FcRn 
Binding kinetics of IgG3 Fc-FcRn interactions were measured by BioLayer 
Interferometry (BLI) using streptavidin (SA) biosensors. Selectively biotinlylated FcRn (using 
sortase-mediated ligation) was immobilized on the SA tip, and IgG3 Fc glycovariants (analyte) 
were placed in solution. FcRn binds to the CH2-CH3 domain interface at both the heavy chains of 
an IgG Fc, thus resulting in a 2:1 binding stoichiometry. Due to the divalent binding nature of the 
receptor, the FcRn-immobilized assay format is prone to avidity effects that may result in an 
heterogeneous binding response.39 However, the FcRn immobilized assay format can also be 
optimized to minimize the avidity effects and produce a more homogenous binding response that 
can be fitted to a 1:1 binding model. Several preliminary FcRn binding experiments varying the 
FcRn loading levels were carried out to find an optimum level. It was observed that having low 
loading levels of receptor (less than 2.5 nm) produced low analyte signal (less than 0.1 nm). A 
loading level of 5-6 nm resulted in a reasonable analyte signal with a relatively more 
homogenous binding response. These binding curves fitted better to a 1:1 binding model and the 
kinetic parameters of binding were determined (Fig. 4.10, Table 4.2). IgG3 Fc binding to FcRn 
exhibited fast association and dissociation kinetics, which has been previously reported for IgG1-
FcRn interaction.33, 39 The tetraglycosylated and diglycosylated IgG3 Fc showed similar affinity 
(KD~2.5 μM) for the receptor suggesting that the additional presence of N392 glycosylation does 
not affect IgG3 Fc binding to FcRn. A relatively weaker affinity (KD ~3 μM) for diglycosylated 
IgG1 Fc was observed.  
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Figure 4.10: Representative BioLayer Interferometry (BLI) binding curves for the interaction of 
FcRn with the IgG3 Fc glycovariants. Experimental and fitted data are shown in red and black 
respectively. 
 
Table 4.2: Kinetic parameters obtained for binding of FcRn with IgG3 Fc glycovariants. Values 
are reported as average and standard deviation of triplicate measurements.   






Diglycosylated IgG3 Fc-N392K 1.5 ± 0.1 0.36 ± 0.03 2.5 ± 0.3 
Tetraglycosylated IgG3 Fc 1.4 ± 0.5 0.38 ± 0.05 2.7 ± 0.3 
Diglycosylated IgG1Fc 0.96 ± 0.03 0.29 ± 0.02 3.0 ± 0.3 
 
4.3.6 Effect of N392 glycosylation on physical stability of IgG3 Fc  
IgG3 Fc glycovariants were analyzed for their biophysical properties and physical 
stability of IgG3 Fc was assessed as a function of temperature stress. Differences in the stability 
profile of tetra- and the di-glycosylated IgG3 Fc can be attributed to the presence of N392 
glycans. Multiple protein biophysical analysis techniques were employed to probe the physical 
stability of IgG3 Fc. The parameters obtained from these techniques are listed in Table 4.3. The 
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overall secondary structure at 10°C was probed by far-UV CD spectroscopy from 260 nm to 200 
nm. The CD spectra for all variants showed a clear minimum at 217 nm, consistent with the β-
sheet rich structure found in immunoglobulin domains (Fig. 4.11A). The effect of temperature on 
the secondary structure was probed by CD thermal melting curves. The tetraglycosylated variant 
showed a lower thermal transition temperature (~60°C) than the diglycosylated variant (~67°C) 
(Fig. 4.11B).   
The overall tertiary structure of the IgG3 Fc glycovariants was evaluated by measuring 
intrinsic Trp fluorescence at 10°C. The wavelength of maximum intensity (λmax) for all the 
glycovariants was found to be in the range of 329-334 nm, indicating an overall similarity 
between them with minor differences (Fig. 4.11C). Structural integrity of the tertiary structure 
was measured as a function of temperature by monitoring peak intensity changes. A comparable 
thermal transition temperature (Tm) value for all the IgG3 Fc glycovariants was observed ranging 
from 54-58°C (Fig. 4.11D), indicating that the presence of N392 glycans do not affect the 
tertiary structure stability to a notable extent. Static light scattering was measured concomitantly 
with fluorescence to characterize temperature-induced aggregation. The tetra- and tri-
glycovariants showed no detectable change in the intensity of scattered light; however, both the 
diglycosylated variants showed an increase in intensity of scattered light with Tonset of ~66°C and 
~64°C for the N392K and N392Q forms respectively (Fig. 4.12B). These results suggest that the 
presence of the N392 glycans protects IgG3 Fc from temperature-induced aggregation. Extrinsic 
fluorescence spectroscopy was used to measure conformational stability by monitoring emission 
from SYPROTM orange dye. The dye’s fluorescence is generally quenched in a protein solution 
but is increased as more apolar regions are exposed upon protein unfolding. The IgG3 Fc 
glycovariants did not show any major difference in thermal transition values (58-60°C) (Fig. 
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4.11E), suggesting no large changes in the tertiary structure stability. Low intensity for the 
N392Q form was probably due to a bad run or low sample concentration. 
 The overall conformational stability was evaluated by differential scanning calorimetry 
(DSC). Typically, DSC thermograms of IgG1 Fc show two major endothermic peaks, 
corresponding to sequential melting of the CH2 and CH3 domains.24 The diglycosylated variants 
from IgG3Fc-N392K/Q showed two major endothermic peaks, which could be fitted to two Tm 
values, Tm1~ 59°C and Tm2~70°C, corresponding to unfolding of the CH2 and CH3 domains 
respectively. Interestingly, the tetraglycosylated variant showed only one major endothermic 
peak, which could be fitted to Tm1~59°C and Tm2~ 62°C (Fig. 4.13, Table 4.3). The 
triglycosylated variant also showed one endothermic peak, which was fitted to a single Tm~62°C. 
An equivalent Tm1 and a reduced Tm2 in the tetraglycosylated IgG3 Fc indicate that the CH3 
domain residing N392 glycans potentially affects the conformational stability of the CH3 domain. 
Aggregation propensity was also measured by monitoring OD350 as a function of temperature. 
The IgG3 Fc glycovariants showed a similar trend as seen in the light scattering measurements, 
where the tetra- and tri- glycosylated variants did not show any detectable change in OD350 
values and both the di-glycosylated variants (N392K/Q) showed a transition around 83-85°C 
(Fig. 4.12A).  
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Figure 4.11: Biophysical characterization of IgG3 Fc glycovariants: tetraglycosylated, 
triglycosylated, diglycosylated (N392K) and diglycosylated (N392Q). Biophysical 
measurements include (A,B) CD spectroscopy (C,D) Intrinsic Trp fluorescence (E) SYPROTM 
extrinsic fluorescence. (A) and (C) are CD and fluorescence spectra measured at 10°C. (B,D,E) 
show changes in the spectra as a function of temperature. 
 
 
Figure 4.12: Biophysical characterization of IgG3 Fc glycovariants: tetraglycosylated, 
triglycosylated, diglycosylated-N392K and diglycosylated-N392Q. Biophysical measurements 




Figure 4.13: Comparison of representative DSC thermograms of IgG3 Fc glycovariants: 
tetraglycosylated, triglycosylated, diglycosylated (N392K) and diglycosylated (N392Q). Overlay 
of all DSC curves is shown in (A) and curve fitted thermograms are shown for (B) 
tetraglycosylated (C) triglycosylated (D) diglycosylated-N392K (E) diglycosylated-N392Q. 
 
Table 4.3: Summary of physical stability parameters obtained by biophysical techniques for 
characterizing the physical stability of IgG3 Fc glycovariants. Values are reported as average and 
standard deviation of triplicate measurements 
Technique Parameter Tetra- Tri- Di- (N392K) Di- (N392Q) 
SYPRO orange 
fluorescence 
Tm (°C) 59.8 ± 0.1 * 58.2 ± 0.1 58.5 ± 0.2 
Tonset (°C) 49.0 ± 0.2 * 48.9 ± 0.2 49.1 ± 0.2 
Intrinsic Fl. melt 
(peak intensity) 
Tm (°C) 56.4 ± 0.1 57.7 ± 0.3 56.4 ± 0.2 54.5 ± 0.6 
Tonset (°C) 47.5 ± 0.2 47.3 ± 0.1 47.2 ± 0.1 45.4 ± 0.2 
Static light 
scattering 
Tonset (°C) n.d. n.d. 66.1 ± 0.2 63.5 ± 0.4 
CD melt Tm (°C) 60.5 ± 0.4 * 67.3 ± 0.3 67.3 ± 0.2 
OD350 Tonset (°C) n.d. n.d. 85.0 ± 0.2 83.0 ± 0.4 
DSC 
Tm1 (°C) 58.6 ± 0.4 62.3 ± 0.2 
59.3 ± 0.1 59.4 ± 0.1 
Tm2 (°C) 62.1 ± 0.1 70.6 ± 0.3 70.3 ± 0.1 
Tonset (°C) 49.0 ± 0.2 47.8 ± 0.1 47.3 ± 0.1 47.4 ± 0.2 
Intrinsic Fl. scan λmax (nm) 330.0 ± 0.6 329.0 ± 0.0 329.3 ± 0.6 333.5 ± 0.5 
CD scan λmax (nm) 217 * 217 217 




4.4.1 Binding interactions of IgG3 Fc glycovariants with Fc receptors 
FcγRIIIA is an activating Fcγ receptor that mediates ADCC by binding to the Fc region 
of IgG in an immune complex. Not only is the presence of N297 glycosylation on the Fc 
important for binding to FcγRIIIA, but the nature of glycans also influences the strength of the 
interaction.40 For example, IgG1 with afucosylated glycoforms at N297 show a higher affinity to 
FcγRIIIA, whereas truncated glycoforms show lower affinity.8, 41 IgG3 shows similar affinity and 
selectivity as IgG1 towards different Fcγ receptors and thus is an attractive IgG subclass to 
investigate glycosylation-dependent FcγRIIIA binding.42 There is an emerging interest in 
correlating Fc effector functions with specific IgG Fc glycoforms since most studies in the past 
have used IgG Fc with heterogeneous mixture of glycoforms, which is naturally present based on 
the choice of the expression host. Currently, there are limited reports in the literature 
characterizing IgG3-FcγRIIIA interactions and none of them mention the N392 glycosylation 
site.11-13 IgG3 Fc glycovariants (Chapter 3) are ideally suited for studying the effect of the N392 
site glycosylation on Fc receptor binding.  
IgG3 Fc with only the N297 site glycosylated exhibited high affinity binding to FcγRIIIA 
in a low nanomolar range similar to IgG1 Fc since both the Fcs bear high mannose glycoforms 
(which are devoid of fucose). Removal of fucose from complex glycans at the N297 site has 
been shown to increase FcγRIIIA binding irrespective of the IgG subclass.43 Prior studies have 
reported similar differences in KD values (less than two fold difference) for IgG1 and IgG312-13 
with an exception of one study where IgG3 was found to bind with a 5-fold higher affinity than 
IgG1.11 The KD values reported in these studies were in the high nanomolar range since the Fc 
glycans were mostly fucosylated.  IgG1 and IgG3 are generally accepted to have similar 
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affinities for FcγRIIIA since the contact residues identified on IgG1 for FcγRIIIA binding (based 
on the IgG1 Fc-FcγRIIIA complex crystal structure) are conserved in IgG3.44-45 The presence of 
additional N392 glycans in IgG3 Fc doesn’t seem to have a large influence on FcγRIIIA binding. 
Structurally, the N392 site is located away from the receptor-binding site, and it is possible that 
the N392 glycans do not induce any long-range conformational changes at the binding site. More 
details about FcγRIIIA binding site and location of N392 glycans are discussed in chapter 5, 
section 5.3.10, based on the crystal structure of tetraglycosylated IgG3 Fc.   
The FcRn receptor plays a critical role in maintaining long circulating half-lives of IgGs 
by binding to IgGs at an acidic pH (pH 6.0) in the early endosomes and recycling them back to 
circulation by releasing IgGs at physiological pH. An increase in IgG binding to FcRn (only at 
acidic pH with no change at neutral pH) results in an extended half-life, and therefore the IgG-
FcRn interaction has received significant attention for improving the pharmacokinetic properties 
of therapeutic antibodies.46 Since FcRn binds to IgG in a 2:1 stoichiometry, the nature of the 
binding response produced from Surface Plasmon Resonance (SPR) or BioLayer Interferometry 
(BLI) techniques is sensitive to the assay format. Generally, immobilizing the receptor and 
having IgG in solution results in a more heterogeneous binding response, while the reverse 
format produces more a homogenous response.39 However, exceptions to this generalization are 
also found in the literature.33, 47 Biotinlylated FcRn was immobilized on streptavidin biosensor in 
our BLI studies since it is a more convenient assay format to test different IgG glycovariants 
without requiring biotinylation of each IgG3 Fc glycovariant. Protein G cannot be used to 
immobilize the Fc for FcRn assay (unlike the FcγRIIIA assay) because it binds to the same 
region on the Fc where also FcRn binds and thus prevents FcRn from binding. In our studies, 
site-specific biotinylation was carried out using sortase-mediated ligation to attach biotin to the 
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C-terminus of FcRn. Generally, the site-specific conjugation techniques are more favorable than 
random amine coupling for surface immobilization since they are likely to maintain the protein 
in a particular orientation across the surface and is not likely to impair its functionality.  
The FcRn receptor binds to the outer face of the CH2-CH3 interface of the Fc, and its 
binding to the Fc is generally known not to be affected by the N297 site glycosylation due to its 
distal location. The N392 site in IgG3 is located at the edge of CH3-CH3 interface close to the 
inner face of CH2-CH3 interface, and the presence of glycans in this region can be predicted to 
potentially affect FcRn binding. However, there was no significant difference between IgG1 Fc, 
tetraglycosylated and diglycosylated IgG3 Fc for binding to FcRn receptor and the KD value for 
all the variants ranged between 2-3 μM. A nominal 2-fold higher affinity for IgG1 (KD~0.63 μM) 
relative to IgG3 (KD~1.10 μM) was reported by Stapleton et al.18 In the same study, it is 
suggested that IgG3 is cleared faster in serum due to inhibition of IgG3 recycling because of an 
intracellular competition between IgG1 and IgG3 during the recycling process. Interestingly, if 
IgG3 is present alone, it is able to recycle as efficiently as IgG1. Based on these findings, it can 
be hypothesized that IgG1 and IgG3 may have similar in-vivo FcRn affinity but due to some 
unknown process (such as a slightly weaker FcRn binding at acidic pH for IgG3 or increased 
binding for IgG3 at neutral pH), IgG3 recycling is inhibited in presence of IgG1. Other 
researchers have also reported similar fold differences between IgG1 and IgG3 for binding to 
FcRn.16, 48 A model showing how IgG3 might have an increased binding to FcRn at neutral pH 
compared to IgG1 is proposed in chapter 5, section 5.3.8, based on the crystal structure of IgG3 
Fc. A monovalent Fc-FcRn interaction is generally considered to be a weak affinity interaction 
with a KD value between 1-2 μM.39, 49 There is a large variability in reported KD values in the 
literature ranging from 10 nM to 3 μM.32-33, 39, 46, 50-52 This discrepancy is primarily because of 
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the assay format used (whether FcRn or IgG is immobilized), quality of the reagents used, 
analyte concentration and the curve-fitting model used. Based on the crystal structure of the 
tetra-glycosylated IgG3 Fc (chapter 5), the N392 glycans appear to point away from the site of 
FcRn binding and this may explain the observed similarities between tetra-and di-glycosylated 
IgG3 Fc for binding to the FcRn receptor. A more detailed explanation is presented in chapter 5, 
section 5.3.10.  
4.4.2 Effect of N392 glycosylation on physical stability of IgG3 Fc  
Antibodies are susceptible to physical degradation and instability issues like aggregation, 
precipitation, conformational changes and unfolding.21 Antibody stability is critical from a 
therapeutic perspective since it can impair its biological activity. The N297 glycosylation is 
considered critical for the conformational stability and integrity of IgG.53 Aglycosylated IgG1 Fc 
exhibits a lower conformational stability for the CH2 domain and a higher aggregation propensity 
compared to its glycosylated form.25-26 Given the high degree of similarity in the primary 
structure of IgG1 and IgG3, the N297 glycosylation can be assumed to be equally important to 
IgG3. The effect of N392 glycosylation on the physical stability of IgG3 Fc was studied by 
comparing the thermal stability of the tetraglycosylated variant with the diglycosylated variant 
from IgG3 Fc-N392K (only has N297 site glycosylated) to highlight the role of N392 
glycosylation. Additionally, to confirm that the results from IgG3 Fc-N392K are due to a lack of 
glycosylation at position 392 and not due to the presence of Lys at 392, we used the 
diglycosylated variant from IgG3 Fc-N392Q, since Gln closely resembles Asn if Asn is not 
glycosylated. Out of the multiple biophysical analysis techniques used in this study, some 
showed no difference between tetra- and di-glycosylated forms, while other techniques were able 
to detect significant differences between them. These results affirm the general consensus in the 
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protein stability community about the value of using multiple biophysical techniques (preferably 
orthogonal) to probe stability profile of therapeutic protein drugs. 
No striking difference in the secondary and tertiary structure among all glycovariants was 
observed based on CD and fluorescence measurements. There is a possibility of some local 
conformation change due to the presence of N392 glycosylation that is not detected by the 
techniques used in this study. The thermal unfolding of IgG3 Fc glycovariants was probed by 
DSC. In most cases, DSC analysis of IgG Fc is quite useful since it is able to resolve thermal 
unfolding of the CH2 and CH3 domains. A higher Tm for the CH3 domain relative to the CH2 
domain is attributed to the strong non-covalent interactions between the CH3-CH3 domains.24 
Removal of N297 glycans in IgG1 Fc has been shown to reduce thermal stability of the CH2 
domain.24 In the tetraglycosylated IgG3 Fc, the presence of additional N392 glycans in the CH3 
domain seems to lower the conformational stability of the CH3 domain. The residue at position 
392 in tetraglycosylated IgG3 Fc (chapter 5) structure lies at the edge of CH3-CH3 interface and it 
may be speculated that glycosylation at this position disrupts the CH3-CH3 interface and in turn 
make CH3 domain less thermally stable. More details about N392 glycans and CH3-CH3 interface 
are presented in chapter 5, section 5.3.10. 
Both the techniques analyzing protein aggregation showed a higher aggregation 
propensity for the diglycosylated IgG3 Fc compared to the tetraglycosylated IgG3 Fc. Exposure 
of hydrophobic residues upon thermal unfolding is suggested to be one of the mechanisms for 
protein aggregation.54 Glycosylation at the N297 site in IgG1 is suggested to shield the 
aggregation prone motifs in the CH2 domain and thereby make it less aggregation prone 
compared to its aglycosylated counterpart.28 Chennamsetty et al. identified the aggregation 
motifs in IgG subclasses, one of which is P395PML398 in the CH3 domain.
29 The N392 site 
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immediately precedes this motif, and it is possible that the N392 glycans shield this motif and 
make it less aggregation prone (described in detail in chapter 5, section 5.3.10).  
In summary, we have shown that the presence of N392 glycosylation on IgG3 does not 
adversely affect the binding of IgG3 Fc to FcγRIIIA and FcRn. Physical stability assessment of 
the N392 site glycosylation showed that the N392 glycans reduces the thermal stability of the 
IgG3 Fc but protects it from temperature-induced aggregation.  
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Chapter 5  Structural characterization of human IgG3 Fc 
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5.1 Introduction 
The Fc region of IgG is generally known to readily crystallize under various conditions 
and hence is named as fragment crystallizable (Fc). The IgG Fc structures deposited in the 
protein databank predominantly belong to IgG1 subclass, either present as free Fc or in complex 
with Fc receptors and other Fc-binding proteins. A list of available IgG1 Fc structure can be 
found elsewhere.1 The first human IgG1 Fc structure was solved by Deisenhofer in 19812 and 
since then multiple IgG1 Fc structures have been published, which either differ in the type of 
glycosylation present or the mutations made to the WT sequence. In recent years, the structures 
of IgG2 Fc3 and IgG4 Fc4 have been reported and were found to be highly similar to the IgG1 Fc 
structure, owing to 95% sequence homology in the Fc region of the IgG subclasses (Fig. 5.3). 
The IgG2 Fc and IgG4 Fc structures provides a structural basis for understanding IgG subclass-
specific properties, such as Fab arm exchange in IgG4.4  
 The structure of IgG Fc resembles a horse-shoe shape dimer comprising of CH2 and CH3 
domains. The CH3 domains in the dimer maintain extensive protein-protein contacts to keep the 
IgG structure together in conjunction with the hinge disulfide bonds. Generally, no interpretable 
electron density for the hinge region is observed in the Fc structures due to its flexible and 
mobile nature. The CH2 and CH3 domains display an immunoglobulin (Ig) fold that is stabilized 
by a conserved disulfide bond. In all the IgG Fc structures, the CH2 domains do not make any 
direct contact with each other and the N297 glycans occupy the space between the two CH2 
domains. Interpretable electron density for oligosaccharides is generally observed in Fc 
structures, which enables determination of the glycan conformation. The N297 glycans lie in 
close apposition to the inner face of the CH2 domain and make extensive non-covalent 
interactions with the protein.1 The glycans on protein are generally known to be very mobile, and 
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therefore considered as a hindrance to glycoprotein crystallization. However, in case of IgG Fc, 
the N297-glycan structure can be reasonably defined primarily due to its unique orientation 
within the Fc structure that allows multiple points of contact with the protein. The N297 site 
glycans in IgG Fc are considered important in maintaining the optimal ‘open’ conformation of 
the CH2 domains5 and removal of glycans has been shown to result in a ‘closed’ conformation 
due to mutual collapse of the CH2 domains.6 The ‘open’ conformation of the CH2 domains is 
believed to be critical for recognition by Fcγ receptors and C1q complement protein, since the 
aglycosylated IgG Fc loses its ability to bind with these ligands.7-8  
In this chapter, we report high-resolution x-ray crystal structures of two variants of 
human IgG3 Fc fragment. The first variant is IgG3 Fc-N392K that is homogeneously 
glycosylated with high mannose, GlcNAc2Man5 (Man5) glycoform at the N297 glycosylation 
site. The second variant is IgG3 Fc that is glycosylated with high mannose glycoforms, 
GlcNAc2Man8-12 (Man8-Man12) at the N297 and N392 glycosylation sites (referred as 
tetraglycosylated IgG3 Fc). To our knowledge, this is the first human IgG3 Fc structure reported 
and also the first Fc structure from any IgG subclass containing the Man5 glycoform. The 
analysis of the Man5-IgG3 Fc structure provides insight into structural basis for some of the 
unusual properties of IgG3 subclass, especially related to binding to protein A, protein G and the 
neonatal Fc receptor (FcRn). Analysis of the tetraglycosylated IgG3 Fc structure provides 
information about the location and orientation of the lesser known N392 site glycans and its 
influence on the IgG3 Fc structure and function. 
5.2 Methods  
 
5.2.1 Production and characterization of Man5-IgG3 Fc and tetraglycosylated IgG3 Fc 
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WT IgG3 Fc and IgG3 Fc-N392K were expressed in the quadruple KO strain of the yeast 
P. pastoris as described in chapter 3, sections 3.2.1-3.2.2. The tetraglycosylated IgG3 Fc and 
diglycosylated IgG3 Fc-N392K were purified from the protein G-purified WT IgG3 Fc and IgG3 
Fc-N392K, respectively by phenyl sepharose chromatography (chapter 3, section 3.2.5). The 
high mannose (HM) glycoforms on IgG3 Fc-N392K were converted to the Man5 glycoform by 
digestion with α-1,2 mannosidase and endomannosidase enzymes (chapter 3, section 3.2.6). The 
prepared Man5-IgG3 Fc and tetraglycosylated IgG3 Fc proteins were characterized by intact 
protein mass spectrometry and SDS-PAGE.  
5.2.2 Crystallization and Data Collection 
Man5-IgG3 Fc was concentrated to 10.8 mg/mL in 150 mM NaCl, 10 mM MES, pH 6.6 
for crystallization screening. All crystallization experiments were conducted Compact Jr. 
(Rigaku Reagents) sitting drop vapor diffusion plates at 20 oC using equal volumes of protein 
and crystallization solution (0.7 uL) equilibrated against 75 uL of the latter. Crystals that 
displayed a prismatic morphology were obtained approximately 1 week from the Wizard 3-4 
screen (Rigaku Reagents) condition B5 (20% (w/v) PEG 4000, 100 mM sodium citrate/citric 
acid pH 5.5, 10% (v/v) 2-propanol). The crystals tended to form contact twins but could be 
readily separated to obtain single crystals for data collection. Samples were transferred to a fresh 
drop composed of 80% crystallization solution and 20% ethylene glycol and stored in liquid 
nitrogen.   
Tetraglycosylated IgG3 Fc was concentrated to 9.0 mg/mL in 150 mM NaCl, 10 mM 
MES, pH 6.6 for crystallization screening. All crystallization experiments were conducted 
Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 oC using equal volumes 
(0.7 µL) of protein and crystallization solution equilibrated against 75 µL of the latter. Crystals 
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that displayed a prismatic morphology were obtained approximately 1 week from the JCSG+ 
screen (Molecular Dimensions) condition A8 (20% (w/v) PEG 3350, 200 mM ammonium 
formate). Cryoprotection was carried out by adding 1µL of a 7 M sodium formate solution was 
added directly to the drop of the initial crystallization screen and samples were then harvested 
and transferred to a vial containing liquid nitrogen. For both IgG3 Fc crystals, X-ray diffraction 
data was collected at the Advanced Photon Source IMCA-CAT beamline 17-ID using a Dectris 
Pilatus 6M pixel array detector. 
5.2.3 Structure Solution and Refinement 
For Man5-IgG3 Fc, intensities were integrated using XDS9-10 via Autoproc11 and the 
Laue class analysis and data scaling were performed with Aimless12 which indicated that the 
highest probability was 2/m (P2 or P21). Structure solution was conducted by molecular 
replacement with Phaser13 using a single subunit form previously determined structure of IgG1 
Fc (PDB: 4DZ8)14 as the search model.15 The top solution was obtained in the space group P21 
that contained two molecules in the asymmetric unit. Coordinate and structure factors were 
deposited to the Wordwide Protein Databank with the accession code 5W38. 
For Tetraglycosylated IgG3 Fc, intensities were integrated using XDS9-10 via 
Autoproc11 and the Laue class analysis and data scaling were performed with Aimless12 which 
indicated that the highest probability was 6/m. Structure solution was conducted by molecular 
replacement with Phaser13 using a single subunit form previously determined structure of IgG3-
N392K as the search model. The top solution was obtained in the space group P61 that contained 
two molecules in the asymmetric unit. For both the solutions, the model was further improved by 
automated model building with ARP/wARP.16 Structure refinement and manual model building 
were conducted with Phenix17 and Coot18 respectively. Disordered side chains were truncated to 
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the point for which electron density could be observed. Structure validation was conducted with 
Molprobity17 and figures were prepared using the CCP4MG package19 and PyMOL. Full data 
processing and refinement statistics are provided in Table 5.1. Man8 glycoform was in-silico 
modeled at the N392 site using GlyProt program.20  Torsional angles between Asn392-GlcNAc1 
as observed in the determined structure were used in the program to model the complete Man8 
structure. 
Table 5.1: Crystallographic data and refinement statistics for Man5-IgG3 Fc and 
Tetraglycosylated IgG3 Fc. 
 
Data Collection Man5-IgG3 Fc 
 
Tetraglycosylated IgG3 Fc 
Unit-cell parameters (Å,o) a=64.43, b=60.44,  
c=71.40, β=109.2  
a=b=97.38,  
c=96.85  
Space group P21 P61 
Resolution (Å)1 45.00-1.80(1.84-1.80) 48.69-2.00(2.05-2.00) 
Wavelength (Å) 1.0000 1.0000 
Temperature (K) 100 100 
Observed reflections 156,654 364,213 
Unique reflections 47,374 35,292 
<I/σ(I)>1 12.7 (2.1) 13.4 (1.7) 
Completeness (%)1 98.4 (97.7) 100 (100) 
Multiplicity1 3.3 (3.2) 10.3 (10.6) 
Rmerge (%)1, 2 5.5 (57.5) 9.8 (132.1) 
Rmeas (%)1, 4 6.6 (69.0) 10.4 (138.7) 
Rpim (%)1, 4 3.6 (37.8) 3.2 (42.1) 
CC1/2 1, 5 0.998 (0.734) 0.998 (0.754) 
Refinement   




Rfactor / Rfree (%)1,3 18.4/22.3 20.5/25.3 
No. of atoms 
(Protein/Water) 
3,378/351 3,277/177 
Model Quality   
R.m.s deviations    
Bond lengths (Å) 0.009 0.007 
Bond angles (o) 1.020 0.906 
Average B-factor (Å2)   
All Atoms 28.1 47.6 
Protein 27.6 47.9 
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Ramachandran Plot    
Most favored (%) 98.6 96.7 
Additionally allowed (%) 1.4 3.0 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity 
measured for the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an  
identical manner using 5% of randomly selected reflections that were not included in the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge
12, 21.  Rpim = precision-indicating (multiplicity-weighted) Rmerge
22-23.  
5) CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data 
24-25. 
 
5.2.4 Binding analysis of IgG3 Fc glycoforms with FcγRIIIA 
Four different glycoforms at the N297 site of IgG3 Fc were used to evaluate the effect of 
truncation of high mannose glycoforms on binding to FcγRIIIA receptor. These glycoforms were 
(i) high mannose (HM) glycoforms (Man8-Man12), obtained directly out of yeast expression, (ii) 
Man5 glycoform, prepared by digestion of HM glycoforms with α-1,2 mannosidase and 
endomannosidase enzymes (iii) Fc-GlcNAc, prepared by digestion of HM glycoforms with 
EndoH enzyme (iv) Deglycosylated Fc, prepared by digestion of HM glycoforms with PNGase 
F. A BioLayer Interferometry (BLI) based binding assay was used to determine binding affinity, 
as previously described in chapter 4, section 4.1.4. 
5.3 Results and Discussion 
 
5.3.1 Characterization of Man5-IgG3 Fc and tetraglycosylated IgG3 Fc 
Both the proteins were characterized by intact protein mass spectrometry and SDS-
PAGE. A gel-shift for Man5-IgG3 Fc was observed relative to HM-IgG3 Fc due to removal of 
mannose residues (Fig. 5.1A). Intact protein MS for Man5-IgG3 Fc showed a peak 
corresponding to the Man5 glycoform on IgG3 Fc (Fig. 5.1B). The abundance of Man5 
glycoform was estimated to be 96% based on MS peak heights. The tetraglycosylated IgG3 Fc 
showed presence of high mannose glycoforms at the N297 and N392 sites in IgG3 Fc (Fig. 
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5.1C). SDS-PAGE for the tetraglycosylated IgG3 Fc is shown in chapter 3, Fig. 3.7. The 
produced proteins were sufficiently pure and homogenously glycosylated, and hence suitable for 
crystallization trials.  
 
Figure 5.1: Characterization of Man5-IgG3 Fc and tetraglycosylated IgG3 Fc. (A) Coomassie 
stained SDS-PAGE of IgG3 Fc (N392K) under reducing conditions. Lane 1: protein G purified 
IgG3 Fc (N392K), lane 2: phenyl sepharose purified diglycosylated HM-IgG3 Fc (N392K), 
lane3: Man5-IgG3 Fc (N392K) (B) intact protein MS spectra of Man5-IgG3 Fc under reducing 
conditions (C) intact protein MS spectra of tetraglycosylated IgG3 Fc under reducing conditions. 
Observed and expected masses for the different high mannose glycoforms are shown in the 
spectra. 
 
5.3.2 Structural analysis of the two IgG3 Fc variants 
Sections 5.3.2 to 5.3.8 describes structural analysis of the Man5-IgG3 Fc variant. We 
have examined structural features of IgG3 Fc and compared it with other IgG subclasses. A 
comparison of key amino acid difference between IgG3 and the other subclasses provides an 
insight into some of the unusual properties of IgG3, especially those related to differential 
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binding to protein A and the FcRn receptor. The importance of glycosylation at N297 site for 
binding to FcγRIIIA is demonstrated from a structural perspective. Sections 5.3.9 and 5.3.10 
describes structural analysis of the tetraglycosylated IgG3 Fc. Analysis of the location and 
orientation of the N392 site glycans in this structure helps to explain the results from the 
biochemical and biophysical studies described in the previous chapter.  
5.3.3 Overall IgG3 Fc structure  
IgG3 Fc crystallized in the space group P21, with one homodimer in the asymmetric unit. 
Ordered electron density was visible for residues L235-L443 and G237-P445 in chain A and B 
respectively. No interpretable electron density was observed for hinge disulfide bonds and for 
residues A231-L234 following the hinge. Both the CH2 and CH3 domains display an 
immunoglobulin fold, which is stabilized by intra-chain disulfide bonds (C261-C321 in the CH2 
and C367-C425 in the CH3). The glycans occupy the space between the CH2 domains, while 
extensive non-covalent contact exists between the two CH3 domains (Fig. 5.2). There is a high 
degree of sequence homology (over 90%) in the Fc region of the IgG subclasses (Fig. 5.3). Most 
of the amino acid differences occur on the surface of the Fc, as illustrated for IgG1 and IgG3 
(Figures 5.2). The following sections describe the influence of key amino acid differences and 
glycosylation on the structural features of IgG3 Fc as well as on some of the unusual properties 
of IgG3, especially its interaction with protein A, protein G and FcRn receptor. 
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Figure 5.2: The IgG3 Fc structure. Side chains of IgG3 Fc (magenta) that is different in IgG1 Fc 
(using PDB id 3AVE as reference) are shown in stick representation. The N297 and N-glycans 
(green) are shown in stick representation. 
 
Figure 5.3: Sequence alignment of IgG1 (3AVE), IgG2 (4HAF), IgG3, and IgG4 (4C54) for the 
hinge and the Fc region. The IgG3 sequence shown here and used for this study is based on 
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IGHG3*11, *12 allele. The amino acid differences between IgG1 and the other IgG subclasses 
are shown in red. Amino acid differences unique to IgG3 are highlighted in blue. 
5.3.4 CH2 domain conformation 
The CH2 domain conformation in IgG3 Fc was compared with representative IgG1, IgG2 
and IgG4 structures. Independent alignment of the CH2 and CH3 domains of different IgG 
subclasses using IgG3 Fc as a reference showed lower RMS (root-mean-square deviation of 
atomic positions) values for the CH3 domain relative to the CH2 domain. The RMS values for the 
CH2 domain superposition using GESAMT26 for IgG1 Fc (3AVE)27, IgG2 Fc (4HAF)3 and IgG4 
Fc (4C54)4 were 1.11 Å/106 Cα, 1.08 Å/105 Cα and 1.14Å/100 Cα respectively, while those for 
the CH3 domains showed 0.29 Å/104 Cα, 0.29 Å/104 Cα and 0.39Å/104 Cα respectively. These 
results suggest that CH3 domain conformation across IgG subclasses remain relatively constant, 
while the CH2 domain shows variability, as previously reported for IgG2 and IgG4 structures. 
The overall CH2 domain conformation can be assessed by measuring the distances between Cα 
atoms of the P238, F241, R301, and P329 residues on both the Fc chains.3 The CH2-CH3 joint 
provides angular freedom to the CH2 domain and orients it relative to the CH3 domain. Moreover, 
amino acid variations between IgG subclasses, crystal packing and crystal conditions can also 
influence CH2-CH2 domain separation.3, 28 IgG3 Fc was crystallized in the P21 space group, 
whereas a majority of the published IgG1 Fc structures belong to the P212121 group. The distance 
between pairs of P238, F241, R301 and P329 residues in the Man5-IgG3 Fc structure is 23.5 Å, 
26.3 Å, 35.5 Å and 29.9 Å respectively, which is about 3-4 Å greater than the range (18.6-20.2 Å 
for P238, 21.5-23.9 Å for F241, 31.9-35.2 Å for R301, 22.6-26.9 Å for P329) of distances 
reported in multiple IgG1 Fc structures that bear complex-type glycans (Table 5.2). A 
pronounced correlation between the CH2 separation and type of glycosylation is generally 
observed. For example, the CH2 domains are more spread apart in Man9-IgG1 Fc than for IgG1 
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Fc with a complex-type glycan.29 Moreover, a progressive decrease in the CH2 separation was 
shown in IgG1 Fc structures when the complex glycans were serially truncated.5 The smallest 
separation was reported in the aglycosylated IgG1 Fc structure (3S7G).6 The Man5 glycoform in 
IgG3 Fc is a truncated form of a Man9 glycan having similar branch points but lacking the 
additional α-1,2 mannose residues (Fig. 5.5A). The CH2 distances in the Man5-IgG3 Fc structure 
were between those found in the Man9-IgG1 Fc structure and the IgG1 Fc with a complex glycan 
structure (Fig 5.4, Table 5.2). Based on these results, it is not possible to tell whether the CH2 
separation in IgG3 Fc was due to amino acid differences in IgG3 and IgG1 and/or the Man5 
glycoform on IgG3 Fc. The IgG3 subclass exhibits the strongest complement dependent 
cytotoxicity (CDC), a process initiated by binding of C1q complement to IgG Fc. The core of the 
C1q complement binding site on IgG1 has been mapped to four spatially close residues in the 
CH2 domain, Asp270, Lys322, Pro329, and Pro331.30 Although these four residues are conserved 
in IgG3, there are other polymorphic differences between IgG1 and IgG3 around the C1q 
binding site. These differences are believed to result in subclass-dependent variations in 
complement activation at the level of C1q binding or the antibody-dependent steps of 
complement cascade. Mutation of one such polymorphic residue, Lys276 in IgG3 to IgG1-like 
Asn276 was shown to reduce complement activation.31 Lys 276 in our Man5-IgG3 Fc structure 
appears to lie close to Lys322, which has been previously determined to be important for IgG3 
driven complement activation.32 
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Figure 5.4: The orientation of the CH2 domain relative to the CH3 domain shown by 
superposition of Fc structures aligned using only one Fc chain. The compared Fc structures with 
different glycan types are Man5-IgG3 Fc (magenta), complex glycan-IgG1 Fc (3AVE) (light 
blue) and Man9-IgG1 Fc (2WAH) (green). The orientation of the Fc is shown in a (A) side view 
and (B) side view rotated by 90° about x-axis. 
 
Table 5.2: Separation between CH2 domain in IgG3 Fc and reported IgG Fc structures 
PBD 
 












5W38 IgG3 Fc (Man5)b P21 1.8 23.5 26.3 35.5 29.9 
1FC1 IgG1 Fc (complex)a P212121 2.9 19.6 23.5 35.2 26.8 
1H3T IgG1 Fc (MN2F)b P212121 2.4 18.3 21.4 32.8 22.0 
1H3U IgG1 Fc (M3N2F)b P212121 2.4 19.2 22.0 32.7 24.2 
1H3X IgG1 Fc (G0F)b P212121 2.4 19.7 21.9 33.9 22.6 
1H3V IgG1 Fc (G2F)b P212121 3.1 19.4 23.2 32.9 26.9 
3AVE IgG1 Fc (complex)a P212121 2.0 19.3 21.8 32.7 25.1 
2DTS IgG1Fc (complex-afucosyl) P212121 2.2 18.6 21.5 32.2 24.2 
3DO3 IgG1 Fc (complex)a P212121 2.5 20.1 22.4 32.8 23.5 
2WAH IgG1 Fc (Man9)b P212121 2.5 30.2 29.8 42.8 36.4 
4Q6Y IgG1 Fc closed (S2G2F)b P21 3.0 13.0 18.5 26.7 21.1 
4Q6Y 
4HAF 
4C54         
IgG1 Fc open (S2G2F)b 
IgG2 Fc (complex)a 



















adenotes heterogeneously glycosylated Fc with complex-type biantennary N-glycans 
bdenotes homogenously glycosylated Fc with the indicated glycoform 
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5.3.5 N-glycosylation 
The Man5 glycoform reported in this structure is an intermediate in the biosynthesis of 
N-linked glycoproteins that is formed just prior to the conversion of high mannose type 
glycoforms into hybrid and complex glycoforms.33 Although, the level of the Man5 glycoform 
found in the normal serum IgG is less than 1%34, it is present at significantly higher levels (up to 
20%) in recombinant mAbs produced in CHO cells.35 Man5-IgG1 is reported to have higher 
binding affinity to FcγRIIIA and higher Antibody Dependent Cellular Cytotoxicity (ADCC) 
when compared to IgG1 bearing complex-type glycoforms.36 Additionally, Man5-IgG1 exhibits 
more rapid clearance than other glycoforms due to uptake by mannose receptors and mannose 
binding proteins.37 Because of these properties, the level of high mannose glycoforms in mAb 
therapeutics is considered as a critical quality attribute (CQA) and demonstrating its effect on Fc 
conformation is important from a Fc glycoengineering perspective.38  
The conserved N297 glycan in IgG1 Fc structures maintains extensive contacts with 
protein.1 The core pentasaccharide (Man3GlcNAc2) common to high mannose and complex-type 
glycoforms in IgG1 Fc structures has been shown to maintain identical protein contacts. 
However in previous IgG1 Fc structures, monosaccharide residues outside of the core 
pentasaccharide maintained different protein contacts depending on whether they were high 
mannose or complex type glycans.2, 29 In both IgG3 Fc chains, ordered electron density for only 
the first three reducing terminal monosaccharide residues was detected, corresponding to Manβ1-
4 GlcNAcβ1-4GlcNAc linked to N297 (Fig. 5.5A,C). No interpretable electron density for the 
terminal mannose residues was detected, presumably due to its higher dynamic nature or 
disordered state.  In contrast, ordered electron density for nine and three sugars out of eleven 
were observed for chain A and B, respectively in the Man9-IgG1 Fc structure (Fig. 5.5A) 
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reported by Crispin et al.29 In an another related IgG1 Fc structure with hybrid glycoforms (Fig. 
5.5A) reported by Bowden et al., electron density was visible for all sugars except the ones 
beyond the Man4 on the α-1,3 arm of one chain and completely invisible on the other chain.28 
The protein-carbohydrate contacts for the three visible sugars on both the chains of IgG3 Fc were 
identical to those previously reported in IgG1 Fc structures.1-2 The contacts found within 
hydrogen-bonding distance are between: the carbonyl oxygen of the D265 side chain and amide 
nitrogen of the N-acetyl group on GlcNAc1, and the Nε atom of the R301 side chain and the 
amide oxygen of the N-acetyl group on GlcNAc2. Also, π-CH type of interactions are possible 
between phenyl ring of F241 and CH moieties from GlcNAc2 and Man3. (Fig. 5.5B) 
 
Figure 5.5: N-glycans in IgG3 Fc structure (A) schematic representation of Man5GlcNAc2 
(Man5), Man9GlcNAc2 (Man9) and hybrid glycoform based on the Essentials system of glycan 
nomenclature (B) close-up view of N297 attached glycans and protein contacts. H-bonds 
between protein and carbohydrate are shown as black dotted lines. (C) ordered glycans from 
chain A in stick representation, shown with the Fo-Fc electron density difference map contoured 
at 3σ. 
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We examined the effect of removal of these interactions on binding of IgG3 Fc to 
FcγRIIIA, a key receptor involved in ADCC activity using a series of sequentially truncated 
IgG3 Fc glycoforms. These glycoforms included high mannose (Man8-Man12 glycoforms, 
potentially having additional protein contacts when compared to Man5), Man5, a single GlcNAc 
monosaccharide residue (disrupting contacts with Man3 and GlcNAc2) and D297 
(deglycosylated by PNGase F treatment, also disrupting contacts with GlcNAc1). Representative 
binding curves for biolayer interferometry (BLI) based Fc-FcγRIIIA binding assay are shown in 
Fig. 5.6 and the results for these binding experiments are given in Table 5.3. The binding assay 
showed similar affinity for the high mannose (Man8-Man12) and Man5 glycoforms. However, a 
10-fold reduction in affinity was observed for GlcNAc-IgG3 Fc glycoform and no detectable 
binding was recorded for the deglycosylated IgG3 Fc using highest receptor concentration of 15 
µM. The weaker affinity of the GlcNAc-IgG3 Fc was driven by a faster dissociation rate, with 
the association rate remaining largely unaffected. A similar trend in FcγRIIIA binding was also 
seen in IgG1 Fc, as previously reported by our group39 and others.40 These results indicate that 
protein-glycan interactions of the core pentasaccharide (GlcNAc2Man3) were necessary in 
maintaining high affinity FcγRIIIA binding, and that the IgG3 Fc interactions with GlcNAc1 are 
essential for FcγRIIIA binding. The functional relevance of protein-glycan contacts observed in 
Fc structures was first demonstrated by Lund et al. using site-specific mutagenesis to disrupt 
important contacts.41-42 In their study, individual mutations of D265, R301, F241 and F243 
residues on a mouse-human chimeric IgG3 caused a reduction in complement activity and 
binding to the receptor FcγRI. The observed protein-glycan contacts mediated by the first two 
GlcNAc’s in our IgG3 Fc structure and the effect of the disruption of these contacts on binding 
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to FcγRIIIA provides a structural basis for the importance of these sugar residues in IgG3-Fcγ 
receptor interactions.  
 
Figure 5.6: Binding analysis of IgG3 Fc glycoforms-FcγRIIIA. Binding curves (BLI curve, red; 
fitted curve, black) with corresponding glycoform structure are shown in panels for following 
glycoforms: (A) Man8-Man12 (B) Man5 (C) Fc-GlcNAc and (D) D297 (deglycosylated). The 
data is shown for FcγRIIIA at concentrations of 800, 400, 200, and 100 nM, which correspond 
with curves from top to bottom. For Fc-GlcNAc, curves for FcγRIIIA at concentrations of 1600, 
800, 400, 200 nM are shown. 
 
Table 5.3: Kinetic parameters obtained for binding of FcγRIIIA with the IgG3 Fc glycoforms 






Man8-Man12 1.6 ± 0.1 6.5 ± 0.2 41.4 ± 2.7 
Man5 1.5 ± 0.1 6.8 ± 0.2 46.5 ± 2.4 
Fc-GlcNAc 1.7 ± 0.4 85.8 ± 7.7 506 ± 113 
D297  nd* nd* nd* 
*not detected at highest receptor concentration of 15 µM. 
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5.3.6 CH2-CH3 domain interface 
The CH2-CH3 interface in IgG class antibodies maintains the orientation of the CH2 
domain relative to the CH3 domain. Moreover, the outer face of the CH2-CH3 domain interface is 
a binding site for multiple Fc binding proteins like FcRn, protein A, protein G, HSV-1 (herpes 
simplex virus 1) Fc receptor, rheumatoid factor and TRIM21 (tripartitie motif 21).43 Any 
structural change at the interface can potentially alter the conformation of the binding site or the 
CH2 domain orientation. The amino acids at the interface are highly conserved among IgG 
subclasses with a few exceptions. In IgG1, IgG2 and IgG4 Fc structures, the core of the interface 
is formed by four stabilizing interactions: two salt bridges between K248-E380 and K338-E430 
through side chains and two hydrogen bonds between L251-H435 and K340-Y373 through main 
chains of L251, K340 and side chains of H435, Y373. All these residues are conserved across 
IgG subclasses except at position 435, where an arginine is present (R435) in IgG3 rather than 
histidine (H435) as in the other subclasses (Fig. 5.3). It must be noted here that only two IgG3 
allotypes (G3m (s,t)/G3m15,16) from the thirteen allotypes contain H435 and these are 
commonly found in Mongoloid population but rare in Caucasoids.44  
Both the IgG3 Fc chains showed similar contacts as seen in IgG1 Fc (3AVE), IgG2 Fc 
(4HAF) and IgG4 Fc (4C54) except for the K248-E380 salt bridge (Fig. 5.7A). The side chain of 
E380 on both IgG3 Fc chains adopted a different rotameric conformation that was away from 
side chain of K248 (Fig. 5.7B). Interestingly, despite having arginine at position 435, both the 
IgG3 Fc chains still maintained a H-bond between residues 251 and 435 (through the main chain 
carbonyl oxygen of L251 and Nε of R435 side chain in place of Nδ1 from H435 side chain) (Fig. 
5.7A). The longer arginine 435 side chain in IgG3 Fc is close to the isoleucine 253 side chain 
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(less than 4 Å distance), whereas histidine 435 is located away from isoleucine 253 in the IgG1, 
2 or 4 subclasses. The conformation of I253 shows variability in the representative IgG1 Fc 
structures but the H435 conformation remains consistent. In comparing these structures to IgG3 
Fc, the I253 and R435 residues in IgG3 Fc are found to be closer than the I253-H435 pair in any 
IgG1 Fc structures (Fig. 5.8A). A water mediated H-bond between Nη2 of R435 side chain and 
the main chain amide nitrogen of I253 appears to be present in the chain A of IgG3 Fc but not in 
chain B (data not shown). Arginine (pKa~12.5), unlike histidine (pKa~6.0) remains positively 
charged at physiological pH and thereby can potentially alter the side chain conformation of I253 
or its local conformation. Isoleucine 253 is a critical residue in the region of IgG Fc where 
protein A, protein G and FcRn bind.2, 45 T339 is another residue at the interface that differs 
across the IgG subclasses. IgG2 and IgG3 contain threonine, while IgG1 and IgG4 have alanine 
at position 339. In the IgG2 Fc structure, T339 has been shown to maintain contact with D376 
either directly or through water mediated H bonds.3 In the IgG3 Fc structure, the side chains of 
T339 and D376 on chain A exists in two conformations, while both residues on chain B adopt a 
single conformation with no contacts between them in either of the chains (Fig. 5.7C). 
Teplyakov et al. have suggested a ball-and-socket joint in the IgG2 Fc structure between a CH2 
residue forming the ball and CH3 residues forming the socket that mediate the pivot of the CH2 
domain relative to the CH3 domain. L251 in the CH2 domain was shown to fit into a socket 
formed by residues M428, H429, E430 and H435.3 These residues are conserved in all IgG 
subclasses except IgG3 where arginine is present at position 435 (Fig. 5.3). In the IgG3 Fc 
structure, R453 does not seem to disrupt the socket and L251 in IgG3 Fc was still able to form a 
similar type of ball-and-socket joint. The longer side chain of R435 can be speculated to extend 
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the socket closer to the CH2 domain owing to the proximity of the R435 and I253 residues and 
thereby may influence the CH2 domain pivot (Fig. 5.8B).  
 
Figure 5.7: CH2-CH3 interface of IgG3 Fc. (A) H-bonds and salt-bridge present between CH2 
(gold) and CH3 (coral) in chain A (B) comparison of CH2-CH3 interface across IgG subclasses. 
The representative Fc structure include IgG1 Fc (3AVE) (blue), IgG2 Fc (4HAF) (purple), IgG3 
Fc (red) and IgG4 Fc (4C54) (cyan). Protein backbone is represented by Cα trace and side chains 




Figure 5.8: Comparison of IgG3 Fc with other Fc structures. (A) conformation of I253 and 
R435/H435 across multiple IgG Fc structures, as shown in the key. (B) ball-and-socket joint in 
IgG3 and IgG2 Fc structure. Side chains are represented by stick in (A) and by ball-and-stick in 
(B). 
A functional significance of the CH2-CH3 interface with respect to Fc receptor binding 
was demonstrated in an IgG1 mutagenesis study.46 In the study, IgG1 with a H435A mutation 
showed 25% lower binding to FcγRIIA, FcγRIIB and FcγRIIIA, while the mutation increased 
binding to FcγRI by same amount. An A339T mutation increased FcγRIIIA binding by 34%. 
Given the distal location of the H435 and A339 from the FcγR binding site, an indirect role of 
the CH2-CH3 interface in FcγR binding through maintenance of CH2 conformation can be 
postulated. In the same study, an E380A mutation resulted in an 119% increase in FcRn affinity. 
E380 doesn't interact directly with FcRn but is a neighboring residue at the binding interface. In 
summary, the CH2-CH3 interface of IgG3 Fc exhibited minor differences compared to that of 
IgG1 Fc, which may be responsible for subtle differences in its Fc receptor interaction pattern.47 
In one particular case, the CH2-CH3 domain interface was shown to generate an Fc-Fc mediated 
hexameric ring structure in the crystal packing of a full-length IgG1 antibody (1HZH).48 
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Functionally, such hexameric structures resulting from antigen bound antibodies on cells is 
shown to be effective activators of CDC by binding strongly to the C1q complement protein 
which also has a hexameric structure.49 The residues involved in the Fc-Fc interface in the crystal 
packing of these structures were located at the CH2-CH3 interface and overlapped with known 
sites for Fc-binding proteins. The CDC activity of IgG1 was shown to be affected by disruption 
of some of the Fc-Fc contacts that were involved in hexamer formation.49 Although, the CH2-
CH3 interface in our IgG3 Fc crystal packing do not generate hexameric ring by symmetry 
operation, the role of interface residues of IgG3 that can potentially mediate Fc-Fc interaction 
warrants further investigation, especially since IgG3 is known to elicit the strongest CDC among 
the IgG subclass.  
5.3.7 IgG3-protein A and protein G interactions 
IgG3 is the only IgG subclass that does not bind to protein A, whereas all IgG subclasses 
bind to protein G. Both, protein A and protein G bind to the outer face of the CH2-CH3 interface, 
where residues from both domains are involved in binding. Protein A and G have overlapping 
but non-identical binding sites on IgG Fc’s. All the residues involved in protein A and/or protein 
G binding are conserved across the IgG subclass except for IgG3-R435.50 H435 in the other IgG 
subclasses maintains a hydrophobic contact with Y133 and L136 of protein A.2 When the H435R 
mutation of IgG1 Fc was modeled on the IgG1 Fc structure in the first published protein A-IgG1 
Fc complex (1FC2), R435 was unable to be accommodated in the complex.2 Although an IgG3 
Fc structure alone does not provide direct information on the lack of an IgG3-protein A binding 
interaction, IgG3 can be reasonably compared with IgG1 in complex with protein A, given the 
highly conserved nature of the binding interface, and some conclusions can be drawn. We used 
the 1FC2 complex and a more recently reported Rituximab Fc-protein A (1L6X) complex to 
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compare IgG3's structure to IgG1's structure in the complex. In both the complexes, the R435 
side chain appears to sterically clash with the phenylalanine (Y133/Y15 in 1FC2/1L6X) and 
glutamine (Q129/Q11 in 1FC2/1L6X) residues of protein A and appear to be more 
conformationally restricted than H435 (Fig. 5.9A-B). Our analysis is backed by the work of 
Stapleton et al., who showed that protein A binding ability of IgG3 is restored when Arg is 
mutated to His.51 In contrast to protein A, H435 was shown to not make any contact with protein 
G in the protein G-IgG1 Fc complex.50 When we compare IgG3 Fc to IgG1 Fc in the complex 
with protein G, the R435 in IgG3 does not appear to sterically clash with protein G and appears 
to be accommodated at the binding interface (Fig. 5.9C). Additionally, R435 in IgG3 can be 
predicted to interact with E27 in protein G through a salt bridge, as the distance between the Nη2 
atom of R435 and Oε2 atom of E27 is 3.5 Å. A study investigating binding affinity differences 
between the IgG subclasses for binding to protein G showed a 3-fold higher affinity for IgG3 
compared to IgG1.52 Based on this information, it could be suggested that the longer R435 side 
chain in IgG3 can potentially form extra contacts with protein G and thereby result in tighter 
binding. Our IgG3 Fc structure provides some insight on the likely role of the arginine residue at 
the 435 position in differential protein A and protein G binding property of IgG3.  
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Figure 5.9: IgG3 Fc at Fc-protein A/G binding interface. IgG3 Fc is superposed on IgG1 Fc in 
the IgG1 Fc-protein A complexes from (A) 1FC2 and (B) 1L6X. (C) IgG3 Fc is superposed on 
IgG1 Fc in the IgG1 Fc-protein G complex (1FCC). Side chains of Fc and protein A/G are 
represented by ball-and-stick and stick respectively. The transparent surface of protein A and G 
are shown in light purple and dark cyan respectively.  
5.3.8 IgG3-FcRn interactions 
The neonatal Fc receptor (FcRn) is responsible for the long half-life of IgG class 
antibodies by rescuing IgG from endosomal degradation. It binds to IgG at acidic pH in the 
endosomes of vascular endothelial cells and recycles it back to circulation by dissociating at pH 
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7.4.53 FcRn binds to the outer face of the CH2-CH3 domain interface overlapping the protein A 
and protein G binding sites. Analysis of the FcRn-IgG binding interface based on the Fc-FcRn 
crystal structure and molecular dynamics simulation revealed three contacts to be most 
stabilizing.45, 54-55 These include a Fc-I253 interaction with a pocket formed by hydrophobic 
residues on FcRn, and salt bridges involving H310 and H435 of the Fc with corresponding E115 
and D130 residues of FcRn which maintain the pH dependence of the interaction. The lower 
half-life of IgG3 (~7 days) has been suggested to be due to an intracellular competition between 
IgG1 (half-life of ~21 days) and IgG3 during the FcRn recycling process. Interestingly, FcRn-
mediated transport models showed that IgG3 was transported as efficiently as IgG1 if present 
alone but only affected in presence of IgG1.51 IgG3 showed a slightly 2-fold weaker affinity at 
pH 6.0 when compared to IgG1 and an increased binding at pH 7.4 relative to IgG1.51 These 
differences were suggested to play a role in less efficient IgG3 recycling also. Interestingly, an 
IgG3 allotype with H435 shows IgG1 like half-life, implying a role for the amino acid at position 
435 in FcRn affinity. Moreover, a H435A mutation in IgG1 was shown to reduce FcRn binding 
by more than 10-fold.46 We modeled the probable IgG3-FcRn binding interface by superposing 
the IgG3 Fc structure on the available IgG1 Fc (YTE)-FcRn complex45, and analyzed various 
scenarios in which R435 can influence FcRn binding. The R435 residue appears to be 
accommodated at the binding interface with some rearrangement (Fig. 5.10). Moreover, R435 in 
IgG3 can be predicted to interact with E133 in FcRn through a salt bridge, as the distance 
between the Nη2 atom of R435 and Oε2 atom of E133 is 3.0 Å. The arginine side chain (free 
amino acid pKa~12.5) remains positively charged at pH 7.4 and can still maintain ionic 
interactions with FcRn, unlike the histidine side chain (free amino acid pKa~6.0) which is likely 
to be less than 10% protonated at pH 7.4. This can contribute to increased binding of IgG3 at 
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physiological pH relative to the other IgG subclasses. Moreover, R435 can indirectly influence 
FcRn binding through I253, given their proximity in the structure (Fig. 5.7A) and the importance 
of I253 at the binding interface (a I253A mutation in IgG1 was shown to result in more than 10-
fold weaker FcRn binding46). Although, the IgG3 Fc structure alone does not provide conclusive 
evidence pertaining to IgG3-FcRn interaction, it helps to shed light on the possible role of 
arginine at position 435 at the binding site. 
 
Figure 5.10: IgG3 Fc at the Fc-FcRn binding interface. IgG3 is superposed on IgG1 Fc (YTE) in 
the Fc (YTE)-FcRn complex (4N0U). Fc and FcRn residues are shown in ball-and-stick and stick 
representation respectively. Transparent surface of FcRn is shown in blue. 
 
5.3.9 Crystal structure of tetraglycosylated IgG3 Fc 
The tetraglycosylated IgG3 Fc (contains high mannose glycans at both the N297 and 
N392 sites) crystallized in a hitherto unreported P61 space group for IgG Fc with a complete 
dimer in the asymmetric unit, and its structure was solved at 2.0 Å resolution (Fig. 5.11A, Table 
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5.1). The Man5-IgG3 Fc (which contains the Man5 glycoform only at the N297 site) crystallized 
in a different space group P21. Most of the published IgG Fc structure belong to a related P212121 
space group with a few in P1, C2, C2221, P6122 and P622 space groups. The six-fold 
crystallographic axis in the tetraglycosylated IgG3 Fc structures generates a hexameric assembly 
of Fc molecules in a helical arrangement (Fig. 5.11C). The CH2 domains of the symmetry related 
Fc structures are oriented inwards facing the axis of the helix, and the Fc-Fc interface is formed 
by contacts between the CH2 domain in chain A of one molecule and CH2 domain in chain B of 
another. Interpretable electron density was observed for residues Pro238 to Leu443 and Gly237 
to Pro445 for chains A and B respectively. Residues Pro291 to Phe296 and Ser298 to Phe301, 
which flank the N297 glycosylation site on chain B were disordered and could not be modeled. 
The overall structure of tetraglycosylated IgG3 Fc is similar to Man5-IgG3 Fc; superposition of 
the two structures using GESAMT26 yields a RMSD deviation of 2.10 Å for Cα of 383 residues. 
For the tetraglycosylated IgG3 Fc structure, interpretable electron density was only visible for 
the first three and four sugars out of ten (GlcNAc2Man8) for chains A and B respectively at the 
N297 site, and for the first two and one sugar out of ten for chains A and B respectively at the 
N392 site (Fig. 5.11B). A similar number of sugars residues (first three out of seven on both 
chains) were visible in the Man5-IgG3 Fc structure. The conformation of N297 glycans and their 
contacts with the CH2 domain were similar in both the IgG3 Fc structures. Based on the 
orientation of the first two GlcNAc residues at the N392 site in the tetraglycosylated IgG3 Fc 
structure, it appears that the glycans at the N392 point towards the N-terminus of Fc and run anti-
parallel to the N297 glycans (Fig. 5.11A).  
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 Figure 5.11: Crystal structure of the tetraglycosylated IgG3 Fc. (A) overall structure of IgG3 Fc 
with interpretable glycan structures at the N297 and N392 sites. Chains A and B of Fc are shown 
in magenta and cyan, respectively and glycans are shown in stick representation (B) Schematic 
representation of the Man8 glycoform and electron density difference omit map (Fo-Fc, green 
mesh) contoured at 3σ showing the glycans at the N297 and N392 sites (C) Top and side-views 
of the symmetry related Fc molecules organized in a helical arrangement. 
Since only a small part of the Man8 structure at the N392 site was visible in the crystal 
structure, the full structure was in-silico modeled using GLYPROT20 to visualize the entire 
oligosaccharide. The modeled Man8 glycan appear to point away from the protein surface and 
remain largely solvent exposed (Fig. 5.12A). Crystal packing analysis revealed presence of a 
cavity large enough to fit Man8 glycan in the vicinity of N392 site between the two Fc molecules 
related to one another by two-fold rotation. The modeled Man8 glycan was found to fit 
reasonably well in this cavity and a possible glycan-glycan interface was revealed between the 
two Fc molecules related by two-fold rotation (Fig. 5.12B).  
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Figure 5.12: Conformation of the in-silico modeled Man8 glycan at the N392 site and its 
orientation in the Fc structure and crystal packing. (A) Tetraglycosylated IgG3 Fc structure with 
modeled Man8 glycan at the N392 site. Chain A and B of Fc are shown in yellow and cyan, 
respectively and glycans are represented by spheres and color matched to their respective chain. 
The FcγRIIIA and FcRn binding sites on Fc are shown in magenta and purple, respectively. (B) 
Organization of modeled N392-Man8 glycan between two Fc molecules (related by two-fold 
rotation) in the crystal packing. Fc is colored by symmetry and glycans are represented by 
spheres and color matched to its respective Fc. The N297 glycans are not shown in this figure for 
the sake of simplicity. 
The N392 glycans are cleaved at much slower rate under native conditions by the 
PNGase F enzyme, which cleaves between the first GlcNAc of N-glycan and the Asn side chain 
(chapter 3, section 3.3.1, Fig. 3.19). Crystallographic analysis of PNGase F with the N, N’-
diacetylchitobiose core showed that the N-acetyl group of first GlcNAc formed one of the site 
for glycan recognition by the enzyme.56 In the tetraglycosylated IgG3 Fc structure, the N-acetyl 
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group of the first GlcNAc at the N392 site is largely buried by the CH3-CH3 domain interface, 
which may explain the inability of PNGase F to cleave glycans at this site. A dramatic difference 
in the levels of fucosylated glycoforms was detected between the two glycosylation sites, as 
about 90% of glycoforms at the N297 site were fucosylated, while no fucosylated glycans were 
detected at the N392 site (chapter 2, section 2.3.3). A fucose residue is added to the first GlcNAc 
of glycan close to the protein surface by α-1,6 fucosyltransferase. Structural analysis of several 
glycoproteins by Thaysen-Anderson et al. suggested that lower levels of fucosylation and higher 
levels of high mannose glycans are associated with the glycosylation sites that have low site 
accessibility.57 In the tetraglycosylated IgG3 Fc structure, the accessible surface area (ASA) for 
the N297 site is 101.2 Å, while ASA for the N392 site is 60.9 Å. About 50% of ASA of the 
N392 site (if exists as Fc monomer) is buried due to formation of CH3-CH3 dimer interface. The 
relatively more shielded N392 site may explain the inaccessibility of α-1,6 fucosyltransferase 
close to the glycoprotein surface. 
5.3.10 Influence of N392 glycans on Fc receptor binding and physical stability of IgG3 Fc 
The in-vitro binding studies of IgG3 Fc with FcγRIIIA and FcRn receptors suggest that 
the additional presence of the N392 site glycans on IgG3 Fc does not have a large impact on 
receptor binding (chapter 4, section 4.2.4). We examined the orientation of the N392 glycans in 
the tetraglycosylated IgG3 Fc structure to help explain our binding results. Structurally, the N392 
glycosylation site is located distal to the FcγRIIIA binding site. The in-silico modeled Man8 
glycan in the tetraglycosylated IgG3 Fc structure show that the glycans from the N392 site are 
oriented away from the receptor binding site and hence may not have a direct influence on 
binding (Fig. 5.12A). Moreover, it could also be proposed that the presence of N392 glycans 
does not induce any long-range conformational changes at the receptor binding site. This is an 
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important observation since prior studies have shown that binding to FcγRIIIA can be affected 
by changes made distal to the binding site, such as amino acid mutations at the CH2-CH3 domain 
interface.58-59 Such effects have been attributed to long-range forces existing in the Fc molecule 
owing to its dynamic and flexible nature.60 The neonatal Fc receptor (FcRn) binds to the outer 
face of CH2-CH3 interface on both the heavy chains of Fc. The N392 site in IgG3 Fc is located at 
the edge of CH3-CH3 interface close to the inner face of CH2-CH3 interface and the presence of 
glycans in this region can be predicted to potentially affect the FcRn binding (Fig. 5.12A). 
However, our binding results suggest that the presence of additional glycans at the N392 site in 
IgG3 Fc does not impact its ability to bind with FcRn. It is possible that the N392 glycans are 
accommodated in the Fc structure such that FcRn binding remains unaffected. In the in-silico 
modeled Man8 glycan in the tetraglycosylated IgG3 Fc structure, the entire glycan is located 
away from the FcRn binding site (Fig. 5.12A). 
The residue at 392 position lies at the edge of the CH3-CH3 interface of Fc. Both Lys (in 
diglycosylated variant, PDB: 5W38) and Asn (in tetraglycosylated variant) at the 392 position 
point away from the interface and their side chains show no contact with the other CH3 domain 
residues (Fig. 5.13A). The Cα- Cα distances between residues at the CH3-CH3 interface in the 
vicinity of Asn/Lys392 residues in both the IgG3 Fc variants were compared to detect changes in 
the inter-CH3 domain separation. The Cα- Cα distances between N/K 392 of one CH3 domain and 
S400’, D399’, and L398’ of the second CH3 domain (prime denotes residue on second CH3 
domain) were increased from 8.26 to 9.08 Å, 7.12 to 7.72 Å, and 8.67 to 8.80 Å in the 
tetraglycosylated IgG3 Fc (N392) structure compared to the diglycosylated IgG3 Fc (K392) 
structure (Fig. 5.13A). Rispens et al. measured differences in the strength of CH3-CH3 interface 
in different IgG3 variants and found that CH3-CH3 dissociation rate was ten fold faster in the case 
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of IgG3 with Asn392 rather than Lys392 (it is not known if the Asn392 was glycosylated in this 
study).61 Taken together, it can be proposed that the N392 glycans may disrupt the interactions at 
the edge of CH3-CH3 interface and thereby can potentially reduce the CH3 domain 
conformational stability. An example of extreme manifestation of glycans disrupting the CH3-
CH3 interface was demonstrated by Ishino et al. by adding glycosylation sites at the core of IgG1 
CH3-CH3 interface to generate the Fc in a completely monomeric state.62 Chennamsetty et al. 
identified aggregation motifs in IgG subclasses, one of which is P395PML398 in the CH3 domain.
63 
This motif succeeds the N392 glycosylation site in IgG3 and is enclosed between the pair of 
N392 glycans in the tetraglycosylated IgG3 Fc structure (Fig. 5.13B). It is possible that the N392 
glycans in IgG3 Fc protects it from aggregation by shielding this aggregation hot-spot. A similar 
effect was demonstrated by introducing an additional glycosylation site in the Fab domain of 
Bevacizumab to shield a potential aggregation hot-spot.64 It was suggested that the extra 
glycosylation protected the antibody against aggregation by increasing the solubility of unfolded 




Figure 5.13: Effect of N392 glycans on the CH3-CH3 interface of IgG3 Fc. (A) comparison of 
CH3-CH3 interface in the tetraglycosylated (gold) and diglycosylated (PDB: 5W38, blue) IgG3 
Fc structures in the vicinity of residue 392, which is glycosylated Asn in the former and Lys in 
the latter structure. Cα- Cα distances between residue 392 and each of L398, D399, and S400 for 
both the Fc chains are shown by red dash lines. (B) location and orientation of N392 glycans 
with respect to the aggregation motif P392PML398 at the CH3-CH3 interface. Prime symbol 
denotes residue from the second CH3 domain. 
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6.1 Summary 
 All four IgG subclasses carry a consensus N-glycosylation site at N297 in the CH2 
domain of the Fc region. The presence of glycosylation at the N297 site is critical for antibody-
mediated effector functions as well as the conformational stability of IgG. Only in case of IgG3, 
there is an additional glycosylation site at N392 in the CH3 domain of the Fc region. This site has 
nearly gone unmentioned in the literature and was only recently found to be glycosylated in 
human serum IgG3.1 However, the biological role of the N392 glycans and its effect on IgG3 
structure and function remains under investigated. The focus of this dissertation work is to 
investigate the influence of N-linked glycosylation on the Fc receptor binding interactions and 
physical stability of IgG3 Fc. Site-specific glycosylation analysis was carried out to characterize 
the glycosylation pattern at the N297 and N392 glycosylation sites on IgG3 isolated from human 
serum. Additionally, we have determined the crystal structure of the Fc fragment of IgG3, whose 
structural features could explain some of the IgG3-specific properties and also our results from 
the biochemical and biophysical studies on IgG3 Fc. The following is a summary of contents 
presented in each chapter of this dissertation work.  
 
Chapter 2: This chapter presents the results for site-occupancy and site-specific glycosylation 
analysis of the N297 and N392 sites in human serum IgG3. The glycosylation site-occupancy 
was determined to be roughly 100% and 10% for the N297 and N392 sites, respectively. The two 
sites showed differences in their glycosylation patterns, characterized by significant variations in 
the levels of core fucose, bisecting GlcNAc and high mannose glycans. These results 
demonstrate that glycan processing is not uniform across the two glycosylation sites in IgG3 and 
factors such as protein primary structure and local conformation around the glycosylation site 
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can influence the site-occupancy and the composition of the oligosaccharide structure. Moreover, 
the detection of N392 glycans in endogenous human IgG3 establishes a biological relevance to 
the lesser known N392 glycosylation site and thereby make a case for its further biological and 
biophysical evaluation.  
 
Chapter 3: This chapter presents the results for recombinant expression and characterization of 
IgG3 Fc in yeast P. pastoris. Two site-specific glycovariants of IgG3 Fc were prepared, one with 
two sites glycosylated (tetraglycosylated) and another with only the N297 site glycosylated 
(diglycosylated) to evaluate the influence of N392 site glycosylation on IgG3 structure and 
function. Both the IgG3 Fc variants showed presence of high mannose glycans at the occupied 
glycosylation sites. The high mannose glycans can be converted to Man5 glycoform by cleavage 
of α-1,2 mannose residues. The mannose trimming reaction was found to be incomplete (only 
78% conversion to Man5) due to presence of modified high mannose glycans (non-cleavable α-
1,2 mannose linkages). To counter this, members of the Tolbert lab deleted few genes in the 
yeast P. pastoris to reduce the levels of these modified glycans. This chapter presents results for 
the susceptibility of high mannose glycans produced in different yeast strains to produce Man5 
glycoform using in-vitro α-1,2 mannosidase digestion. A significant improvement in Man5 
conversion was observed (~95%) with additional knock-outs of PNO1, BMT1 and BMT2 genes.  
 
Chapter 4: This chapter presents the results for the influence of the N392 site glycans on the 
binding of IgG3 Fc with Fc receptors and the physical stability of IgG3 Fc. An activating Fcγ 
receptor, FcγRIIIA, and the neonatal Fc receptor (FcRn) were recombinantly produced in P. 
pastoris, and an in-vitro kinetic binding assay was developed to determine the binding affinity. 
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The binding results revealed that the binding of IgG3 Fc to both of the receptors is not largely 
influenced by the additional presence of N392 site glycans. Assessment of the impact of the 
N392 site glycans on physical stability of IgG3 Fc revealed that the presence of N392 site 
glycans reduced the conformational stability of IgG3 Fc but improved the colloidal stability of 
IgG3 Fc.  
 
Chapter 5: This chapter presents high-resolution x-ray crystal structures of tetraglycosylated and 
diglycosylated IgG3 Fc. General structural features of IgG3 Fc are described and compared to 
the available Fc structures from the other IgG subclasses. The important amino acid differences 
between IgG3 and the other subclasses that have been implicated in IgG3-specific properties, 
related to binding to protein A, protein G and FcRn, are discussed from a structural perspective. 
The observed protein-glycan (from the N297 site) contacts in the IgG3 Fc structure, supported by 
the results that show reduced binding to FcγRIIIA upon glycan truncation (and hence the loss of 
protein-glycan contacts), provides a structural basis for the importance of N297 glycosylation in 
receptor binding. The location and orientation of the N392 site glycans in the tetraglycosylated 
IgG3 Fc structure helps to provide an explanation for the non-effect of the N392 glycans on the 
receptor binding interactions of IgG3 Fc and the observed effects on the physical stability of 
IgG3 Fc. 
 
6.2 Conclusions  
 This dissertation work explored the influence of the N297 and N392 site glycosylation on 
the structure, Fc-receptor interaction, and physical stability of human IgG3 Fc. The differences in 
the glycosylation pattern between the N297 and N392 sites on human serum IgG3 indicate site-
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specific variations in glycan processing. These variations are likely due to the relatively buried 
nature of the N392 glycosylation site within the Fc structure, which potentially limits the 
accessibility of the glycan modifying enzymes. The yeast P. pastoris served as a suitable 
expression host to produce IgG3 Fc that is glycosylated at the N392 site, which enabled 
biochemical and biophysical characterization of the N392 site glycans. No large change in the 
binding affinity of IgG3 Fc for FcγRIIIA and FcRn was detected due the additional presence of 
N392 site glycans. The structural location and orientation of the N392 glycans could explain the 
non-effect of the N392 glycans on the Fc receptor binding interactions of IgG3 Fc. The impact of 
the N392 glycans on the physical stability of IgG3 Fc can be explained by the position of these 
glycans at the CH3-CH3 interface. Amino acid differences between IgG3 and the other IgG 
subclasses, which have been attributed to result in IgG3-specific properties were mapped in the 
structure and a structural basis for differential binding of IgG3 to protein A and FcRn is 
proposed. The functional significance of the observed protein-glycan (from the N297 site) 
contacts in the structure is demonstrated by reduced binding affinity to FcγRIIIA upon glycan 
truncation.  
  
6.3 Future directions 
 This dissertation work provides preliminary information about the immunological role of 
N392 site glycosylation in human IgG3. The presence of additional N392 glycans on IgG3 Fc 
was shown to have no effect on binding to FcγRIIIA and FcRn; however, the possibility of its 
influence on binding to other types of Fcγ receptors cannot be ruled out. Generally, assessment 
of IgG binding affinity to FcγRIIIA is a good surrogate for prediction of IgG-mediated ADCC 
activity, but, in this case, an ADCC assay would be useful to check if the N392 glycans play any 
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role that is not directly related to binding with FcγRIIIA, such as formation of an immune 
complex. Based on the crystal packing around the N392 glycosylation and the accessible nature 
of N392 glycans, it could be suggested that the N392 glycans may influence Fc-Fc interactions. 
IgG-IgG interactions through the Fc region have been implicated in the formation of immune 
precipitates and reaction of rheumatoid factor (autoantibody) with the Fc of IgG.2 Further studies 
will be required to test this hypothesis. There is another immunologically relevant Fc receptor, 
TRIM21, that bind to the CH2-CH3 interface.3 It remains to be investigated if the N392 glycans 
have any effect on binding to this receptor.   
 Mannose-Binding Lectins (MBL) and Ficolins are lectins (carbohydrate binding proteins) 
that play an important role in the innate immune system by recognizing sugars on the surface of 
invading pathogens. These pathogen-bound lectins bind to natural IgG (polyreactive IgG 
secreted by B cells in absence of infection) and form an immune complex, which can be cleared 
by antibody effector functions.4 It will be interesting to see if the N392 glycans on IgG3 are 
recognized by these lectins and thereby have a potential role in the innate immune system. This 
is an attractive hypothesis on two counts. First, natural IgG predominantly belong to IgG3 
subclass5 and second, due to the accessible nature of terminal mannose and GlcNAc sugars 
present at the N392 site, which are recognition motifs for the MBL and Ficolins. Lastly, 
molecular dynamic simulations of IgG3 Fc might be useful to better understand the effect of 
N392 glycans on the conformational stability of IgG3 Fc. Such studies will now be possible with 
the available crystal structure of IgG3 Fc.  
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